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ABSTRACT 
The immunosuppressive agents (IAs) rapamycin, cyclosporin A and tacrolimus, as well as 
glucocorticoids are used to prevent rejection of transplanted organs and to treat autoimmune 
disorders. Despite their desired action on the immune system, these agents have serious long-
term metabolic side-effects, including dyslipidemia and new onset diabetes mellitus after 
transplantation.  
The overall aim is to study the effects of IAs on human adipose tissue glucose and lipid 
metabolism, and to increase our understanding of the molecular mechanisms underlying the 
development of insulin resistance during immunosuppressive therapy.  
 
In Paper I and II, it was shown that rapamycin and the calcineurin inhibitors, cyclosporin A 
and tacrolimus, at therapeutic concentrations, had a concentration-dependent inhibitory effect 
on basal and insulin-stimulated glucose uptake in human subcutaneous and omental 
adipocytes. Rapamycin inhibited mammalian target of rapamycin complex (mTORC) 1 and 2 
assembly and phosphorylation of protein kinase B (PKB) at Ser473 and of the PKB substrate 
AS160, and this leads to impaired insulin signalling (Paper I). On the other hand, cyclosporin 
A and tacrolimus had no effects on expression or phosphorylation of insulin signalling 
proteins (insulin receptor substrate 1 and 2, PKB, AS160), as well as the glucose transport 
proteins, GLUT4 and GLUT1 (Paper II). Instead, removal of GLUT4 from the cell surface 
was observed, probably mediated through increased endocytosis, as shown in L6 muscle-
derived cells. These studies suggest a different mechanism for cyclosporin A and tacrolimus, 
in comparison to rapamycin, with respect to impairment of glucose uptake in adipocytes. 
In Paper III, all three IAs increased isoproterenol-stimulated lipolysis and enhanced 
phosphorylation of one of the main lipases involved in lipolysis, hormone-sensitive lipase. 
The agents also inhibited lipid storage, and tacrolimus and rapamycin down-regulated gene 
expression of lipogenic genes in adipose tissue. All three IAs increased interleukin-6 (IL-6), 
but not tumor necrosis factor α (TNF-α ) or adiponectin, gene expression and secretion.  
In Paper IV, we proposed that FKBP5 is a novel gene regulated by dexamethasone, a 
synthetic glucocorticoid, in both subcutaneous and omental adipose tissue. FKBP5 expression 
in subcutaneous adipose tissue is correlated with clinical and biochemical markers of insulin 
resistance and adiposity. In addition, the FKBP5 gene product was more abundant in omental 
than in subcutaneous adipose tissue.  
 
In conclusion, adverse effects of immunosuppressive drugs on human adipose tissue glucose 
and lipid metabolism can contribute to the development of insulin resistance, type 2 diabetes 
and dyslipidemia in patients on immunosuppressive therapy. The cellular mechanisms that 
are described in this thesis should be further explored in order to mitigate the metabolic 
perturbations caused by current immunosuppressive therapies. The findings in this thesis 
could potentially also provide novel pharmacological mechanisms for type 2 diabetes as well 
as other forms of diabetes. 
 
Keywords: Cyclosporin A, tacrolimus, rapamycin, glucocorticoids, new onset diabetes after 
transplantation, adipocytes, insulin signalling, glucose uptake, lipolysis, lipogenesis 
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INTRODUCTION 
 
Insulin resistance and diabetes 
The term diabetes mellitus describes a metabolic disorder of multiple aetiology 
characterised by chronic hyperglycaemia, and resulting from defects in insulin secretion, 
insulin action, or both (1). Diabetes mellitus is classified on the basis of the pathogenic 
process that results on hyperglycemia or on the circumstances present at the time of 
diagnosis. There are four main types of diabetes mellitus: type 1, type 2, gestational 
diabetes and secondary diabetes. Typically type 1 diabetes results from autoimmune 
destruction of insulin-producing β-cells in the pancreas and type 2 diabetes from insulin 
resistance combined with insulin deficiency. Gestational diabetes is formally defined as 
glucose intolerance with onset or first recognition during pregnancy. The last group, so 
called secondary diabetes, includes genetic defects of β-cell function; diseases of the 
exocrine pancreas, such as pancreatitis or cystic fibrosis; other endocrinopathies (e.g., 
acromegaly); and pancreatic dysfunction and/or insulin resistance caused by drugs.  
 
Type 2 diabetes 
Type 2 diabetes is the most common form of diabetes and is caused by a combination of 
genetic and environmental factors (2). Currently, about 200 million people have type 2 
diabetes, and the prediction is that by 2030 about 400 million people worldwide will have 
type 2 diabetes (3). The high prevalence of diabetes and its complications has vast 
socioeconomic consequences. The development of type 2 diabetes is usually preceded by 
impaired insulin sensitivity in skeletal muscle, adipose tissue and liver, a metabolic 
condition called insulin resistance and commonly driven by a sedentary lifestyle and 
obesity (2). As a consequence the β-cells in the pancreas produce more insulin to 
overcome the insulin resistance in peripheral tissues. Eventually β-cells fail to produce 
enough insulin to overcome insulin resistance, leading to hyperglycaemia and 
development of type 2 diabetes. 
 
Several factors have been proposed to contribute to insulin resistance, including increased 
circulating non-esterified fatty acids, inflammatory cytokines (e.g. tumor necrosis factor 
α, TNF-α and interleukin-6, IL-6), adipokines (e.g. resistin) and defects in mitochondrial 
lipid oxidation (2). On the other hand, the β-cell dysfunction has been attributed to 
glucose toxicity, lipotoxicity and islet amyloid deposits. Moreover, genome-wide 
association studies have provided support that genetic factors are also important in 
predisposing some individuals to type 2 diabetes and insulin resistance (4), including 
polymorphisms of calpain 10 and peroxisome proliferator-activated receptor γ (PPARγ) 
(5). 
Introduction 
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Drug-induced diabetes 
It is well known that medications may cause unwanted side-effects, although designed to 
relieve symptoms and improve quality of life. There are several drugs that may induce 
diabetes (secondary diabetes) and these include glucocorticoids, other immunosuppressive 
agents (IAs), diuretics, β-blockers and antipsychotic agents (6). This can be caused by 
impaired insulin secretion from the pancreatic β-cells or by insulin resistance in peripheral 
tissues and liver, or, most commonly, by both. In many cases, the underlying mechanisms 
are not fully understood and warrant further investigation. The focus will be on IAs since 
this is most relevant in the context of this thesis. 
 
Complications of diabetes 
Although, diabetic long-term complications develop gradually, they can eventually be 
disabling or even life-threatening (7). Generally the diabetic long-term complications are 
divided into micro- (diabetic nephropathy, neuropathy and retinopathy) and 
macrovascular complications (coronary artery disease, peripheral arterial disease and 
stroke) (8). The cardiovascular mortality in type 2 diabetic patients is more than double 
compared with age-matched subjects, being the major cause of death in people with 
diabetes. 
 
Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in 
many countries. It accounts for approx 45 to 50% of cases of ESRD in the United States 
and approximately 25% of cases with ESRD in Sweden. Diabetic nephropathy is the 
aetiology of ESRD in approximately 25% of kidney transplant recipients transplanted in 
the United States and in Sweden the proportion is somewhat lower (9-11). 
 
Diabetes presents particular challenges both in the pre-transplant evaluation and after 
transplantation (12). These challenges are related to the high incidence of cardiovascular 
disease among patients with diabetes, and an increased risk of bacterial and fungal 
infections compared with transplant recipients without diabetes. In addition, glycemic 
control is often more difficult after transplantation. This is because immunosuppressive 
regimens used after transplantation have detrimental effects on both pancreatic β-cell 
function and peripheral insulin action as discussed in detail in this thesis. Therefore, IAs 
makes it difficult to achieve target glucose levels and prevent the recurrence of the 
diabetic lesions in the transplanted kidney.  
 
Combined kidney-pancreas transplantation is an established treatment for selected 
patients with type 1 diabetes and ESRD (13). Patients where the potential benefit of a 
combined transplant outweighs the increased morbidity of the surgical procedure and the 
use of lifelong immunosuppression are also considered. Combined kidney-pancreas 
transplantation, if successful, improves both patient survival and quality of life.  
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A few patients with type 1 diabetes not controlled by exogenous insulin therapy and 
without substantial renal disease may be considered as candidates for pancreas 
transplantation alone (14). An alternative to solid organ pancreas transplantation is 
transplantation of pancreatic islets. In 2009 ∼400 individuals have received allogenic 
isolated pancreatic islets with ∼40 centers world-wide actively engaged in further 
developing this therapy (15). All these modes of transplantation currently require 
treatment with life-long immunosuppressive therapy. 
 
Immunosuppressive drugs and adverse metabolic effects 
In the early/mid-1980s, the discovery and introduction of modern IAs into clinical 
practice was a major breakthrough to prevent and treat allograft rejection, resulting in an 
improved long-term patient and graft survival after solid organ transplantation (16). A 
commonly used basic immunosuppressive protocol uses a higher immunosuppressive load 
in the early post-transplant phase, commonly a calcineurin inhibitor (cyclosporin A or 
tacrolimus), glucocorticoids and an antiproliferative agent (e.g. azathioprine or 
mycophenolate mofetil). During the subsequent maintenance phase, lower levels of a 
calcineurin inhibitor or a inhibitor of the mammalian target of rapamycin (mTOR) is 
combined with the lowest dose possible of glucocorticoids and/or one of the anti-
proliferative agents. Individualized immunosuppressive protocols aim to combine the 
most effective drug combination to balance the risk of rejection against long-term adverse 
drug effects. However, even with these individualized protocols, long-term outcome of 
solid organ transplantation is hampered by the development of metabolic perturbations, 
like diabetes, dyslipidemia and hypertension (17-19). Taken together these metabolic 
complications are associated with an increased risk of non-fatal and fatal cardiovascular 
events, and other adverse outcomes including infections, malignancies, reduced patient 
and graft survival (18, 20). 
 
New-onset diabetes after transplantation (NODAT)  
Diabetes as a long-term complication after kidney transplantation was first identified in 
1964 by Starzl et al. (21). Since then, it has become clear that new onset diabetes after 
transplantation (NODAT) is a common metabolic complication, with reported incidence 
rates up to 50% during the first year after transplantation (19, 22). Most patients develop 
NODAT within the first 6 months after transplantation, although the cumulative incidence 
continues to increase also after this period (17). 
 
Similar to type 2 diabetes, both decreased insulin secretion and increased insulin 
resistance seem to be principal pathogenic components of NODAT (23, 24). Accordingly, 
adoption of current American Diabetes Association diagnostic criteria for type 2 diabetes 
was recommended for the diagnosis of NODAT (25).  
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In addition to other risk factors (Table 1), immunosuppressive therapy and obesity are 
reported to be modifiable risk factors for the development of NODAT. Montori et al 
reported that 74% of the variability of the incidence of NODAT could be explained by the 
immunosuppressive therapy (19). This may be due to the fact that different IAs can 
produce different metabolic perturbations (Table 2). 
 
 
Table 1. Non-modifiable and modifiable risk factors for new onset diabetes (NODAT). 
Non-modifiable risk factors Modifiable risk factors 
- Age > 40 years 
- Ethnicity 
- Family history of diabetes  
- Genetic susceptibility  
- HLA mismatches 
- Deceased donor 
- Acute rejection history 
- Male donor 
- Polycystic kidney  
 
- Obesity 
- Metabolic syndrome 
- Immunosuppression  
      glucocorticoids  
      cyclosporin A 
      tacrolimus 
      rapamycin 
- Hyperlipidemia 
- Pre-transplant IGT 
- Hepatitis C and cytomegalovirus infection  
HLA, human leukocyte antigen; IGT, impaired glucose tolerance. Adapted from (26). 
 
 
The association between glucocorticoid therapy and the development of diabetes was 
established in the 1960s (21). The diabetogenic effect of glucocorticoids is dose-
dependent and includes reduction in insulin synthesis and insulin sensitivity, increased 
hepatic gluconeogenesis and central obesity (27-30) (Table 2). The introduction of more 
active IAs, including the calcineurin inhibitors cyclosporin A and tacrolimus, made it 
possible to lower corticosteroid doses and thereby reduce the incidence of NODAT (31). 
Unfortunately, cyclosporin A and tacrolimus are also diabetogenic, probably due to both 
reduced insulin secretion from the pancreas and impaired insulin sensitivity in peripheral 
tissues (32-39) (Table 2). Moreover, treatment with the newer IA rapamycin also 
increases the risk for NODAT, in a similar manner (40, 41) (Table 2). 
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Table 2. Drug-induced new onset diabetes (NODAT): potential pathogenic mechanisms. 
Immunosuppressive drug Pathogenic mechanisms 
Glucocorticoids ↓ Peripheral insulin sensitivity (27)  
↓ Insulin synthesis and secretion (28) 
↑ Hepatic gluconeogenesis (29) 
↑ Central obesity (30) 
Cyclosporin A ↓ Peripheral insulin sensitivity (32-34) 
↓ β-cell mass (35) 
↓ Insulin synthesis and secretion (CsA<FK) (36) 
Tacrolimus ↓ Peripheral insulin sensitivity (37, 38) 
↓ β-cell mass (35) 
↓ Insulin synthesis and secretion (FK>CsA) (36) 
Rapamycin ↓ Peripheral insulin sensitivity (40) 
↓ Insulin synthesis and secretion (41) 
CsA, cyclosporin A; FK, tacrolimus 
 
 
Dyslipidemia  
Dyslipidemia is a well-recognized metabolic complication of immunosuppressive therapy 
with reported incidence rates of 20% to 80%, during the first year after transplantation 
(18, 42, 43). Clinical studies have shown that immunosuppressive therapy, and most 
markedly rapamycin, may increase serum levels of triacylglycerol (TAG), total 
cholesterol, low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) 
cholesterol, free-fatty acids (FFA) and apolipoprotein B, in a dose-dependent manner (44-
47).  
 
Although immunosuppressive therapy has been strongly associated with NODAT and 
dyslipidemia, its effects on glucose and lipid metabolism in human adipose tissue have 
not been studied in details previously.  
 
Adipose tissue  
Adipose tissue is mainly divided into two subtypes, white and brown fat (48). White fat is 
widely distributed and represents the primary site of lipid storage. Brown fat is relatively 
scarce and is specialized in thermogenesis, dissipating heat to maintain body temperature. 
We will focus on white adipose tissue, since it is most relevant to the context of this 
thesis. White adipose tissue is mostly composed of adipocytes, surrounded by connective 
tissue that is highly vascularised and innervated. It also contains macrophages, fibroblasts 
and adipocyte precursor cells.  
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Storage of triglycerides 
The classical view of the white adipose tissue is that it stores and delivers energy 
substrate, under the control of several regulatory factors, such as insulin, catecholamines 
and the autonomic nervous system (49). The energy stores in adipocytes are determined 
mainly by a balance between fatty acid storage as TAG and release of FFA from TAG via 
lipolysis (Figure 1). Approximately 90% of the lipids in the adipocyte is composed of 
TAG (50). 
 
In the fed state, the concurrent increase in insulin, glucose and lipid levels in blood drives 
the storage of TAG in adipocytes (49). TAG synthesis requires glycerol-3 phosphate and 
acyl-CoA as substrates (Figure 1). Glycerol-3 phosphate is derived via glycolysis from 
glucose and via glyceroneogenesis from sources other than glucose and glycerol, like 
lactate (51). Acyl-CoA is derived from uptake of FFA from the circulation and re-
utilization of FFA released from the adipocyte. The acyl-CoA is then attached to glycerol, 
via esterification or so-called re-esterification (51). FFA from circulation is provided by 
hydrolysis of TAG in VLDL particles and chylomicrons catalysed by lipoprotein lipase 
(LPL) at the luminal surface of capillary endothelial cells (52). The hydrolysed FFA are 
taken up by adipocytes via specific fatty acid transporters (CD36 and fatty-acid-binding 
protein, FABP). The intracellular FFA is then converted to acyl-CoA (53). In humans’ 
adipocytes the endogenous synthesis of acyl-CoA from glucose (known as de novo 
lipogenesis) seems to be of minor importance (54). 
 
There are two major pathways for TAG synthesis. The glycerol phosphate pathway 
includes the acylation of glycerol-3-phosphate, through a step-wise addition of acyl 
groups, catalysed by distinct enzymes (glycerol-3-phosphate acyltransferase; 1-
acylglycerol-3-phosphate acyltransferase; lipin 1) (55). The second pathway generates the 
acylation of diacylglycerol from monoacylglycerol by monoacylglycerol acyltransferase 
(MGAT) (56). These 2 pathways share the final step in converting diacylglycerol into 
TAG, which is catalysed by diacylglycerol acyltransferase (DGAT). 
 
Conversely, in the fasting state or when energy expenditure is increased for example 
during exercise, adipose tissue provides energy via hydrolysis of TAG into glycerol and 
FFA, a process known as lipolysis (Figure 1) (49). Catecholamines (e.g. epinephrine) 
stimulate lipolysis through the activation of β-adrenergic receptors, which activates 
adenylate cyclase, increasing cAMP production. A rise in cAMP activates protein kinase 
A (PKA), which leads to activation of the lipases adipose triacylglycerol lipase (ATGL), 
hormone-sensitive lipase (HSL) and monoacylglycerol lipase (57-59). This process leads 
to the breakdown of TAG into FFA and glycerol. In addition to lipases other proteins, like 
perilipin, are important for lipolysis (58). Perilipin is a lipid-droplet coating protein that 
acts as a barrier to lipases, thereby maintaining a low rate of basal lipolysis. 
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Insulin is a powerful anti-lipolytic hormone in adipose tissue. Insulin inhibits lipolysis by 
activation of phosphodiesterase 3B, which degrades cAMP, thus reducing PKA and 
subsequently HSL activity (Figure 1) (60). Additional, circulation factors, such as, 
glucocorticoids, TNF-α, IL-6 and adiponectin, can also regulate lipolysis. Disturbances in 
the pathways regulating the storage and release of energy by adipose tissue may lead to a 
reduced capacity of adipocytes to keep lipids from the circulation and other tissues. Fatty 
acids may become elevated in the circulation and TAG may accumulate in pancreas, liver, 
muscle and heart (61). This so-called ectopic fat deposition may seriously affect the 
function of these organs and contribute to the pathogenesis of obesity-related conditions 
such as insulin resistance, diabetes and cardiovascular diseases.  
 
 
 
Figure 1 - Overview of the lipid storage and lipolysis in adipocytes. Adapted from (50, 
55). Free-fatty acids (FFA); Lipoprotein lipase (LPL); fatty acid binding protein 4 
(FABP4/aP2); acyl-CoA synthase (ACS); acetyl-CoA carboxylase (ACC); Fatty acid 
synthase (FAS); diacylglycerol (DAG); diacylglycerol acyltransferase (DGAT); 
triacylglycerol (TAG); diacylglycerol (DG); monoacylglycerol (MG); adipose 
triacylglycerol lipase (ATGL); hormone-sensitive lipase (HSL); monoacylglycerol lipase 
(MGL); β adrenergic receptor (β-AR); adenylate cyclase (AC); protein kinase A (PKA).    
Introduction 
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Adipose tissue as an endocrine organ 
In addition to its role as storage for TAG, adipose tissue is also well known to secrete a 
variety of bioactive peptides, collectively called adipokines (62). Adipokines act at both 
locally (autocrine/paracrine) and systemically (endocrine) levels and may profoundly 
influence glucose and lipid metabolism. Increased levels of IL-6 and TNF-α, have been 
proposed to contribute to insulin resistance and dyslipidemia, while adiponectin is an 
insulin sensitising adipokine (62). 
 
Adipose tissue distribution and metabolic disease 
The main white adipose tissue depots are located subcutaneously and intra abdominally, 
respectively (48). Subcutaneous adipose tissue is located beneath the skin and can be 
divided into deep and superficial adipose tissue. Intra abdominal adipose tissue is 
composed of the retroperitoneal and the visceral depot, which is located inside the 
peritoneal cavity, and includes the omental and the mesenteric fat. 
 
Central obesity, in particular visceral obesity, has been associated with a cluster of 
metabolic alterations, which include insulin resistance, components of the metabolic 
syndrome and increased risk of cardiovascular disease (63-65). The physiological basis 
for these associations may be the anatomical location of the visceral depot in relation to 
other organs and differences in function and response to regulating signals. Unlike 
subcutaneous adipose tissue, visceral fat tissue is drained into the portal vein, which has 
direct contact with the liver (66). Therefore, it can affect hepatic glucose and lipid 
metabolism directly. Genetic susceptibility combined with environmental factors have 
major influence on adipose tissue distribution (67). Several endocrine hormones, like 
growth hormone, sex steroids and cortisol, play fundamental roles in regulating body fat 
distribution (67).  
 
Body mass index (BMI) is the most commonly used index of body composition in clinical 
practice (68). In adults, a BMI between 18.5 and 24.9 kg/m2 corresponds to normal, BMI 
between 25.0 and 29.9 kg/m2 to overweight, and BMI of ≥30.0 kg/m2 is defined as 
obesity. As described above, the common complications of obesity, such as insulin 
resistance, type 2 diabetes and cardiovascular disease, are more closely related to the 
distribution of body fat than to the absolute amount of adiposity (63-65). As simple 
measures, the waist-hip ratio and sagittal abdominal diameter, are often used and reflect 
the degree of abdominal obesity. Other methods to assess fat distribution include 
bioelectrical impedance analysis (69), computed tomography and magnetic resonance 
imaging (68). These last two imaging methods have the advantage of being able to 
distinguish subcutaneous adipose tissue from visceral adipose tissue, but they are also 
more expensive and technically complex. 
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Obesity is associated with a chronic inflammatory response characterised by abnormal 
adipokine and cytokine production, and the activation of pro-inflammatory signalling 
pathways (70). However, the precise physiological events leading to the initiation of the 
inflammatory response and its potential metabolic consequences are not yet completely 
understood. It is believed that during expansion of adipose tissue, adipocyte hypertrophy 
and hyperplasia may lead to cell hypoxia and activation of cellular stress pathways (71). 
This may cause adipose tissue inflammation and release of cytokines and other pro-
inflammatory signals. Cytokines, such as TNF-α and IL-6 produced by adipose tissue, can 
also promote inflammation and insulin resistance. As a part of the chronic inflammatory 
process, locally secreted chemokines attract pro-inflammatory macrophages, which in 
turn also release cytokines and further activate the inflammatory program in adipocytes 
(72). 
 
Insulin action in adipose tissue 
Insulin is a pleiotropic hormone which has diverse anabolic and anti-catabolic functions 
in adipose tissue (73). This includes stimulation of glucose uptake, inhibition of lipolysis 
and stimulation of de novo fatty acid synthesis in adipocytes. Insulin also stimulates gene 
expression of several adipokines and transcription factors, which are important for 
adipose tissue growth and differentiation, including SREBP1c and PPARγ (74, 75).  
 
The major insulin signalling (phosphoinositide 3-kinase (PI3K) dependent) is 
schematically depicted in Figure 2. Insulin signalling is initiated by the binding of insulin 
to the extracellular α-subunit of the insulin receptor (IR) on the cell surface, resulting in 
the autophosphorylation of a number of residues in the transmembrane β-subunits (76). 
The active tyrosine kinase phosphorylates insulin receptor substrate (IRS) proteins. The 
IRS proteins function as docking proteins for other signalling proteins containing Src 
homology 2 domains. IRS1 and IRS2 are best characterised, and are the main docking 
proteins for the binding of the p85 regulatory subunit of PI3K, which leads to the 
activation of the catalytic subunit p110 (77). PI3K mediates many of the intracellular 
effects of insulin, including threonine phosphorylation of PKB and its activation (73). 
Serine phosphorylation of PKB by the mTOR complex 2 (mTORC2) (78) is also 
necessary for the full activation of PKB. Moreover, PKB activates AS160 (PKB substrate 
of 160 kDa) that quickly increases glucose transport by increasing the rate of glucose 
transporter (GLUT) 4-vesicle exocytosis and slightly decreases the rate of internalization 
(79). GLUT1 is another glucose transporter present in adipose tissue. GLUT1 is less 
abundant than GLUT4 and it has been proposed to act as a constitutive transport protein 
(80). In the basal state, GLUT4 continuously recycles between the plasma membrane and 
intracellular compartment, with only about 3-10% of the total GLUT4 protein pool 
localized at the cell surface (81). However, in response to insulin stimulation, up to ~50% 
Introduction 
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of GLUT4 is rapidly (within 5-10 min) translocated to the cell surface, thus increasing 
transmembrane glucose transport. 
 
Activation of the described PI3K/PKB pathway is thought to mediate many of the 
metabolic effects of insulin. Besides glucose transport, it inhibits lipolysis and it promotes 
mTOR signalling and expression of adipokines and transcription factors. In addition to the 
PI3K pathway, there are however alternative pathways. Thus, activation of the CAP-Cbl-
TC10 signalling pathway has been suggested to play an important role for insulin-
stimulated GLUT4 translocation and glucose uptake (73). Moreover, insulin can also 
stimulate the mitogen-activated protein kinase (MAPK) cascade initiating a 
transcriptional programme that is involved in cellular proliferation and differentiation.   
 
 
 
Figure 2 – Overview of the insulin signalling pathway. Adapted from (73).  
Insulin receptor (IR); insulin receptor substrate 1, 2 (IRS1, IRS2), phosphoinositide 3-
kinase (PI3K), phosphatidylinositol (4,5)-biphosphate (PIP2), phosphatidylinositol 
(3,4,5)-triphosphate (PIP3), phosphoinositide-dependent kinase 1 (PDK1), protein kinase 
B (PKB), PKB substrate of 160 kDa (AS160) and glucose transporter 4 (GLUT4).  
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Glucocorticoids 
Glucocorticoids are steroid hormones produced in the adrenal cortex under the control of 
the hypothalamic-pituitary-adrenal axis (82). The main glucocorticoid in humans is 
cortisol. The name glucocorticoid (glucose + cortex + steroid) is derived from the role in 
the regulation of the metabolism of glucose, synthesis in the adrenal cortex and steroidal 
structure. Various synthetic glucocorticoids are available, e.g. prednisone, prednisolone 
and dexamethasone (83). These are used to treat diseases caused by an overactive immune 
system, such as inflammatory diseases and autoimmune diseases or to prevent organ 
rejection after transplantation. 
 
Glucocorticoids induce their anti-inflammatory and immunosuppressive effects mainly 
through regulation of gene transcription (84) (Figure 3, pathway A). Glucocorticoids 
diffuse passively into the cells through the plasma membrane due to their lipophilic 
structure and form a complex with the glucocorticoid receptor. The glucocorticoid 
receptor is a multi-protein complex containing co-factors; heat-shock proteins (Hsp, such 
as Hsp70 and Hsp90) and immunophilins (such as 51 kDa FK506-binding protein, 
FKBP51) (85). Upon glucocorticoid binding the complex translocates to its site of action 
in the nucleus. It suppresses the transcription of inflammatory and immune genes (e.g. IL-
2) and induces transcription of anti-inflammatory genes (e.g. annexin 1) (84). 
 
 
 Figure 3 – Pathways for inhibition of the immune system by immunosuppressive drugs 
(84, 86). (A) Glucocorticoids; (B) calcineurin inhibitors cyclosporin A and tacrolimus; 
and (C) mTOR inhibitor rapamycin. Glucocorticoid receptor (GR); FK506-binding 
protein (FKBP); interleukin-2 (IL-2); mammalian target of rapamycin (mTOR).  
Introduction 
20 
 
It is well known that glucocorticoids also produce many serious side-effects that limit 
their use, including high blood glucose levels, central obesity, depression and anxiety (27, 
30), but the metabolic side-effects are the ones most relevant to the context of this thesis.  
 
Cortisol, is a powerful insulin-antagonistic hormone (29) that regulates a variety of 
important metabolic functions and may promote the development of insulin resistance, 
hyperglycaemia and features of the metabolic syndrome (82). Cortisol opposes the effects 
of insulin, including impaired insulin-dependent glucose uptake in peripheral tissues, 
enhanced gluconeogenesis in liver and impaired insulin secretion from pancreatic β-cells 
(28, 29). The effects of glucocorticoids is exemplified in clinical syndromes of excess 
(Cushing’s syndrome) or during prolonged corticosteroid therapy (87, 88). Cortisol excess 
is characterised by central obesity and other components of the metabolic syndrome, such 
as glucose intolerance and hypertension. Central obesity, in particular visceral adiposity, 
is associated with insulin resistance, cardiovascular disease and the metabolic syndrome, 
as previously reported (64). Consequently, it is of interest to further explore the response 
of adipose tissue to cortisol. 
 
Glucocorticoids cause sex- and depot-specific regulation of processes and/or gene 
expression. For example, glucocorticoids stimulate adipose tissue lipoprotein lipase 
production and activity, predominantly in visceral fat tissue, particularly in men (89, 90), 
possibly contributing to central obesity. In contrast, glucocorticoids in subcutaneous 
adipose tissue stimulate lipolysis, particularly in women (91), resulting in reduced lipid 
storage and increased release of fatty acids to the circulation. This may partly explain the 
excess of visceral obesity observed in conditions with elevated levels of cortisol. 
Furthermore, the capacity of glucocorticoids to impair glucose uptake appears to be more 
prominent in the visceral compared to the subcutaneous fat depot (92). Accordingly, 
dexamethasone has been demonstrated to down regulate critical signalling proteins in the 
visceral fat depot, e.g. IRS1 and PKB (92, 93). However, the molecular mechanisms for 
the underlying differential regulation of subcutaneous and visceral adipose tissue by 
glucocorticoids are still unknown. 
 
Recently, key metabolic pathways regulated by dexamethasone treatment were identified 
by microarray analysis in human subcutaneous and omental adipose tissue from severely 
obese individuals (94) and in human skeletal muscle (95). In these studies, 
dexamethasone increases gene networks that promote carbohydrate and amino acid 
catabolism and lipid deposition, while genes related to inflammatory pathways were 
suppressed. Identification of biomarkers and new pharmacological targets would be 
valuable in the prevention and treatment of glucocorticoid-induced metabolic 
dysregulation and could potentially also be of relevance for other metabolic conditions. 
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The calcineurin inhibitors, cyclosporin A and tacrolimus 
The introduction of calcineurin inhibitors has significantly improved the outcome of 
transplantation and autoimmune diseases (96). In addition to the expected beneficial 
action on the immune system, calcineurin inhibitors are associated with long-term side-
effects. These include dose-dependent renal and hepatic toxicity and metabolic effects 
important for the patient’s long-term outcome. Cyclosporin A and tacrolimus are the 
calcineurin inhibitors currently used in the clinic. 
 
Cyclosporin A is a lipid-soluble cyclic undecapeptide produced by Tolypocladium 
inflatum, a fungus first isolated in 1970, from a soil sample collected in Norway (97). 
Since its clinical introduction in 1983, cyclosporin A has become the first line treatment 
for prevention of rejection of transplanted organs and for certain autoimmune diseases. 
Tacrolimus (also known as FK506) is a lipid-soluble macrocyclic lactone, first isolated in 
1987, from the soil fungus Streptomyces tsukubaensis, in the Tsukuba region of northern 
Japan.  
 
Cyclosporin A and tacrolimus mediate its immunosuppressive actions by blocking the 
expression of the IL-2 gene in activated T-lymphocytes, a growth factor critical for T-cell 
proliferation (98) (Figure 3, pathway B). Although they are structurally related, upon 
entering the T-cell cytoplasm they bind distinct intracellular receptors referred to as 
immunophilins; cyclophilin for cyclosporin A and FK506-binding protein (FKBP) for 
tacrolimus (99). The drug-immunophilin complexes bind to and inhibit the activity of 
calcineurin, a calcium dependent serine/threonine phosphatase required for early T-cell 
activation (99, 100). Furthermore, by preventing the calcineurin-mediated 
dephosphorylation of the transcription nuclear factor of activated T-cells (NFAT), 
cyclosporin A and tacrolimus block the translocation of the NFAT from the cytoplasm to 
the nucleus (100). NFAT is involved in the transcription activation of genes for cytokines 
such as IL-2. In all parameters of T-cell inhibition, tacrolimus appears to be 10-100 fold 
more active than cyclosporin A. Moreover, tacrolimus is more potent and the clinical 
therapeutic plasma concentration is lower than for cyclosporin A, 6-20 nM and 40-120 
nM, respectively (101, 102). 
 
Effects of calcineurin inhibitors on glucose and lipid metabolism 
Both in vitro and biopsy studies in man and animals indicate that calcineurin inhibitors 
inhibit insulin production and secretion from the β-cells of the islets of Langerhans in a 
dose dependent manner (35, 36, 103). This effect is mediated through cell death, impaired 
insulin production, and/or diminished insulin secretion. Clinical studies have mainly 
confirmed these pre-clinical results (23, 104, 105). However, a recent study with healthy 
human volunteers treated during 5 h with clinically relevant doses of cyclosporin A and 
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tacrolimus, reported that both drugs acutely increased insulin sensitivity, while the first 
phase and pulsatile insulin secretion remained unaffected (106). These contradictory 
results may be explained by the fact, that a younger and healthier population were 
exposed short-term to the effect of calcineurin inhibitors, whereas previous studies 
usually include longer exposures and older populations. The divergent results also 
highlight the complexity of these drugs and suggest that their diabetogenicity may be 
time, dose and situation dependent. 
 
Furthermore, studies in both human and mice/rodents have indicated that calcineurin 
inhibitors are associated with reduced insulin sensitivity in peripheral tissues, as well as, 
impaired endothelial function (23, 32-34). In humans, the simultaneous use of 
glucocorticoids has made it difficult to define the underlying mechanism of the 
calcineurin inhibitors in insulin resistance, since glucocorticoids per se, are associated 
with increased insulin resistance (107). Direct effects of cyclosporin A and tacrolimus on 
human adipocytes have never been studied previously and such results are now reported 
in the present thesis. 
 
The calcineurin inhibitors, cyclosporin A and tacrolimus, also increase serum levels of 
cholesterol, TAG, LDL and VLDL, in a dose-dependent manner (44-47). In addition, 
cyclosporin A and tacrolimus increase LDL oxidation and fatty acid content in LDL 
(108). Although, calcineurin inhibitor therapy has been associated with reduced LPL 
(109) and hepatic triglyceride lipase (110) activity, little is known about the effects of 
calcineurin inhibitors on adipocyte lipid metabolism and on adipose tissue expression of 
genes involved in regulation of lipid metabolism. 
 
Several randomised clinical trials and meta-analyses, have suggested that tacrolimus has a 
more diabetogenic profile than cyclosporin A (96, 111-113), although in other reports the 
differences between the two agents were not significant (114, 115). In contrast, 
cyclosporin A has been associated with greater adverse effects on the patient’s lipid 
profile (44, 108, 111). 
 
The mTOR inhibitor rapamycin 
Rapamycin (also known as sirolimus) is a lipophilic macrocyclic lactone, produced by the 
bacterium Streptomyces hygroscopicus, which was isolated in 1970 on the Easter Island 
Rapa Nui, and from here the name rapamycin is derived (116). Rapamycin was developed 
initially as an antifungal agent, but was abandoned because of its immunosuppressive 
effect. In the early 1990s rapamycin-related research renewed the clinical interest, and in 
1997 rapamycin was approved as an IA in kidney transplantation. For the time being the 
role of rapamycin in transplant immunosuppression remains undecided (117). The 
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prevailing belief is that the calcineurin inhibitors, mycophenolate mofetil and 
glucocorticoids should be standard therapy in renal transplantation both in terms of 
tolerability and outcomes. In addition, rapamycin displays a wide range of organ and 
tissue toxicity owing to the critical role of its site of action (the mTOR) in the signal 
transduction pathways of numerous cytokines, growth factors, hormones and nutrients. 
 
Rapamycin is structurally similar to tacrolimus, and it binds the same FKBP 
immunophilin species (Figure 3, pathway C) (118). However, the resulting complex does 
not affect calcineurin activity, and therefore it does not block the calcineurin-dependent 
activation of cytokine genes (118). Instead, rapamycin renders the T-cells unresponsive to 
IL-2. The molecular target of the rapamycin-FKBP complex in T-cells is mTOR. mTOR 
controls proteins that regulate mRNA translation initiation and progression from the G1 to 
the S phase of the cell cycle, and thus its suppression inhibits T-cells proliferation (119). 
The therapeutic concentration in plasma for rapamycin is 10 to 26 nM (120). 
 
mTOR signalling 
mTOR is a conserved serine-threonine kinase that controls protein synthesis, cell survival 
and proliferation (121). mTOR is a large protein (289 kDa) that belongs to the 
phosphatidylinositol kinase-related kinase family and is detected in nearly all eukaryotic 
organisms and cell types (122). mTOR forms two physically and functionally distinct 
multi-protein complexes, the mTOR complex 1 (mTORC1) and 2 (mTORC2). Several 
components of mTORC1 and mTORC2 have been identified. Raptor is a unique 
component of mTORC1, while rictor and stress-activated map kinase-interacting protein 1 
(Sin1) are unique components of mTORC2. mTOR signalling is regulated by growth 
factors, insulin, nutrients (e.g. amino-acids), stress, oxygen and energy status. The mTOR 
signalling pathway is shown in Figure 4.  
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Figure 4 – Overview of the mTOR signalling pathway. Adapted from (122). 
Insulin receptor (IR); insulin receptor substrate 1 and 2 (IRS1, IRS2), phosphoinositide 3-
kinase (PI3K), phosphatidylinositol (4,5)-biphosphate (PIP2), phosphatidylinositol 
(3,4,5)-triphosphate (PIP3), phosphoinositide-dependent kinase 1 (PDK1), protein kinase 
B (PKB), PKB substrate of 160 kDa (AS160), glucose transporter 4 (GLUT4) tuberous 
sclerosis proteins 1 and 2 (TSC1, TSC2), mammalian target of rapamycin complex 1 and 
2 (mTORC1, mTORC2), serum- and glucocorticoid-induced protein kinase 1 (SGK1), 
protein kinase C α (PKCα), p70 ribosomal S6 kinase (p70S6K), 4E binding proteins 1 
(4B-BP1), 5’-AMP-activated protein kinase (AMPK), stress-activated map kinase-
interacting protein 1 (Sin1). 
 
 
The mTOR pathway responds to growth factors through the PI3K-PKB pathway. mTOR 
and PI3K signalling are connected through the tuberous sclerosis proteins (TSC) 1 and 2. 
TSC1 and TSC2 compose a heterodimer that negatively regulates mTORC1 (123). 
Nutrients, especially amino acids, also activate mTORC1 and 2 independently of the 
TSC1/2 complex (124), but the exact mechanism is not yet identified. In addition 
mTORC1 mediates protein synthesis, and consequently requires higher level of cellular 
energy. mTORC1 detects the cellular energy level ratio by the 5’-AMP-activated protein 
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kinase (AMPK) (125). Upon activation, mTORC1 regulates protein synthesis and 
transcription of many genes involved in glucose and lipid metabolism by activation of p70 
ribosomal S6 kinase (p70S6K) and 4E binding proteins 1 (126). The phosphorylation of 
p70S6K and 4E binding proteins 1 are standard markers of mTORC1 activity. 
 
A crucial element of mTORC1 signalling is its inhibitory feedback loop on insulin-
induced glucose uptake through inhibitory phosphorylation of IRS1 on multiple serine 
residues (127). Phosphorylation of IRS1 on serine residues interferes with PI3K/PKB 
pathway, inhibiting insulin action on glucose uptake (128). mTORC1 is also thought to 
modulate protein synthesis through stimulation and transcription of ribosomal RNA and 
ribosomal biogenesis (129) and to play a role in mitochondrial biosynthesis and 
autophagy (130). 
 
On the other hand, mTORC2 regulates cell proliferation and survival, metabolism and 
actin organization (122). mTORC2 promote serine phosphorylation of PKB, which is 
required for its maximal activation (78). Often, mTORC2 activation is determined by 
measuring the serine phosphorylation of PKB.  
 
Rapamycin is known to be an mTORC1 inhibitor (131). However, it has been proposed, 
that prolonged rapamycin treatment of 3T3-L1 adipocytes and other cell types, can also 
disrupt the mTORC2 complex and thereby decrease serine phosphorylation of PKB (132). 
 
Effects of mTOR signalling in adipose tissue: adipogenesis and lipid storage  
mTORC1 is essential for differentiation and maintenance of adipocytes by regulating 
transcription factors critical for the early commitment of embryonic stem cells to 
adipogenic progenitors (133). It also regulates the transcription of factors for terminal 
differentiation, including the master regulators PPARγ and SREBP1 (134, 135). In 
addition, mTORC1 activates lipin 1 (136). Lipin 1 is involved in diacylglycerol synthesis 
and also a coactivator of transcription factors involved in lipid metabolism, including 
PPARγ and SREBP1.  
 
Effects of rapamycin on glucose and lipid metabolism  
The diabetogenic effect of rapamycin is well-documented. Clinical studies have 
demonstrated that treatment with rapamycin alone or in combination with calcineurin 
inhibitors (137, 138) is associated with insulin resistance, higher incidence of NODAT 
and dyslipidemia. 
 
However, the observed in vitro effects of rapamycin on glucose metabolism are 
conflicting and its mechanisms of actions have not yet been clarified. In fact, some in 
vitro studies have shown that rapamycin relieves the mTORC1 repression of IRS-
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1/PI3K/PKB signalling, leading to enhanced insulin stimulated glucose uptake in different 
cell types, including in L6 cells, 3T3-L1 cells and differentiated human adipocytes (128, 
139, 140). In contrast, other studies have suggested that long-term treatment of 3T3-L1 
adipocytes (141, 142) and L6 cells (143) with rapamycin reduce their insulin dependent 
glucose uptake capacity. The reason for the differences between these studies is not clear 
but different cell lines, drug concentrations and/or experimental conditions may partially 
explain the differences found. 
 
Rapamycin increases serum levels of total, LDL and VLDL cholesterol, TAG, and FFA 
(46, 47). Consistent with its effects in humans, chronic rapamycin treatment in rats causes 
hyperlipidemia and inhibits adipogenesis (144, 145). In addition, these studies show that 
mTOR inhibition with rapamycin impairs lipid deposition in adipose tissue by inhibiting 
the PPARγ activation and expression of downstream target genes involved in lipid 
storage. In addition to effects on lipogenic pathways, in vitro studies have also shown that 
rapamycin stimulates lipolysis via ATGL expression (146) and phosphorylation of HSL 
(147) in 3T3-L1 cells.  
 
Since rapamycin can affect the activity of both mTORC1 and mTORC2, several studies 
have been performed to determine which of the complexes that is involved in the effects 
of rapamycin on the dysregulation of lipid metabolism. Mice lacking the mTORC1 
substrate, p70S6K, as well as mice with adipose-specific knockout of raptor, an mTORC1 
essential component, are lean and are prevented from diet-induced obesity and 
dyslipidemia (146, 148-150). On the other hand, mice with fat cell ablation of rictor, a 
mTORC2 essential component, have normal adipose tissue mass, are unable to suppress 
lipolysis in response to insulin, and have elevated circulating FFA and glycerol (151). 
Thus both mTORC1 and mTORC2 in fat cells seems to have an important role in whole-
body energy homeostasis and inhibition with rapamycin can disrupt lipid homeostasis. 
 
Although the effects of mTOR inhibition with rapamycin on adipocyte lipid metabolism 
have been investigated before, particularly in rodents and in vitro in 3T3-L1 cells, to our 
knowledge, the effects of rapamycin on human adipocytes have not been studied so far.  
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AIMS 
 
The overall aim was to study the effects of immunosuppressive agents on human adipose 
tissue glucose and lipid metabolism. These studies could contribute to increase our 
understanding of the molecular mechanism for the metabolic adverse effects of such 
drugs.  
  
The specific aims were to: 
 
Investigate the direct effects of the mTOR inhibitor rapamycin on glucose uptake in 
human subcutaneous and omental adipocytes, and to characterise its interaction with the 
insulin signalling pathway (Paper I). 
 
Investigate the effects of the calcineurin inhibitors, cyclosporin A and tacrolimus, on 
glucose uptake in human adipocytes and their impact on insulin action and on the glucose 
transport machinery (Paper II). 
 
Explore the effects of rapamycin, cyclosporin A and tacrolimus on lipolysis, lipid storage 
and expression of genes involved in lipid metabolism in human subcutaneous and omental 
adipocytes and adipose tissue (Paper III). 
 
Study the effects of dexamethasone on gene expression in human subcutaneous and 
omental adipose tissues, aiming to identify novel mechanisms explaining glucocorticoid-
induced insulin resistance (Paper IV). 
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METHODS 
 
Detailed description of material and methods is given in each individual paper.  
 
Subjects and samples 
Subjects were recruited via advertisement or before elective abdominal surgery, mainly 
kidney donation. Subjects with diabetes, endocrine disorders and cancer or other major 
illnesses, as well as ongoing medication with systemic glucocorticoids and immune-
modulating therapies were excluded from the studies. Anthropometric measurements 
including body composition assessed by bioimpedance were obtained in all subjects (69). 
Subjects were fasted overnight (>10 h) and venous blood samples were collected for 
analysis of glucose, insulin and lipids by routine methods at the Department of Clinical 
Chemistry, Sahlgrenska University Hospital. A more detailed description of adipose 
tissue donors is found in Papers I-IV. The studies were approved by the Regional Ethics 
Review Board in Gothenburg. All participants gave their written informed consent. Due 
to limited amount of tissue, not all experiments were performed in the adipose sample 
from each subject. The clinical characteristics of adipose tissue donors and samples used 
in Papers I-IV are shown in Table 3. 
 
Table 3 – Clinical characteristics of adipose tissue donors and samples in Papers I-IV.  
 Paper I Paper II Paper III Paper IV 
Male/Female (n)  25M/39F 19M/25F 26M/34F 10M/15F 
Age (years) 23-72 23-70 18-72 28-60 
BMI (kg/m2) 21-37 20-36 21-36 21-31 
Fat mass (%) 14-45 18-49 14-49 13-39 
Incubations Rapamycin CsA/FK CsA/FK/Rap Dexamethasone 
     
Adipocytes      
    Subcutaneous Glucose uptake 
Insulin signalling  
Glucose uptake 
Insulin signalling  
Lipolysis  
Lipid storage 
Lipolytic proteins  
Glucose uptake 
    Omental  Glucose uptake Glucose uptake - Glucose uptake 
     
Adipose tissue     
    Subcutaneous IRS1/2 (PCR) - Lipogenic genes 
and proteins 
(PCR, WB) 
Gene expression 
(Microarray and 
PCR) and WB 
    Omental - - Lipogenic genes 
and proteins 
(PCR, WB) 
Gene expression 
(Microarray and 
PCR) and WB 
CsA, cyclosporin A; FK, tacrolimus; Rap, rapamycin; PCR, real-time polymerase chain reaction; 
WB, western blot 
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Subcutaneous adipose tissue biopsies were obtained by needle aspiration from the lower 
part of the abdomen after local dermal anaesthesia with lidocaine. Alternatively, 
subcutaneous and omental biopsies were obtained during elective abdominal surgery, 
after induction of general anaesthesia. Biopsies were transferred to the laboratory for 
immediate processing and biopsies obtained from surgery were cut into smaller pieces 
(approximately 1-2 mm3). 
 
Adipocyte isolation and fat cell size 
Adipocytes were isolated from adipose tissue (Paper I-IV) according to methods 
previously reported (152). Briefly, adipose tissue was digested with collagenase type II 
(from Clostridium histolyticum) in Hank’s medium supplemented with 6 mM glucose, 4% 
BSA, 0.15 µM adenosine, pH 7.4, in a gently shaking water-bath at 37ºC for 60 min. 
Isolated adipocytes were filtered through a 250 µm nylon mesh and were washed four 
times and suspended in Hank’s medium. The first media collected from the isolated 
adipocytes contains the stromal vascular fraction, and was used for culture and 
differentiation of the pre-adipocytes (Paper II).  
 
The average cell diameter was measured in subcutaneous and omental adipocytes isolated 
from all subjects (Paper I-IV), as previously reported (153) and is described in Paper I. 
 
Adipocyte and adipose tissue incubation 
In Paper I and II, isolated subcutaneous and omental adipocytes were pre-incubated for 
short- (15 min and/or 3h) or long-term (20 h) with either rapamycin (0.001–10 µM), 
cyclosporin A (0.001–1 µM) or tacrolimus (0.001–1 µM) to study effects on glucose 
uptake and on relevant proteins of the insulin signalling pathway. For short-term 
incubations, adipocytes were diluted to a lipocrit of 5% in Hank’s medium (4% bovine 
serum albumin, 0.15 µM adenosine and pH 7.4) without glucose, while for long-term 
incubations adipocytes were placed in polystyrene flasks containing DMEM (6 mM 
glucose, 10% foetal bovine serum, 1% penicillin-streptomycin) at 37ºC, 5% CO2 with 
gentle rotation (~30 rpm) in a culture chamber.  
 
In Paper III, subcutaneous adipocytes were incubated with or without rapamycin (0.01 
µM), cyclosporin A (0.1 µM) or tacrolimus (0.1 µM) in a gently shaking water bath at 
37ºC for 2 h, to study the effects of the IAs on lipolysis and lipid storage. In addition, to 
study the effects of the IAs on lipolytic proteins, subcutaneous adipocytes were pre-
incubated for 15 minutes, with or without rapamycin (0.01 µM), cyclosporin A (0.1 µM) 
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or tacrolimus (0.1 µM) in a shaking water-bath at 37ºC, before isoproterenol (1 µM) was 
added for an additional 60 min.   
 
Abdominal subcutaneous and omental adipose tissue was incubated in DMEM (6 mM 
glucose, 10% foetal bovine serum and 1% penicillin-streptomycin) with or without 
rapamycin (0.01 µM, Paper I and III), cyclosporin A (0.1 µM, Paper III) or tacrolimus 
(0.1 µM, Paper III) for 20 h and dexamethasone (0.003-3 µM, Paper IV) for 24 h at 37ºC 
and 5% CO2. Adipose tissue was thereafter snap-frozen for gene expression studies 
(Paper I, III and IV) and protein (Paper III and IV) analysis, or treated with collagenase 
for adipocyte isolation and glucose uptake studies (Paper IV). Incubation medium was 
used to measure adiponectin and IL-6 released in the medium (Paper III). Simplified 
schematic figure on adipose tissue and adipocytes sample experiments is shown in Figure 
5. 
 
 
Figure 5 – Simplified schematic figure on adipose tissue and adipocytes sample 
experiments. SC, subcutaneous; OM, omental; Short-term incubation: 15 min - 3 h; Long-
term incubation: 20 h - 24 h. 
 
Glucose uptake assay 
Glucose uptake in subcutaneous and omental adipocytes was assessed according to a 
previously reported technique (154) and is described in Paper I. Briefly, following short-
term incubation (15 min) at 37ºC with either rapamycin, cyclosporin A or tacrolimus 
(Paper I-II) in glucose-free medium, adipocytes were incubated for a further 15 min with 
or without human insulin (6 nM). Then D-[U-14C] glucose was added and the incubation 
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continued for another 45 min. The cells were then separated from the medium by 
centrifugation through silicone oil and the cell-associated radioactivity was determined by 
scintillation counting. Under these experimental conditions, glucose uptake is mainly 
determined by the rate of transmembrane glucose transport (155) and calculated according 
to the following formula: cellular clearance of medium glucose = (cell-associated 
radioactivity ×  volume)/(radioactivity of medium ×  cell number ×  time) (154). 
 
After long-term incubation (20 h) with either rapamycin, cyclosporin A or tacrolimus 
(Paper I and II) in a glucose containing medium, the cells were washed and diluted in a 
glucose-free medium and glucose uptake was assessed as described above. After 
incubation of adipose tissue with or without dexamethasone (Paper IV), adipocytes were 
isolated and glucose uptake was performed as described above.  
 
Protein extraction and immunoblotting 
After the indicated pre-incubations (Paper I-III), adipocytes were stimulated with or 
without a maximal insulin concentration (6 nM) for an additional 15 min. Thereafter, the 
cells were lysed in ice-cold buffer at 4ºC during 2 h and the insoluble substances were 
sedimented through centrifugation. The protein content of adipocytes lysate was measured 
with the bicinchoninic acid protein assay kit and stored at -80ºC. 
 
To obtain adipose tissue lysates (Paper III and IV), adipose tissue was homogenized in 
lysis buffer using a Tissue Lyser. Thereafter the protocol continues as previously 
described for adipocyte lysates. 
 
Immunoblotting (Paper I-IV) was performed as described in Paper I. Briefly, equal 
amount of protein from each sample were loaded in polyacrylamide gels and proteins 
were separated according to their electrophoretic mobility using SDS-PAGE. The proteins 
were then transferred to a nitrocellulose membrane and detection of the proteins of 
interest was done with the respective primary antibodies, followed by the corresponding 
secondary antibody linked to horseradish peroxidase. Detection of the proteins was made 
with a chemiluminescence reagent and visualized using Chemidoc XRS detection system 
or on high performance chemiluminescence film.  
For mTOR and IRS1 immunoprecipitation (Paper I), the primary antibodies were coupled 
with protein G-coupled Dynabeads, as suggested by the manufacturer. Thereafter, 0.5 mg 
of cell lysates were incubated overnight at 4ºC with 1 µg of antibody coupled with G-
coupled Dynabeads. Samples were subjected to SDS-PAGE and continued, as previously 
reported, for immunoblotting. 
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Gene expression 
RNA from subcutaneous and omental adipose tissue (Paper I, III and IV) was extracted 
according to the manufacturer’s instructions using the Qiagen Lipid Tissue Kit. The 
extracted RNA was quantified at 260 nm in a spectrophotometer and cDNA was 
synthesized with the Applied Biosystems High Capacity cDNA Reverse Transcriptase kit. 
 
Microarray 
Microarrays provide a powerful research tool for determination of thousands of genes 
(transcripts) in a single experiment. It allows visualization of which genes are expressed 
in a particular tissue under a particular set of conditions, and that can be used to test, as 
well as, generate new hypothesis. 
Microarray analysis was performed as described in Paper IV. Briefly, we used the Human 
Exon 1.0 ST Array from Affymetrix that allows monitoring of over 28,000 gene 
transcripts in the human genome. For gene expression analysis of human adipose tissues 
that was incubated either with or without dexamethasone (Paper IV), total RNA was 
extracted, amplified and used to generate sense-strand cDNA synthesis. The sense-strand 
cDNA was fragmented and biotin-labelled before hybridization with the microarray. After 
scanning, the microarray results were analysed with Array Studio Microanalysis 
Software. To compare the effects of dexamethasone treatment on subcutaneous and 
omental adipose tissue the statistical general linear model was used. 
 
Real-time PCR  
Real-time polymerase chain reaction (real-time PCR) is one of the most sensitive 
techniques to verify DNA microarray results and further explore the expression of genes 
of interest. Real-time PCR was performed as described in Paper I, III and IV.  
We used the ABI Prism 7900 HT Sequencing Detection System that takes advantage of 
the 5’ nuclease activity of Taq DNA polymerase to generate a fluorescent signal during 
the thermal cycling of the PCR. The measured fluorescence reflects the amount of 
amplified product in each cycle. The cycle number at which enough amplified product 
accumulates to yield a detectable fluorescent signal, is called the threshold cycle. To 
adjust for differences between the samples not caused by the incubation, for example 
dilutions and pipetting errors, the data needs to be normalized. Therefore, it is crucial the 
use of a reference (housekeeping) gene. The normalization was performed with the 
housekeeping gene 18S rRNA. In Paper I and III, quotient of the expression for each 
gene was normalized to control, and calculated as a relative fold change.  
In Paper IV, a standard curve for each primer-probe set of pooled adipose tissue cDNA 
was used. Therefore, the relative concentrations of the target gene and the housekeeping 
gene were calculated from the standard curve. 
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Lipolysis and lipid storage 
Lipolysis was performed according to a previous reported technique (156) and as 
described in Paper III. In brief, the isolated adipocytes were incubated with or without 
rapamycin (0.01 µM), cyclosporin A (0.1 µM) and tacrolimus (0.1 µM) and with or 
without isoproterenol (0.01 and 1 µM) and insulin (0-100 µU/ml) in a shaking water bath 
at 37ºC for 2 h. The medium was then separated from the adipocytes, and the glycerol 
concentration on the medium was measured by colorimetric absorbance in a kinetic 
enzymatic analyser and used for estimations of the effects of the IAs on the lipolysis.  
 
14C-glucose and 14C-palmitate incorporation into TAG were used to measure adipocyte 
lipid storage (Paper III). Briefly, isolated adipocytes were incubated with or without 
rapamycin (0.01 µM), cyclosporin A (0.1 µM) or tacrolimus (0.1 µM) in a gentle shaking 
water bath at 37ºC for 2 h. For 14C-glucose incorporation, the medium was supplemented 
with or without insulin (1000 µU/ml) and D-[U-14C] glucose (0.26 mCi/L, 0.86 µM). For 
14C-palmitate incorporation, the medium was supplemented with [1-14C] palmitic acid 
(1.0 µCi/ml) and sodium-palmitate/BSA-mix (0.12 mM sodium palmitate, 40% BSA). 
Adipocytes were then separated from medium, and the triglyceride associated 
radioactivity was measured by scintillation counting after lipid extraction according to 
Dole and Meinertz method (157). 
 
GLUT4 trafficking in L6 cells 
The L6 cell line was originally isolated in 1968 from primary cultures of rat thigh muscle 
(158). L6 cell exhibits many of the skeletal muscle characteristics seen in vivo, like the 
ability to differentiate into myotubes, express several proteins typical of skeletal muscle, 
including GLUT4 glucose transporter, respond to insulin and glucose uptake. In Paper II, 
we used L6 cells that express the GLUT4 protein with a c-myc epitope inserted into the 
first ectodomain. One advantage of the L6-GLUT4myc cells is that this cell line provides 
a quantitative colorimetric assay to measure the dynamic availability of the myc-epitope 
to the extracellular milieu, without the need to permeabilize or fractionate the cells. 
Differentiation into myotubes is not necessary to measure glucose uptake or GLUT4myc 
translocation.  
 
L6-GLUT4myc cells were cultured in MEM-α supplemented with 10% FCS, at 37ºC, 5% 
CO2. At confluence 2 days after seeding, L6-GLUT4myc cells were used to study the 
effects of either cyclosporin A (0.1 µM) or tacrolimus (0.1 µM) on glucose uptake, cell 
surface GLUT4myc and GLUT4myc internalization and externalization, as described in 
Paper II. Cellular transport of 2-deoxy-glucose was measured according to a previously 
described technique (159). The amount of cell surface GLUT4myc and GLUT4myc 
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internalization and externalization was determined by an antibody-coupled colorimetric 
absorbance assay, as previously described (160). The data for the kinetics of GLUT4 
endocytosis traffic were fitted by nonlinear regression for a single exponential association 
(161). 
 
Statistical analyses  
Results are given as mean ± standard error of the mean (SEM) unless otherwise stated.  
Comparisons between treated and untreated cells or tissue were performed within the 
same individuals to minimize the effects of confounding variables. A p-value <0.05 was 
considered statistically significant. All variables were tested for normality using the 
Shapiro-Wilk test. The Student’s paired t-test was applied to compare means of 
continuous and normally distributed variables; otherwise, the Wilcoxon test was used. 
Bivariate correlations were performed with Pearson or Spearman correlation coefficients, 
as appropriate, and statistically significant (p<0.05) variables were log-transformed (if not 
normally distributed) and subjected to multivariate analysis via step-wise linear regression 
analysis. Statistical analysis was performed using the SPSS package version 18 (SPSS 
Inc. Chicago, IL). 
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SUMMARY OF RESULTS 
 
Details of the results can be found in Papers I-IV. 
 
Paper I 
Rapamycin impairs glucose uptake and alters mTOR and insulin signalling in 
human subcutaneous and omental adipocytes 
 
Short- and long-term incubation of human subcutaneous and omental adipocytes with a 
therapeutic concentration of rapamycin (0.01 µM), reduced basal and insulin stimulated 
glucose uptake by 20-30%, when compared to untreated cells. This effect was 
concentration dependent (1 nM-10 µM), with a maximal reduction of glucose uptake by 
40%. In addition, the degree by which rapamycin inhibited insulin-stimulated glucose 
uptake, correlated positively with body fat mass and the subcutaneous fat cell diameter, 
and negatively with the serum levels of HDL cholesterol. Thus, the inhibition of glucose 
uptake by rapamycin was more pronounced in adipocytes from lean patients (lower fat 
mass) with smaller adipocytes, and higher serum levels of HDL-cholesterol. 
 
Rapamycin inhibited mTORC1 and mTORC2 complex assembly and also inhibited 
insulin-stimulated PKB Ser473 phosphorylation, an mTORC2 substrate. Short- and long-
term incubation with rapamycin had no effect on p70S6K protein levels, but as expected, 
reduced the insulin-stimulated phosphorylation (~80 %) of p70S6K, an mTORC1 
substrate. Rapamycin did not change the amount of IRS1 or its tyrosine phosphorylation 
in subcutaneous adipocytes, but reduced phosphorylation of IRS1 on several serine 
residues (307, 616 and 636), compared with untreated adipocytes. 
 
Rapamycin incubation induced a time-depended decrease in IRS2 protein levels (up to 
~35% reduction after 20 h incubation) in adipocytes, whereas IRS2 mRNA levels were 
increased by ~50% in adipose tissue. In addition, rapamycin incubation reduced insulin-
stimulated phosphorylation of IR by up to 50% after 20 h incubation, but had no effects 
on IR, PKB, GLUT4/1 and p85-PI3K protein levels. 
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Paper II 
Cyclosporin A and tacrolimus reduce glucose uptake in human subcutaneous and 
omental adipocytes without effecting expression or activation of insulin signalling 
proteins. Cyclosporin A and tacrolimus remove GLUT4 from the cell surface via an 
increased rate constant of endocytosis in L6 cells. 
 
Short- and long-term incubation with either cyclosporin A or tacrolimus reduced both 
basal and insulin stimulated glucose uptake in subcutaneous and omental adipocytes. The 
inhibitory effect was concentration-dependent (10 nM-1 µM), by up to 40%, and occurred 
at therapeutic concentrations used as immunosuppressive therapy. 
 
Incubation of adipocytes with tacrolimus reduced IR phosphorylation by ~30%. However, 
the proteins levels and phosphorylation of relevant insulin signalling proteins (IRS1, 
IRS2, PKB, AS160, GLUT4/1, mTOR and p70S6K) was unaffected by both cyclosporin 
A and tacrolimus. In addition, cyclosporin A and tacrolimus, reduced by 60% the amount 
of insulin-stimulated GLUT4 at the adipocyte surface, but had no effect on basal amounts 
of GLUT4 at the cell surface. 
 
The effects of cyclosporin A and tacrolimus on glucose uptake and amount of GLUT4 at 
the cell surface were also investigated in L6 cells. Cyclosporin A and tacrolimus inhibited 
insulin-stimulated glucose uptake and the amount of GLUT4myc at the cell surface in L6 
cells. No effects of the agents were detected in basal (non-stimulated) conditions. In 
addition, cyclosporin A and tacrolimus increased the insulin-stimulated GLUT4myc rate 
for endocytosis by 30 and 47%, respectively. This suggests an increased rate of GLUT4 
internalization, which may reduce the exposure of the GLUT4 at the cell surface 
membrane, and contribute to the reduction in glucose uptake. 
 
Paper III 
Rapamycin, cyclosporin A and tacrolimus enhance lipolysis and inhibit lipid storage 
in human subcutaneous adipocytes. Tacrolimus and rapamycin altered the 
expression of lipogenic genes in human subcutaneous and omental adipose tissue. 
 
All three IAs, rapamycin, cyclosporin A and tacrolimus, increased isoprenaline-induced 
lipolysis by 20-35%, and isoprenaline-stimulated phosphorylation of HSL Ser563, one of 
the main lipases involved in lipolysis. In addition, rapamycin increased basal lipolysis by 
~20% in subcutaneous adipocytes, and reduced both gene and protein expression of 
perilipin. Perilipin is a lipid droplet coating protein that serves important functions in the 
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regulation of basal and hormonally stimulated lipolysis. Rapamycin reversed the 
antilipolytic effect of insulin, whereas no effects were observed for cyclosporin A or 
tacrolimus.   
 
Furthermore, the IAs reduced lipid storage by 20-35%, whereas the insulin-stimulated 
lipogenesis was down regulated by ~10%. Rapamycin reduced the expression levels of 
genes involved on fatty acid uptake and storage (FABP4/aP2 and SREBP1, respectively) 
in subcutaneous adipose tissue. In contrast, the gene expression of LPL was increased by 
rapamycin in both depots. It was also observed that tacrolimus inhibited the gene 
expression of genes involved in the uptake and transport of fatty acids (CD36 and 
FABP4/aP2, respectively) in both subcutaneous and omental adipose tissue. No effects 
were observed with cyclosporin A in any of the studied lipogenic genes. 
 
The gene expression of IL-6, an adipokine known to have pro-inflammatory effects, was 
increased in subcutaneous and omental adipose tissue that was incubated with all three 
IAs, although only significant for the subcutaneous depot. An increase in IL-6 was also 
observed in the incubation media from the subcutaneous adipose tissue, upon incubation 
with rapamycin. On the other hand, no changes were observed on the expression of either 
TNF-α or adiponectin upon exposition of adipose tissue to the three IAs. 
 
Table 3 shows a summary of the effects of the IA on human adipocytes/adipose tissue 
glucose and lipid metabolism (Paper I-III). 
 
 
Table 3. Summary of IA effects on human adipocytes/adipose tissue. From Paper I-III. 
 Rapamycin Cyclosporin A Tacrolimus 
Glucose uptake ↓ ↓ ↓ 
IR-phosphorylation ↓ ↔ ↓ 
IRS1 Ser phosphorylation ↓ nd nd 
IRS2 protein ↓ ↔ ↔ 
PKB Ser473 phosphorylation ↓ ↔ ↔ 
GLUT4 endocytosis nd ↑ ↑ 
Lipolysis ↑ ↑ ↑ 
Lipid storage ↓ ↓ ↓ 
Lipogenic genes ↓ ↔ ↓ 
IL6 gene expression/production ↑ ↑ ↑ 
↓, decreased; ↑, increased; ↔, no change; nd, not done 
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Paper IV 
Dexamethasone increased the expression of FKBP5 is human subcutaneous and 
omental adipose tissue and the expression of FKBP5 was correlated with clinical and 
biochemical markers of insulin resistance. 
 
DNA microarray analysis showed that dexamethasone at a supra-physiological and a 
maximally effective concentration (3 µM) suppressed genes related to 
immune/inflammatory responses. The two genes with the greatest increase in gene 
expression after dexamethasone incubation were FKBP5 and cannabinoid receptor 1 
(CNR1). In contrast, rapamycin decreased FKBP5 gene expression in both adipose tissue 
depots. Moreover, dexamethasone increased the FKBP5 gene and its protein (FKBP51) 
expression in a dose-dependent manner in both fat depots. Basal FKBP51 protein levels 
were 10-fold higher in omental than in subcutaneous adipose tissue. FKBP5 gene 
expression in subcutaneous depot positively correlated with serum insulin, homeostasis 
model assessment-insulin resistance (HOMA-IR) and subcutaneous adipocyte diameter. 
This suggests that its gene expression in subcutaneous adipose tissue may be increased in 
states of insulin resistance. In addition, the fold change in gene expression exerted by 
dexamethasone was negatively correlated with HbA1c, BMI, HOMA-IR and serum 
insulin, but only in subcutaneous adipose tissue. 
 
In this study only serine-rich and transmembrane domain containing 1 (SERTM1) gene 
displayed a different response to dexamethasone in the two fat depots. SERTM1 gene 
expression was clearly down-regulated in omental adipose tissue, but unchanged in 
subcutaneous adipose tissue. The leptin and metallopeptidase inhibitor 4 (TIMP4) genes, 
encoding for secreted factors, were also up-regulated by incubation with dexamethasone 
in both subcutaneous and omental adipose tissue. 
 
In addition, dexamethasone reduced basal and insulin-stimulated glucose uptake in 
subcutaneous and omental adipocytes, but omental adipocytes had a greater sensitivity to 
the metabolic effects of dexamethasone. 
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DISCUSSION 
 
Immunosuppressive agents have remarkably improved the success rate of organ 
transplantation. Besides the expected increase in infection susceptibility, development of 
other adverse effects has become evident following long-term use of these drugs. These 
undesired effects include diabetes, dyslipidemia, cardiovascular diseases and 
malignancies, and have an adverse effect on patient morbidity and mortality. Thus, studies 
on the underlying mechanisms by which these drugs affect glucose and lipid metabolism, 
are warranted in order to develop pharmacological approaches for treatment and 
prevention that mitigate these unwanted side-effects. 
 
Adipose tissue is a well recognized endocrine organ that participates actively in energy 
regulation, through a network of endocrine, paracrine and autocrine signals (62). 
Importantly, dysregulation of adipose tissue metabolism may lead to a cluster of 
metabolic alterations that may affect total body glucose and lipid metabolism and insulin 
sensitivity. 
 
Effects of rapamycin, cyclosporin A and tacrolimus on 
glucose uptake 
Similar to type 2 diabetes, new onset diabetes (NODAT) results from an imbalance 
between insulin sensitivity and insulin secretion (23, 24). It is well established by both in 
vitro and clinical studies that IAs impair pancreatic β-cell proliferation and insulin 
production in a dose dependent manner (35, 36, 41, 103). The potential impact of the IAs 
on insulin sensitivity is less clearly defined. Several clinical studies have indicated that 
treatment with IAs can reduce insulin sensitivity in peripheral tissues (23, 32, 33, 137, 
162), but the underlying mechanism(s) are not known. 
 
In Paper I and II we show, for the first time, that rapamycin, cyclosporin A and 
tacrolimus, within the range of the clinical therapeutic concentrations, impair both basal 
and insulin stimulated glucose uptake in human subcutaneous and omental adipocytes. 
The inhibitory effects of the IAs on glucose uptake could be detected already after a short-
term incubation time (75 min) and at concentrations even lower than those recommended 
during immunosuppressive therapy. 
 
Results from randomized clinical trials and meta-analyses demonstrate a higher incidence 
of NODAT in patients treated with tacrolimus than with cyclosporin A (96, 111-113), but 
these findings has not been confirmed by others (114, 115). In our in vitro model (Paper I 
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and II), rapamycin, cyclosporin A and tacrolimus had similar dose-response effects on 
glucose uptake, with a maximal inhibition of ~40% in subcutaneous adipocytes. 
 
It is thought that visceral adiposity is more metabolically active than subcutaneous fat and 
more strongly associated with adverse metabolic risk, including insulin resistance (63, 
64). However, in our in vitro model we did not find any differences in the IAs effects on 
glucose uptake between subcutaneous and omental adipocytes. Interestingly, 
subcutaneous adipocytes from lean subjects and with a normal lipid pattern (higher HDL-
cholesterol levels) may be more sensitive to the inhibitory effects of rapamycin on 
glucose uptake (Paper I). On the other hand, adipocytes from obese individuals are 
usually larger (hypertrophic) and characterised by reduced insulin sensitivity already at 
baseline (163). This may mask a worsening of glucose uptake by rapamycin incubation. 
 
Newly all transplanted patients need to take at least one of the IAs for the rest of their life, 
and the long-term effects may take place over a long period of time. Therefore, we 
investigated whether a longer incubation time (20 h) with the IAs could have a more 
pronounced inhibitory effect on adipocyte glucose uptake. The degree of inhibition of 
insulin-stimulated glucose uptake after short- and long-term incubation with either 
rapamycin, cyclosporin A or tacrolimus (Paper I and II) appear to be similar. However, 
we can not directly translate our findings from long-term incubation (20 h) in an in vitro 
model, to long-term clinical use for several years. 
 
Adipose tissue only accounts for ~10% of the insulin-stimulated whole body glucose 
uptake, whereas skeletal muscle and liver are the major sites for insulin-stimulated 
glucose uptake (164). A reduction in the relatively small glucose uptake by adipose tissue 
is unlikely to lead to a marked whole body insulin resistance during immunosuppressive 
therapy in vivo. However, there is strong evidence that dysfunction of the adipose tissue 
plays a crucial role in the development of insulin resistance (165). In line with this, a 
mouse with adipose tissue-selective depletion of GLUT4 promotes impaired glucose 
intolerance, apparently due to secondary insulin resistance in muscle and liver (166). This 
suggests that besides contributing to whole-body glucose uptake, adipose tissue can also 
regulate glucose metabolism in other-insulin sensitive tissues. In addition, impaired 
insulin signalling in adipose tissue, including reduced IRS1 expression, impaired PKB 
activity and reduced GLUT4 expression, is detected in normoglycemic individuals with 
genetic predisposition to type 2 diabetes (167). Therefore, impaired insulin action in 
adipose tissue could represent an early stage before whole body glucose intolerance (165). 
In addition, all three IAs reduced L6 muscle-derived cells insulin-stimulated glucose 
uptake. This suggests that these agents may not only reduce glucose uptake in adipocytes, 
but also in other insulin-sensitive cells such as muscle cells.  
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Effects of rapamycin, cyclosporin A and tacrolimus on insulin 
signalling 
In our study (Paper I), we show that rapamycin reduces mTOR-raptor (components of 
mTORC1), mTOR-rictor and mTOR-Sin1 (components of mTORC2) interactions. This 
suggests that rapamycin inhibits both mTORC1 and mTORC2 complex formation in 
human adipocytes. Rapamycin is known to be an mTORC1 inhibitor. Sarbassov et al 
(132) has previously demonstrated that in several cell types, including 3T3-L1 cells, 
prolonged rapamycin treatment also inhibits mTORC2 complex formation. mTORC2 
assembly is necessary for the serine phosphorylation of PKB (78). An impairment of 
mTORC2 could therefore contribute to the decreased PKB serine phosphorylation and 
down-regulation of AS160 phosphorylation observed in adipocytes incubated with 
rapamycin. Phosphorylation of AS160 is required for GLUT4 translocation to the plasma 
membrane and subsequent glucose uptake (79).  
 
Several studies have shown that activation of the mTOR pathway is implicated in 
development of insulin resistance and type 2 diabetes (128, 168). These studies have 
demonstrated that the mTOR-p70S6K pathway directly increases phosphorylation of 
IRS1 at several serine residues and thus inhibits its function, promotes its degradation, 
and, possibly, inhibits insulin signalling (127). In contrast, more recent studies have 
demonstrated that adipocytes from obese patients with type 2 diabetes have attenuated 
mTOR signalling (169). In fact, multi-site serine phosphorylation of IRS1, has been 
shown to modulate both negative and positive feedback signals (170). Surprisingly, in 
Paper I, reduction of phosphorylation of several IRS1 serine residues by rapamycin did 
not alter the insulin-stimulated tyrosine phosphorylation of IRS1 or its association with 
the p85 subunit of PI3K. Interestingly, a previous study has demonstrated that long-term 
treatment with rapamycin reduces insulin-stimulated IRS1 tyrosine phosphorylation in 
circulating mononuclear cells, and that this reduction is correlated to the increase in the 
patient’s insulin resistance (171). 
 
In addition, rapamycin reduced IRS2 protein expression levels. IRS2 together with IRS1, 
are the most important IRS proteins in the regulation of glucose uptake (77). IRS2 
knockout mice did not only show insulin resistance of muscle, fat and liver, but also 
manifest diabetes as a result of β-cell failure (172). 
 
mTOR inhibition with rapamycin has often shown discrepant findings, but in our in vitro 
model, mTOR inhibition with rapamycin resulted in inhibition of glucose uptake and 
impaired insulin signalling. These effects may contribute to insulin resistance during 
therapy with rapamycin. 
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In Paper II, we show that although phosphorylation of IR was inhibited by tacrolimus, the 
expression and phosphorylation of insulin signalling proteins (IRS1, IRS2, p85-PI3K and 
PKB) was unaffected by both cyclosporin A and tacrolimus, as was mTOR and p70S6K. 
In addition, we demonstrate that cyclosporin A and tacrolimus reduced insulin-stimulated 
levels of the glucose transporter GLUT4 at the plasma membrane but they did not change 
total protein levels of GLUT4 or GLUT1. These results suggest that the inhibitory effect 
of cyclosporin A and tacrolimus on cell surface GLUT4 and glucose uptake are not 
mediated thought effects on insulin signalling proteins. Other alternatives to PKB 
signalling also need to be considered in future studies. For example, the atypical PKC 
isoforms, PKCλ and PKCζ, increase GLUT4-dependent glucose uptake when activated by 
PI3K (173). Conversely, overexpression of dominant-negative forms of these PKC 
isoforms inhibits insulin-stimulated glucose transport and translocation of the GLUT4 to 
the plasma membrane (174). 
 
The intracellular trafficking that regulates the amount of GLUT4 at the cell surface is a 
dynamic complex itinerary that involves different steps (175). The translocation of 
GLUT4 to the plasma membrane, a process called exocytosis, is initiated by the release of 
GLUT4 storage vesicles from intracellular retention and GLUT4 translocation to the cell 
surface (which likely involves transport of GLUT4 storage vesicles along cytoskeleton 
structures). Subsequent tethering, docking and fusion of GLUT4 storage vesicles at the 
plasma membrane are also required for an efficient GLUT4 surface delivery. Finally, 
GLUT4 is internalized from the plasma membrane through a process called endocytosis.   
 
In Paper II, we used L6 muscle derived cells to determine the exocytic and endocytic 
rates of the GLUT4 transporter (160). We show, for the first time, that in L6 cells, 
cyclosporin A and tacrolimus inhibit insulin-stimulated glucose uptake and affect GLUT4 
trafficking by increasing the insulin-stimulated rate for endocytosis. In contrast to the 
effects on human adipocytes, cyclosporin A and tacrolimus did not affect non-stimulated 
glucose uptake and GLUT4 trafficking in muscle cells. In both muscle and adipose cells 
GLUT4 internalization occurs through both clathrin-dependent and clathrin-independent 
endocytosis, but different mechanisms may operate in muscle and adipocyte cells (175). 
In addition, internalization is also distinctly regulated in the two cell types, since insulin 
reduces the rate of endocytosis in adipocytes (176), but not in muscle (177) cells. 
 
A key question is how cyclosporin A and tacrolimus alter intracellular trafficking of 
GLUT4? Additional studies, evaluating the effects on protein expression or co-
localization experiments with other proteins involved in GLUT4 trafficking (e.g. clathrin 
and transferrin) are necessary to confirm that cyclosporin A and tacrolimus can affect the 
GLUT4 endocytosis rate. 
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Given the fact that IR tyrosine phosphorylation was reduced by tacrolimus, alternative 
possibilities not involving the PI3K-PKB-AS160 pathway should also be considered. For 
example, IR directly phosphorylates Munc18c (178) and signals through TC10α (179) 
which are required for normal insulin-stimulated GLUT4 uptake. Inhibition of IR tyrosine 
phosphorylation by tacrolimus may impair activation of these pathways and contribute to 
the reduced glucose uptake and this should be further investigated.  
 
The results in Paper I and II suggest that pharmacological concentrations of the anti-
mTOR rapamycin and the calcineurin inhibitors, cyclosporin A and tacrolimus, have 
similar inhibitory effects on glucose uptake in human adipocytes, but through effects on 
different signalling mechanisms (Figure 6). In contrast to rapamycin, cyclosporin A and 
tacrolimus seem to reduce cellular glucose uptake without affecting expression or 
activation of insulin signalling and seemingly by increasing the rate for endocytosis, as 
demonstrated in L6 cells. 
 
 
Figure 6 – Schematic overview of sites of action for rapamycin, cyclosporin A and 
tacrolimus interference with insulin action. Insulin receptor (IR); insulin receptor 
substrate 1, 2 (IRS1,2), phosphoinositide 3-kinase (PI3K), phosphoinositide-dependent 
kinase 1 (PDK1), protein kinase B (PKB), PKB substrate of 160 kDa (AS160), glucose 
transporter 4 (GLUT4) tuberous sclerosis proteins 1, 2 (TSC1, 2), mammalian target of 
rapamycin complex 1, 2 (mTORC1, 2), serum- and glucocorticoid-induced protein kinase 
1 (SGK1), protein kinase C α (PKC),  p70 ribosomal S6 kinase (p70S6K), 4E binding 
proteins 1 (4B-BP1).  
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Effects of rapamycin, cyclosporin A and tacrolimus on lipid 
metabolism 
In Paper III, we show that rapamycin, cyclosporin A and tacrolimus increase 
isoproterenol-stimulated lipolysis in human subcutaneous adipocytes and that rapamycin 
also increase basal lipolysis. The mechanism underlying these effects on lipolysis is not 
known, but our results show that the three IAs increased phosphorylation of HSL on 
Ser552, one of the major sites controlling HSL activity (180). Soliman et al (147), also 
demonstrated that rapamycin increases lipolysis and phosphorylation of HSL, without 
affecting cellular cAMP levels, or PKA phosphorylation. Besides PKA, HSL 
phosphorylation on Ser552 is also regulated by glycogen synthase kinase-4 (181). Other 
protein kinases (e.g. extracellular signal-regulated kinase and AMPK) have also been 
shown to regulate HSL enzyme activity by phosphorylation of other serine sites. Thus 
assessment of activation of other regulators of HSL will be important in further work 
evaluating the effects of IAs on lipolysis. 
 
In addition, rapamycin also reduced perilipin gene and protein expression. Isolated 
adipocytes of perilipin null mice exhibit elevated basal lipolysis because of the loss of the 
protective function of perilipin (58). Therefore reduced perilipin protein levels may 
contribute to increase basal lipolysis during rapamycin incubation. Notably, rapamycin 
impaired the antilipolytic effect of insulin, while cyclosporin A and tacrolimus did not 
(Paper III). PKB is critical for the ability of insulin to activate phosphodiesterase 3B, and 
thereby its antilipolytic effect (182). Thus, the inhibitory effect of rapamycin on PKB 
serine phosphorylation (Paper I) could also have contributed to this finding. 
 
In Paper III we also show that rapamycin, cyclosporin A and tacrolimus reduce the 
synthesis of TAG from fatty acids (esterification) and glucose (lipogenesis). The 
inhibition on glucose uptake by rapamycin (Paper I) and by cyclosporin A and tacrolimus 
(Paper II) could also contribute to the reduced lipogenesis. 
 
Surprisingly in Paper III, we show that LPL gene expression was increased by rapamycin 
in both subcutaneous and omental adipose tissue. LPL mediated hydrolysis of circulating 
lipoprotein-TAG provides the adipocytes with fatty acids (52). Thus increased LPL gene 
expression by rapamycin would contribute to adipose tissue clearance of circulating 
lipoprotein-TAG. Previous studies have shown that rapamycin reduces LPL gene 
expression and activity in the retroperitoneal adipose tissue of rats (144, 145) and LPL 
activity in human plasma (183). When considering the conflicting results between our and 
previous studies regarding LPL expression in adipose tissue, it should be emphasized that 
activity, rather than gene expression, is most relevant to measure, and this has been not 
measured so far. 
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We also observed an inhibition of the expression of two PPARγ target genes, the CD36 
and FABP4/aP2 in adipose tissue incubated with tacrolimus. PPARγ is a “master 
regulator” of adipogenesis and adipocyte lipid metabolism (184). In addition, it has been 
implicated in playing an important role in obesity-related metabolic diseases such as 
hyperlipidemia, insulin resistance, and coronary artery disease. A co-ordinated down-
regulation of CD36 and PPARγ by tacrolimus has been shown in a human THP-1 
macrophage model (185). Therefore it is important to further investigate effects of 
tacrolimus on PPARγ in human adipose tissue in future studies. 
 
Recent studies have demonstrated that mTORC1 plays an active role in lipid synthesis by 
promoting activation of SREBP1, a fundamental transcription factor involved in insulin 
mediated fatty acid synthesis (186). The SREBP1 gene gives rise to two proteins, 
SREBP1a and SREBP1c, by alternative splicing. The transcription potency of SREBP1a 
is higher than that of SREBP1c, but SREBP1c is the dominant isoform involved in 
insulin-mediated fatty acid synthesis. In Paper III, we show that rapamycin, during non-
stimulated conditions, inhibits SREBP1 gene expression (both isoforms), as well as it co-
activator lipin 1 (186) in subcutaneous adipose tissue. In contrast, FAS gene expression 
was not changed by rapamycin, indicating that SREBP1c activity was not affected. 
Consequently, the effects of rapamycin on SREBP1a and SREBP1c in human adipose 
tissue should be further investigated and especially insulin-stimulated conditions should 
be evaluated. 
 
In addition to effects on lipid storage, treatment of subcutaneous and omental adipose 
tissue with either rapamycin, cyclosporin A or tacrolimus (Paper III), lead to an increase 
in IL-6 gene expression and secretion. IL-6 is a circulating cytokine that is involved in 
different cellular processes and has both pro-inflammatory and anti-inflammatory 
properties (62). Adipose tissue IL-6 expression and circulating IL-6 concentrations are 
positively correlated with obesity, dyslipidemia, impaired glucose tolerance and insulin 
resistance (187). In addition, high levels of IL-6 in the circulation are associated with 
reduced adipose tissue glucose uptake (188) and increased lipolysis (189). Thus, we can 
not exclude that reduction of glucose uptake or stimulation of lipolysis after incubation 
with the IAs, could be an indirect effect of secreted IL-6 in the incubation media. 
 
In Paper I, II and III, incubation with either rapamycin, cyclosporin A or tacrolimus 
reduced both basal and insulin stimulated glucose uptake in human adipocytes, enhanced 
lipolysis stimulation and impaired lipid storage partially via down-regulation of lipogenic 
genes in adipose tissue. Hence, these findings may contribute to higher circulating levels 
of glucose, glycerol and FFA production, and a reduced plasma lipid clearance, promoting 
insulin resistance in skeletal muscle, liver and pancreatic β-cells (61). Plasma FFA are 
recognized as one of the major substrates for hepatic VLDL production (190). Therefore, 
simultaneous increase in FFA delivery and reduced VLDL catabolism by adipocytes 
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during immunosuppressive therapy can contribute to increased hepatic VLDL secretion. 
This can provide one explanation for the increased plasma VLDL levels observed during 
immunosuppressive therapy (44, 46). Fatty acid flux into muscle can also increase the 
intramuscular levels of lipid metabolites, such as acyl CoA and diacylglycerol (191) and 
contribute to insulin resistance in skeletal muscle by defects in insulin signalling (192). 
 
Effects of dexamethasone on adipose tissue gene expression 
Endogenous glucocorticoid excess (e.g. Cushing’s syndrome) or during prolonged 
corticosteroid therapy, induces hyperglycemia, insulin resistance, central obesity and 
other components of the metabolic syndrome including dyslipidemia and hypertension 
(82, 193). Central obesity, in particular visceral obesity, is associated with increased risk 
of cardiovascular diseases (194). It also contributes to the development of the components 
of the metabolic syndrome and inflammation, as well as activation of the immune system. 
Thus, identification of genes regulated by glucocorticoids in adipose tissue, that may be 
associated with insulin resistance and activation of the inflammatory/immune system, are 
of interest and may indicate novel biomarkers for adipose tissue insulin resistance induced 
by glucocorticoids. 
 
In Paper IV, we identified an expected down-regulation of expression of genes related to 
immune/inflammatory responses in both subcutaneous and omental adipose tissue 
incubated with dexamethasone, according to microarray analysis. The genes with the 
greatest increase in gene expression after dexamethasone incubation were CNR1 and 
FKBP5. CNR1 is mostly expressed in central nervous system, but it is also found in other 
peripheral tissues, including adipose tissue (195). Recently, it has been suggested that 
CNR1 modulation alters cytokine production (e.g. adiponectin) in human omental adipose 
tissue (196). CNR1 has not previously been identified as a gene regulated by 
glucocorticoids in adipose tissue and our findings thus warrant further investigations. 
 
 FKBP5 is a member of the family of immunophilins with peptidyl cis-trans isomerase 
activity (197). The protein encoded by this gene, FKBP51 was firstly shown to mediate T-
cell inhibition by forming a complex with tacrolimus and rapamycin (198, 199). 
Subsequently, the protein was shown to be involved in the modulation of glucocorticoid 
receptor function, by forming a complex with the heat shock proteins Hsp70/Hsp90 (200). 
It is well established that FKBP5 reduces glucocorticoid sensitivity and several studies 
have presented data supporting the induction of FKBP5 by glucocorticoids (85, 201). To 
the best of our knowledge, this is the first study reporting that FKBP5 gene and protein 
levels are regulated by dexamethasone in both human subcutaneous and omental adipose 
tissue. In contrast, rapamycin reduced FKBP5 gene expression (Paper IV). This suggests 
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that the dexamethasone-mediated increase in FKBP5 gene expression is not a general 
effect related to immunosuppressive therapy. 
 
A recent discovery suggests that FKBP5 has functions extending beyond its role in 
glucocorticoid receptor signalling. It was shown that FKBP51 acts as a scaffolding protein 
for PKB and to its phosphatase, PH domain leucine-rich repeat protein phosphatase, and it 
promotes dephosphorylation of PKB (202). This has potentially important implications 
for PKB activity and down-stream effects. 
 
Interestingly, basal FKBP5 gene expression in subcutaneous adipose tissue was correlated 
positively with HOMA-IR, subcutaneous adipocyte diameter and serum insulin. This 
suggests that FKBP5 gene expression is increased in states of insulin resistance. Some 
studies have shown a correlation between plasma cortisol concentration and components 
of the metabolic syndrome and insulin resistance (calculated as HOMA-IR) (203, 204), 
although this has not been found by others (205). In addition, obesity and insulin 
resistance are associated with increase expression of adipose tissue 11-beta 
hydroxysteroid dehydrogenase type 1, that converts inactive cortisone into active cortisol 
locally (206). Thus we can not exclude the possibility that the observed high basal levels 
of FKBP5 in subcutaneous adipose tissue in individuals displaying insulin resistance may 
be due to increased circulating and/or tissue levels of cortisol in these individuals. 
Unfortunately plasma cortisol levels and other parameters of glucocorticoid metabolism 
were not measured in the blood samples from the subjects in Paper IV.  
 
Therefore, FKBP5 gene expression seems to be correlated with insulin resistance and 
adiposity and is altered by dexamethasone and rapamycin. These findings suggest that 
FKBP5 can be one important link between the insulin resistance and the immune 
modulation caused by these drugs and awaits further confirmation.  
 
In an attempt to identify potential links between genes induced by dexamethasone and 
secreted factors, we also identified leptin and TIMP4. Leptin appear to be regulated by 
dexamethasone in both subcutaneous and omental adipose tissue, as reported by 
microarray studies (94). However, plasma leptin levels increase with adiposity (207), 
thus, it may not be an optimal biomarker to study effects of glucocorticoids. TIMP4 is a 
metalloproteinase inhibitor and it is up-regulated in human cardiovascular disorders, 
suggesting its use as a marker for vascular inflammation (208). TIMP4 has not previously 
been identified as a gene regulated by glucocorticoids in adipose tissue, and our findings 
may warrant further investigations on its potential utility as a biomarker. 
 
Previous studies have demonstrated sex- and depot-specific differences in sensitivity and 
responsiveness to glucocorticoid effects. Our group has previously reported that 
glucocorticoids reduce the glucose uptake capacity in omental but not in subcutaneous 
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human adipocytes (92). In parallel, a down-regulation of the cellular levels of the insulin 
signalling proteins IRS1 and PKB were demonstrated in omental adipocytes. Thus, 
identification of genes differentially regulated by dexamethasone may help to identify 
mechanisms by which glucocorticoids contribute to depot differences in adipose tissue 
function. Surprisingly, in our study (Paper IV) only one gene, SERTM1, was differently 
regulated by dexamethasone at supra-physiological concentrations in the two fat depots. 
SERTM1 displayed a clear change only in the omental adipose tissue. However, 
SRETM1 is a gene with unknown function, thus further studies are needed to determine 
whether this gene can contribute to the depot differences in sensitivity and responsiveness 
to glucocorticoid effects. 
 
The primary advantages of in vitro studies are that they give rapid readouts, are relatively 
inexpensive and permit simplification, so that a specific mechanism in tissues or cells can 
be tested. But, even though we have used human adipose tissue in our studies, we need to 
be cautions when extrapolating in vitro results to the in vivo situation. Nonetheless, 
impairment of glucose uptake and dysregulated lipolysis and lipid storage in adipocytes 
may be mechanisms underlying impaired glucose and lipid metabolism observed in 
patients treated with immunosuppressive agents. The perturbations found in adipose 
tissue, may also have an impact in other insulin sensitive tissue such as skeletal muscle 
and liver. Firstly, similar mechanisms could be relevant in those tissues and, secondly, 
dysregulated adipose metabolism can lead to altered inter-tissue signalling, i.e. via 
adipokines that in turn affect metabolism in other tissues. 
 
We have elucidated effects of immunosuppressive agents on human adipose metabolism 
and we propose links to inflammatory mechanisms. Figure 7 gives an overview of the 
demonstrated drug effects and the hypothetical interactions between pathways. 
  
Figure 7 – Hypothetically schematic overview of effects of rapamycin, cyclosporin A and 
tacrolimus and dexamethasone on adipose tissue metabolism. 
References 
49 
 
CONCLUDING REMARKS  
 
Taken together, our results suggest that therapeutic concentrations of rapamycin, 
cyclosporin A and tacrolimus impair glucose uptake in human subcutaneous and omental 
adipocytes, via partly different mechanisms. The effects of rapamycin on glucose uptake 
may be explained by the decreased mTORC1 and mTORC2 assembly and by alterations 
in the insulin signalling pathway. Tacrolimus and cyclosporin A, on the other hand, seem 
to reduce cellular glucose uptake without affecting expression or activity of insulin 
signalling components. Instead, cyclosporin A and tacrolimus may enhance the rate of 
endocytosis of the glucose transporter GLUT4, thus leading to a redistribution from the 
surface to the interior of the cell. In addition, rapamycin, cyclosporin A and tacrolimus 
enhance lipolysis in adipocytes and they inhibit lipid storage and the expression of related 
genes. This may contribute to dyslipidemia and also to insulin resistance found in patients 
on immunosuppressive therapy.  
 
Furthermore, we show that dexamethasone influences gene expression similarly in the 
two studied fat depots, i.e. subcutaneous and omental adipose tissue. FKBP5 was 
identified as being strongly regulated by dexamethasone, in both subcutaneous and 
omental adipose tissue. In addition, its expression appears to be correlated with markers 
of insulin resistance and adiposity. FKBP5 may be a mechanism involved in 
glucocorticoid-induced insulin resistance and it could potentially also provide a link 
between regulation of nutrient metabolism and immune response.  
 
It should be acknowledged that the molecular mechanisms associated with the 
development of insulin resistance and dyslipidemia during immunosuppressive therapy 
need to be explored in more detail, and tissues other than adipose should also be 
addressed. Importantly, the clinical relevance of the present findings needs to be 
demonstrated in controlled trials in patients treated with immunosuppressive agents. 
 
In conclusion, adverse effects of immunosuppressive agents on human adipose tissue 
glucose and lipid metabolism may contribute to the development of insulin resistance, 
diabetes and dyslipidemia in patients receiving such drugs. The cellular mechanisms 
described in this thesis may provide novel pharmacological approaches for prevention and 
treatment of metabolic disorders associated with immunosuppressive therapy. Such 
mechanisms could potentially also be of relevance for future treatments for type 2 as well 
as other forms of diabetes. 
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a b s t r a c t
Rapamycin is an immunosuppressive agent used after organ transplantation, but its molecular effects on
glucose metabolism needs further evaluation. We explored rapamycin effects on glucose uptake and
insulin signalling proteins in adipocytes obtained via subcutaneous (n = 62) and omental (n = 10) fat
biopsies in human donors.
At therapeutic concentration (0.01 lM) rapamycin reduced basal and insulin-stimulated glucose
uptake by 20–30%, after short-term (15 min) or long-term (20 h) culture of subcutaneous (n = 23 and
n = 10) and omental adipocytes (n = 6 and n = 7). Rapamycin reduced PKB Ser473 and AS160 Thr642
phosphorylation, and IRS2 protein levels in subcutaneous adipocytes. Additionally, it reduced mTOR–rap-
tor, mTOR–rictor and mTOR–Sin1 interactions, suggesting decreased mTORC1 and mTORC2 formation.
Rapamycin also reduced IR Tyr1146 and IRS1 Ser307/Ser616/Ser636 phosphorylation, whereas no effects
were observed on the insulin stimulated IRS1–Tyr and TSC2 Thr1462 phosphorylation.
This is the ﬁrst study to show that rapamycin reduces glucose uptake in human adipocytes through
impaired insulin signalling and this may contribute to the development of insulin resistance associated
with rapamycin therapy.
 2012 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Rapamycin (or sirolimus) is a macrolide antibiotic and immuno-
suppressive agent used as a non-nephrotoxic alternative to calci-
neurin inhibitors in organ transplantation, but adverse effects
including development of proteinuria, diabetes, dyslipidemia and
impaired wound healing in the post-operative period have caused
concern (Cravedi et al., 2010; Cutler et al., 1999).
Rapamycin inhibits the mammalian target of rapamycin
(mTOR). mTOR exists in two physically and functionally distinct
multiprotein complexes located in the cytoplasm and in the nu-
cleus; the mTOR complex 1 (mTORC1: mTOR, raptor, mLTS8, dep-
tor and the regulatory component PRAS40) and the mTOR complex
2 (mTORC2: mTOR, rictor, stress-activated protein kinase interact-
ing protein 1 (Sin1), protor, mLST8 and deptor) (Dowling et al.,
2010; Rosner and Hengstschlager, 2008). mTORC1 can be activated
by insulin via the insulin signalling pathway, the insulin receptor
(IR), insulin receptor substrate (IRS1), phosphatidylinositol 3-ki-
nase (PI3K), protein kinase B (PKB) and tuberous sclerosis complex
2 (TSC2)/TSC1 (Howell and Manning, 2011; Manning et al., 2002;
Polak and Hall, 2009). mTORC1 is rapamycin sensitive and regu-
lates cell growth, proliferation, gene transcription, protein synthe-
sis and ribosomal biogenesis (Dowling et al., 2010) by
phosphorylation of two downstream effectors, the p70 S6 kinase
(p70S6K) and the eukaryotic initiation factor 4E-binding protein
0303-7207/$ - see front matter  2012 Elsevier Ireland Ltd. All rights reserved.
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1 (Polak and Hall, 2009). mTORC2 controls cytoskeleton regulation
and cell survival by phosphorylation of PKB, and is considered as
rapamycin insensitive (Polak and Hall, 2009). However, long-term
treatment with rapamycin inhibits the formation of mTORC2 in
some cell types, including 3T3-L1 adipocytes (Hagan et al., 2008;
Sarbassov et al., 2006).
Several in vitro studies have shown that rapamycin relieves the
repression of IRS-1/PI3K/PKB signalling in states of increased activ-
ity of mTOR/p70S6K and lead to enhanced insulin stimulated glu-
cose uptake and AKT phosphorylation in L6-muscle and 3T3-L1
cells and in differentiated human adipocytes (Berg et al., 2002;
Tremblay et al., 2005; Tremblay and Marette, 2001). Contradictory
to the in vitro ﬁndings, treatment with rapamycin in combination
with calcineurin inhibitors (Johnston et al., 2008), or conversion
to rapamycin from calcineurin inhibitors (Teutonico et al., 2005)
is associated with insulin resistance and an increased risk of new
onset diabetes after transplantation (NODAT). Other studies have
shown that treatment with rapamycin does not increase the inci-
dence of NODAT and even may improve glucose metabolism
in vivo (Egidi et al., 2003). The reasons for these conﬂicting ﬁndings
are not yet clear.
Despite considerable interest in the metabolic effects of rapa-
mycin on glucose uptake in human insulin-sensitive tissues, stud-
ies on the effects on freshly isolated mature human adipocytes are
absent. In this study we aim to explore potential metabolic effects
of rapamycin on glucose uptake in freshly isolated mature human
subcutaneous and omental adipocytes and to elucidate possible
underlying mechanisms related to insulin signalling.
2. Material and methods
2.1. Study population
Human abdominal subcutaneous (sc, n = 62) and omental
(n = 10) adipose tissues biopsies were obtained from 64 non-dia-
betic subjects (25 men/39 women; body mass index (BMI) 21–
37 kg/m2; age 23–72 years) by needle aspiration from the lower
part of the abdomen (n = 39) after dermal local anaesthesia with
lidocaine (Xylocain; AstraZeneca, Södertälje, Sweden), or during
elective abdominal surgery (n = 25) after induction of general
anaesthesia. Anthropometric measurements including body com-
position assessed by bioimpedance were obtained in all subjects
(Lukaski et al., 1986). Fasting venous blood samples were collected
for analysis of glucose, insulin and lipids by routine methods at the
Department of Clinical Chemistry, Sahlgrenska University Hospital.
Clinical and biochemical characteristics of adipose tissues donors
are shown in Table 1. Subjects with diabetes, other endocrine dis-
orders, cancer or other major illnesses, as well as ongoing medica-
tion with systemic glucocorticoids and immune modulating
therapies, were excluded from the study. Three subjects used local
inhalation treatment with b2-agonist and glucocorticoids for asth-
ma, two subjects had ongoing treatment with low-dose anti-
depressants (venlafaxine and sertraline, respectively) and one pa-
tient had ongoing antihypertensive treatment with amlodipine.
The study was approved by the Regional Ethical Review Board in
Gothenburg and all participants gave their written informed
consent.
2.2. Chemicals
Dulbecco’s modiﬁed Eagle’s medium (DMEM), Hank’s medium
199, foetal bovine serum (FBS), penicillin–streptomycin (PEST),
Nupage Novex Bis–Tris Mini-Gels and Protein G-coupled Dynabe-
ads were obtained from Invitrogen Corporation (Paisley, UK). Col-
lagenase, type II from Clostridium histolyticum, bovine serum
albumin (BSA), dimethyl sulfoxide (DMSO), CHAPS (3-[(3-cholam-
idopropyl)dimethylammonio]-1-propanesulfonate), adenosine
(adenine riboside) and rapamycin were obtained from Sigma
Chemical Co. (St. Louise, MO, USA). D-[U-14C] glucose (speciﬁc
activity, 200–300 mCi/mM) and enhanced chemiluminescence
(ECL)™ Western Blotting Detection Reagents were purchased from
Amersham Biosciences GE Healthcare (Buckinghamshire, UK). Hu-
man Insulin Actrapid, 100 U/ml was purchased from Novo Nordisk
A/S (Copenhagen, Denmark). Down corning 200/100cS ﬂuid (sili-
con oil) was obtained from Silicone Products, VWR International
(Leicestershire, UK). Bicinchoninic acid protein (BCA) assay kit
was purchased from Thermo Scientiﬁc (Rockford, IL, USA). Okadaic
acid was from Alexis Biochemicals (Lausen, Switzerland). RNeasy
lipid tissue mini-kit was purchased from Qiagen (Hilden, Ger-
many). High capacity cDNA reverse transcriptase kit, Human 18S
rRNA, Universal PCR Master Mix, primers and probes were pur-
chased from Applied Biosystems (Foster City, CA, USA). Anti-IRS1,
anti-phospho-IRS1 (Ser307), anti-IRS2, anti-insulin-receptor b-
subunit (IR), p85 subunit of phosphoinositide 3-kinase (PI3-kinase)
and anti-stress-activated protein kinase-interacting protein 1
(Sin1) were purchased from Upstate Biotechnology (Lake Placid,
NY, USA). Anti AS160, anti-phospho-AS160 Thr642, anti-PKB1,
anti-phospho-PKB Thr308, anti-phospho-PKB Ser473, anti-phos-
pho-IRS1 (Ser616), anti-mTOR, anti-raptor, anti-rictor, anti-p70S6
Kinase, anti-phospho p70S6K (Thr421/Ser424), anti-insulin recep-
tor b (Tyr1146), anti-GLUT4, anti-GLUT1, anti-tuberous sclerosis
complex-2 (TSC2), anti-phospho TSC2 (Thr1462), anti-rabbit and
anti-mouse HRP linked secondary antibodies were obtained from
the Cell Signaling Technologies (Beverly, MA, USA). Anti-phos-
pho-IRS1 (Ser636), anti-actin, anti-glyceralhehyde-3-phosphate
dehydrogenase (GAPHD) and anti-phospho-Tyr was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.3. Adipocyte isolation and incubation
Surgical biopsies were cut into small pieces. Thereafter, the adi-
pose tissue frombothneedle and surgicalbiopsieswasdigestedwith
collagenase type II in Hank’s medium containing 6 mM glucose, 4%
BSA, 0.15 lM adenosine, pH 7.4 (adjusted with NaOH) for 60 min
at 37 C in a shaking water bath. After ﬁltration through a 250 lm
nylon mesh the isolated adipocytes were washed four times in
Table 1
Anthropometry and fasting blood chemistry of the donors of subcutaneous and
omental adipose tissues.
Variable Subcutaneous Omental
N (male/female)a 24/38 4/6
Age (years) 50 ± 12 44 ± 15
Body mass index (kg/m2) 27.2 ± 4.1 26.5 ± 2.3
Waist-hip ratio (WHR) 0.92 ± 0.10 0.94 ± 0.07
Systolic blood pressure (mmHg) 131 ± 17 130 ± 11
Diastolic blood pressure (mmHg) 82 ± 11 75 ± 6b
Fat cell diameter (lm) 99.8 ± 12.0 92.3 ± 12.0
HbA1c (mmol/mol, IFCC)c 34.1 ± 2.9 33.0 ± 2.2
Glucose (mM) 5.1 ± 0.5 5.0 ± 0.6
Insulin (mU/L) 7.5 ± 3.9 7.7 ± 3.5
HOMA-IR indexd 1.7 ± 1.0 1.7 ± 0.7
Body fat mass (%) 30.0 ± 7.6 30.3 ± 6.8
Triglycerides (mM) 1.1 ± 0.4 1.4 ± 0.7
Cholesterol (mM) 5.7 ± 1.2 5.5 ± 1.8
LDL-cholesterol (mM) 3.6 ± 1.0 3.6 ± 1.5
HDL-cholesterol (mM) 1.7 ± 0.6 1.7 ± 0.6
Data are means ± SD.
HbA1c, glycosylated haemoglobin; LDL, low-density lipoprotein; HDL, high density
lipoprotein.
a Paired subcutaneous and omental surgical biopsies obtained from 8 subjects.
b p < 0.05, subcutaneous versus omental.
c Normal range 27–46 mmol/mol (IFCC standard).
d Calculated as: fasting insulin (mU/L)  fasting glucose (mM)/22.5.
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Hank’smediumwithout glucose (4%BSA, 0.15 lMadenosine andpH
7.4, adjusted with NaOH). Due to limited amount of adipose tissue,
all experiments could not be performed in all subjects and in both
adipose tissues (fresh cells experiments: glucose uptake (sc,
n = 23; omental, n = 6); lysates (sc, n = 18) and/or 20 h incubation
experiments: glucose uptake (sc, n = 10; omental, n = 7); lysates
(sc, n = 8); mRNA expression (sc, n = 21)). The average cell diameter
was measured in isolated sc and omental adipocytes from all sub-
jects. In brief, 0.2 ml of cell suspension was placed on a siliconized
glass slide and the diameters of 100 consecutive cells fromeach sub-
ject were determined by light microscopy using a calibrated ocular
(Lundgren et al., 2007). For the 20 h incubations the adipocyteswere
placed in polystyrene ﬂasks containing DMEM with 6 mM glucose,
10% FBS, 1% PEST in absence or presence of rapamycin (0.01 lM),
and incubated at 37 C under a gas phase of 5% CO2 with gentle agi-
tation (30 rpm) in a culture cupboard (Lundgren et al., 2004). After
incubation the cells were washed in fresh Hank’s medium without
glucose before further experiments.
For the experiments 0.01 lM (10 nM) rapamycin was selected
as the standard total concentration, unless otherwise speciﬁed,
since it is within the therapeutic range (10–26 nM) recommended
and used in clinical practice in patients after organ-transplantation
(Wyeth, 1999).
2.4. Glucose uptake
The isolated adipocytes were diluted ten times in Hank’s med-
ium without glucose and pre-incubated for 15 min in absence or
presence of rapamycin (sc: 0–10 lM; omental: 0.01 lM) in a shak-
ing water-bath, and thereafter stimulated or not with insulin (25 or
1000 lU/ml) and/or okadaic acid (1 lM). After an additional
15 min, D-[U-14C] glucose (0.26 mCi/L, 0.86 lM) was added to
the medium and the accumulation of glucose followed for
45 min. The glucose uptake in sc and omental adipocytes freshly
isolated and after 20 h incubation with rapamycin, was performed
as previous reported (Yu et al., 1997). Under these experimental
conditions, glucose uptake is mainly determined by the rate of
transmembrane glucose transport (Kashiwagi et al., 1983) and cal-
culated according to the following formula: cellular clearance of
medium glucose = (c.p.m. cells  volume)/(c.p.m. medium  cell
number  time) (Yu et al., 1997). For adipocytes incubated for
20 h the incubation continued in absence or presence of rapamycin
(0.01 lM) with or without addition of insulin (1000 lU/ml), and
thereafter the procedure continued as described above. All experi-
ments were performed in triplicates.
2.5. Adipocyte lysates, immunoprecipitation and immunoblotting
After adipocyte incubation in the absence or presence of rapa-
mycin (0.01 lM) for 15 min, 3 h or 20 h, and thereafter with or
without a maximal insulin concentration (1000 lU/ml) for an addi-
tional 15 min, the cells were separated from medium and lysed at
4 C for 2 h in lysis buffer (25 mM Tris–HCl, pH 7.4; 0.5 mM EGTA;
25 mMNaCl; 1% Nonidet P-40; 1 mMNa3VO4; 10 mMNaF; 0.2 mM
leupeptin; 1 mM benzamidine; 0.1 mM 4-(2-aminoethyl)-benze-
nesulfonylﬂuoride hydrochlorine; 0.1 lM okadaic acid) as previ-
ously described (Renstrom et al., 2005). Immunoprecipitation
with IRS1 and mTOR was performed only in adipocytes incubated
3 h with rapamycin. For mTOR immunoprecipitation experiments
the cell lysis buffer contained 0.3% of CHAPS to achieve maximum
mTOR complex recovery, as previously described (Kim et al., 2002).
The insoluble substances were sedimented through centrifugation
at 12 000g at 4 C, during 15 min, and protein content was mea-
sured with the BCA protein assay kit. For immunoprecipitation,
0.5 mg of cell lysates incubated overnight at 4 C with 1 lg of
anti-mTOR or anti-IRS1 antibody coupled with G-coupled
Dynabeads. Total lysate (15 lg/lane) or immunoprecipitated pro-
tein samples were subjected to SDS–PAGE, transferred to nitrocel-
lulose membrane and immunoblotted with primary antibody
diluted according to the manufacturer’s instructions and thereafter
with appropriate secondary antibody. Detection was made by ECL
with high performance ﬁlm.
2.6. Real time-PCR
Sc adipose tissue (n = 21) incubated for 20 h with or without
rapamycin (0.01 lM), as described above, was used for IRS1 and
IRS2 mRNA quantiﬁcation. RNA was isolated with RNeasy lipid tis-
sue mini-kit and used for cDNA synthesis using High Capacity
cDNA Reverse Transcriptase kit. The gene expression samples
was analysed using an ABI Prism 7900HT Sequence Detection Sys-
tem (Applied Biosystems) applying gene-speciﬁc custom-designed
primers and probes (sequences used are available on request). Rel-
ative quantiﬁcation of mRNA levels was plotted as the fold change
compared with the basal state, using 18S rRNA as endogenous
control.
2.7. Statistical analysis
Results are given as mean ± standard error of the mean (SEM),
or as indicated. Results for protein levels and/or phosphorylation
(immunoblotting) of adipocytes incubated 3 h with rapamycin
were shown only if rapamycin effects differed from that of
15 min and 20 h incubations. Differences between treatments for
glucose uptake, protein content or phosphorylation level (parame-
ters not normally distributed were log transformed) was deter-
mined using paired t-test or ANOVA, as appropriate; and
Wilcoxon signed-rank test was used to analyse differences be-
tween treatments for mRNA expression. Bivariate linear regres-
sions were used to assess correlations between change in insulin
stimulated glucose uptake after rapamycin treatment and anthro-
pometric and biochemical variables (age, BMI, WHR, systolic and
diastolic blood pressure, sc adipocyte diameter, HbA1c, HOMA-IR,
body fat mass (%), cholesterol, triglycerides, HDL-cholesterol and
maximum insulin stimulated glucose uptake (% of basal)). Only sig-
niﬁcant bivariate linear regressions are shown. Variables display-
ing associations in the bivariate regressions (p < 0.05) were
subsequently included in the multivariate step-wise regression
analysis. Comparisons between treated and untreated cells were
performed with cells from the same individual to minimise con-
founding variables. A p < 0.05 was considered statistically signiﬁ-
cant. Statistical analyses were performed using the SPSS package
version 18 (SPSS Inc., Chicago, IL).
3. Results
The anthropometric and biochemical characteristics of the sc
and omental adipocyte donors are shown in Table 1. The character-
istics were similar between sc and omental adipocyte donors with
exception of the diastolic blood pressure (p < 0.05). The study pop-
ulation had a wide range of age (23–72 years) and BMI (21–37 kg/
m2), but on average normal insulin sensitivity (assessed by the
HOMA-IR index) and lipid proﬁle (Table 1).
3.1. Glucose uptake in sc and omental adipocytes
The maximum relative response to insulin stimulation was
approximately 2- to 3-fold in fresh isolated adipocytes (173 ± 9%
of basal, p < 0.05, in sc; 285 ± 31% of basal, p < 0.05, in omental;
Fig. 1A). After a 20 h incubation the insulin stimulated glucose up-
take was similar between sc and omental adipocytes (Fig. 1B), but
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the relative insulin response tended to be slightly lower than in
freshly isolated adipocytes (164 ± 21% of basal, p < 0.05, in sc;
203 ± 22% of basal, p < 0.05, in omental).
3.2. Effect of rapamycin on glucose uptake in sc and omental
adipocytes
Abdominal obesity, and in particular increased visceral fat accu-
mulation, is associated with the metabolic syndrome including
insulin resistance and type II diabetes (Kissebah and Krakower,
1994). For this reason the effects of rapamycin on glucose uptake
was addressed in omental adipocytes besides the more readily
accessible sc adipocytes. After a short-term pre-incubation
(15 min) with 0.01 lM rapamycin, both basal and insulin stimu-
lated glucose uptake (1000 lU/ml) was impaired in sc and omental
adipocytes, as compared with untreated adipocytes (sc, basal 20%
and insulin 27%, p < 0.05; omental, basal 21% and insulin 24%,
p < 0.05; Fig. 1A). After long-term incubation (20 h) with rapamy-
cin, basal glucose uptake was inhibited by 10%, while insulin
stimulated glucose uptake was inhibited by 30% (p < 0.05) in ma-
ture sc and omental adipose cells, when compared with untreated
adipocytes (Fig. 1B).
A dose–response relationship for rapamycin is found in sc adi-
pocytes (1 nM–10 lM) with a maximal inhibition of 40% on basal
and insulin stimulated glucose uptake at 1 and 10 lM (Fig. 1C).
Similarly, rapamycin inhibited the sub-maximal and maximally
insulin stimulated glucose uptake (25 and 1000 lU/ml), with IC50
values of 0.01 lM (Fig. 1C).
Incubation of human sc adipocytes with okadaic acid (1 lM)
produces a similar effect on glucose uptake as the maximally effec-
tive insulin concentration, and when combined with insulin, a
partial additive effect was seen (Fig. 1D). Short-term pre-incuba-
tion (15 min) of the adipocytes with rapamycin impaired both
the effect of okadaic acid and the effects of combined stimulation
with okadaic acid and insulin on glucose uptake, as compared with
untreated adipocytes (p < 0.05, Fig. 1D).
3.3. Impact of body fat mass, sc adipocyte diameter and serum-HDL on
rapamycin inhibition of insulin stimulated glucose uptake
Using a bivariate linear model, the proportion of rapamycin
inhibition of insulin-stimulated glucose uptake, calculated as a
percentage change from pre-treatment values, correlated posi-
tively with the body fat mass, but this correlation was only signif-
icant in females (female, r = 0.604, p < 0.05; male, r = 0.528,
Fig. 2A). Rapamycin change also correlated positively with the sc
adipocyte diameter (r = 0.547, p < 0.01, Fig. 2B). In addition, the
serum HDL-cholesterol of the sc adipocytes donors, negatively cor-
relates with the rapamycin change of insulin-stimulated glucose
uptake (r = 0.538, p < 0.01). When entering these variables in a
step-wise multivariate analysis, adjusting for gender, only HDL-
cholesterol remained a signiﬁcant predictor of rapamycin inhibi-
tion of insulin stimulated glucose uptake (r2 = 0.33, p < 0.01 for
model).
3.4. Effect of rapamycin on p70S6K, mTOR complexes, PKB, TSC2 and
AS160 protein levels and phosphorylation
To study the effect of rapamycin on the mTOR pathway, the
phosphorylation of the mTOR downstream substrate p70S6K was
assessed (Fig. 3A). Rapamycin did not affect total p70S6K protein
levels under basal or insulin stimulated conditions (15 min and
Fig. 1. Rapamycin reduces sc and omental adipose tissues glucose uptake. Freshly isolated human sc and omental adipocytes were incubated (A) short-term (15 min pre-
incubation) and (B) long-term (20 h pre-incubation) with 0.01 lM rapamycin. Thereafter, the incubation continued in absence or presence of insulin (1000 lU/ml) for an
additional 15 min, before D-[U-14C]-glucose was added, and the glucose uptake was assessed during the following 45 min. (C) Freshly-isolated human sc adipocytes pre-
incubate during 15 min with different rapamycin concentrations (0–10 lM) and the incubation continued in absence or presence of insulin (25 and 1000 lU/ml) before
glucose uptake was measured as previously described. (D) Freshly-isolated human sc adipocytes pre-incubate during 15 min with or without rapamycin (0.01 lM) and
thereafter incubation continued for 15 min without or with insulin (1000 lU/ml) and/or okadaic acid (1 lM) before glucose uptake was measured as previously described.
Experiments were performed in triplicates and expressed as cellular glucose clearance (ﬂ per cell per second) (A, B and D), or a ratio relative to basal (C). Data are presented as
mean ± SEM, (A, n = 23 and n = 6 for sc and omental, respectively; B, n = 10 and n = 7 for sc and omental, respectively; C, n = 6 and D, n = 5). Rap, rapamycin; SC, subcutaneous
adipocytes; OM, omental adipocytes; OkAc, okadaic acid; Ins, insulin. ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001.
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20 h, Fig. 3A). Instead, rapamycin inhibited basal and insulin stim-
ulated phosphorylation of p70S6K on Thr421/Ser424 at both
15 min and 20 h incubation (80% reduction, p < 0.05; Fig. 3A).
To determine if the impaired glucose uptake after rapamycin
treatment could be explained by changes in PKB protein amounts
or phosphorylation, Western blot analyses were performed. Incu-
bation with rapamycin did not affect the PKB protein levels or insu-
lin stimulated PKB phosphorylation on Thr308, whereas insulin
stimulated PKB phosphorylation on Ser473 was signiﬁcantly de-
creased both short-term and long-term (15 min and 20 h:
p < 0.01; Fig. 3B). In addition, rapamycin inhibited insulin stimu-
lated Thr642 phosphorylation of AS160, at both incubation times
(15 min and 20 h, p < 0.05; Fig. 3C). Since rapamycin inhibits the
PKB phosphorylation on Ser473, we studied whether the phos-
phorylation of the PKB substrate TSC2 was potentially inhibited
(Fig. 3C). Rapamycin did not change the protein expression of
TSC2 or phosphorylation of Thr1462, which regulates its activity
(Fig. 3C). These results suggest that TSC2 phosphorylation is not
an important mechanism explaining rapamycin-induced mTORC1
inhibition.
mTOR immunoprecipitates were analysed to determine the
mTORC1 unique partner raptor and the mTORC2 unique partners
rictor and Sin1 protein interaction (Fig. 3D). Rapamycin did not af-
fect the protein levels of mTOR, raptor, rictor or Sin1 in total lysates
from sc adipocytes after 3 h incubation (Fig. 3D). Instead, rapamy-
cin reduced the amount of raptor recovered with the mTOR immu-
noprecipitate (by 60% and 80% upon incubation with 0.01 and
0.1 lM rapamycin, respectively, p < 0.05, Fig. 3D). In addition, 3 h
incubation with 0.01 and 0.1 lM rapamycin, also inhibited the
amount of rictor and Sin1 recovered with the mTOR immunopre-
cipitate, although this effect was only signiﬁcant for the higher rap-
amycin concentration (0.1 lM rapamycin: 70% for rictor and
40% for Sin1, p < 0.05, Fig. 3D).
3.5. GLUT4, GLUT1, p85 subunit of PI3K and IRS1 protein levels, gene
expression and phosphorylation
Total protein expression of GLUT4, GLUT1 and p85 subunit of
PI3K was similar between adipocytes incubated with or without
rapamycin (Fig. 4A).
The total IR protein levels were similar in adipocytes incubated
with or without rapamycin (0.01 lM) (Fig. 4B), but the insulin-
stimulated phosphorylation of IR Tyr1146, one of the autophosph-
orylations sites in the b subunit (Wilden et al., 1990), was
decreased in the rapamycin treated adipocytes (40% reduction
after 15 min incubation, p < 0.05; 50% reduction after 20 h incuba-
tion, p < 0.01; Fig. 4B).
Rapamycin did not change IRS1 protein amount in sc adipocytes
or mRNA expression in human sc adipose tissue (Fig. 4C and D,
respectively). Compared to basal, insulin stimulated phosphoryla-
tion of IRS1 on Ser616 was increased by 900% (p < 0.001) and
Ser636 was increased by 100% (p < 0.05), and although not signiﬁ-
cant, Ser307 phosphorylation was increased by 50% after 15 min
incubation (Fig. 4E). Moreover, rapamycin reduced the phosphory-
lation of the IRS1 serine residues 307, 616 and 636, after short-
term (15 min) as well as long-term incubation (20 h) (Fig. 4E).
IRS1 immunoprecipitates were analysed to determine insulin
stimulated IRS1 tyrosine phosphorylation and the IRS1 associated
p85 subunit of PI3K (Fig. 4F). Insulin caused a 20-fold increase in
IRS1–Tyr phosphorylation and IRS1–p85 association (p < 0.001,
Fig. 4F), that was not changed by rapamycin treatment (Fig. 4F).
3.6. IRS2 protein and gene expression
The IRS2 protein levels were reduced by 25% and 35% in sc adi-
pocytes after incubation with 0.01 lM rapamycin during 3 and
20 h, respectively (p < 0.05, Fig. 5A). But, the IRS2 mRNA levels of
sc adipose tissue were increased by 50% after 20 h incubation
with 0.01 lM rapamycin, when compared with untreated adipose
tissue (p < 0.001, Fig. 5B).
4. Discussion
To our knowledge this is the ﬁrst study reporting effects of rap-
amycin in freshly isolated mature human sc and omental adipo-
cytes. This study demonstrated that rapamycin, within the range
of the therapeutic concentrations used in organ transplantation,
impaired both basal and acute insulin stimulated glucose uptake
in human sc and omental adipocytes to a similar extent. We also
showed that short-term incubation with rapamycin reduced the
insulin stimulated glucose uptake in sc adipocytes by up to 40%
in a concentration dependent manner (10 nM–10 lM). Previous
studies have suggested that long-term treatment of 3T3-L1 adipo-
cytes (Cho et al., 2004; Veilleux et al., 2010) and L6 myotubes cells
(Sipula et al., 2006) with rapamycin reduces their insulin depen-
dent glucose uptake capacity. In contrast, others (Tremblay et al.,
2005) have reported that short-term rapamycin treatment (1 h)
of 3T3-L1 cells and differentiated human preadipocytes in states
Fig. 2. Rapamycin induced change in insulin stimulated glucose uptake correlates with body fat mass and adipocyte diameter. Linear regression analysis between the
percentage changes (D-change) of insulin stimulated glucose uptake after rapamycin incubation with (A) adipocyte donors body fat mass and (B) sc adipocytes diameter.
Freshly isolated sc adipocytes were pre-incubated for 15 min with 0.01 lM rapamycin in a glucose-free medium. Thereafter, the incubation continued in presence of insulin
(1000 lU/ml) for an additional 15 min, before D-[U-14C]-glucose was added, and the glucose uptake was assessed during the following 45 min. Experiments were performed
in triplicates and expressed as insulin stimulated glucose uptake after rapamycin incubation compared with the control situation (no rapamycin incubation). Female, n = 16;
male, n = 7. FM, body fat mass (%).
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of increased activity of mTOR/S6K pathway, relieve the repression
of IRS1/PI3–K/PKB signalling leading to increased insulin stimu-
lated glucose transport. The reasons for the differences between
these ﬁndings and the current study are unclear, but suggest that
rapamycin may have different effects on glucose uptake dependent
on whether the adipocytes have elevated basal mTOR/S6K activa-
tion or not. Although rapamycin seems to improve glucose uptake
in insulin resistant states induced by prolonged insulin exposure
and excess nutrient activation of mTOR (Berg et al., 2002; Tremblay
et al., 2005; Tremblay and Marette, 2001; Ueno et al., 2005), its
inhibition in non-mTOR activation states rather seems to contrib-
utes to impairment in glucose uptake (Cho et al., 2004; Sipula
et al., 2006; Veilleux et al., 2010).
Okadaic acid is an inhibitor of protein phosphatases type 1
(PP1) and 2A (PP2A), and stimulates glucose transport and PKB ki-
nase activity independent of PI3K activation, in human adipocytes
(Rondinone et al., 1999; Rondinone and Smith, 1996). Rapamycin
inhibited okadaic acid stimulated glucose uptake, suggesting that
PKB or a downstream target has a critical role on rapamycin glu-
cose inhibitory effect.
The proportion of the inhibition of glucose uptake by rapamycin
correlated positively with body fat mass and adipocyte diameter,
and negatively with HDL-levels suggesting that adipocytes from
lean subjects with a normal lipid pattern might be more sensitive
to the inhibitory effects of rapamycin on glucose uptake. However,
our study does not allow us to rule out the possibility that the pro-
portionally lower reduction of insulin stimulated glucose uptake
upon rapamycin treatment in obese subjects might be due to
pre-existing insulin resistance in these adipocytes. This condition
may mask any further worsening of insulin resistance, and it must
be acknowledged that the number of subjects is limited.
Treating human adipocytes in culture with rapamycin do not
directly reﬂect the systemic effects of rapamycin in humans, but
the rapamycin-induced reduction in glucose uptake in adipocytes
Fig. 3. Rapamycin inhibits insulin stimulated p70S6K, PKB Ser473 and AS160 Thr642 phosphorylation and mTORC1 and mTORC2 assembly in human sc adipocytes. Isolated
human sc adipocytes were exposed for 15 min and 20 h in absence or presence of rapamycin (0.01 lM) and thereafter stimulated with or without insulin (1000 lU/ml) for
additional 15 min, before lysis and subsequent immunoblotting analysis of (A) p70S6K protein levels and phosphospeciﬁc antibody against p70S6K (Thr421/Ser424) (n = 3–5)
and (B) PKB protein levels and phosphospeciﬁc antibody against PKB Thr308 and PKB Ser473 (n = 5–7) and (C) TSC2 and AS160 protein levels and phosphospeciﬁc antibody
against TSC2 Thr1462 and AS160 Thr642 (n = 5–6). (D) Total lysates and mTOR immunoprecipitates prepared from isolated sc adipocytes incubated for 3 h, in absence and
presence of rapamycin (0.01 and 0.1 lM) were immunoblotted for levels of mTOR, raptor, rictor and Sin1 (n = 3–6). Control and rapamycin treated conditions for protein
levels and phosphorylation of p70S6K, PKB, TSC2 and AS160 are different parts of the same gel. Results show representative gels and mean ± SEM of densitometry analysis.
Densitometry measures of phosphorylation were normalised for the respectively protein levels. Ins, insulin; Rap, rapamycin. ⁄p < 0.05; ⁄⁄p < 0.01.
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could be a potential explanation of the previously described
impairment in glucose metabolism in rapamycin/sirolimus-treated
subjects (Johnston et al., 2008; Teutonico et al., 2005).
Since the effect of rapamycin on glucose uptake was similar in
the sc and omental adipocytes, and due to limited amounts of
omental adipose tissue, the effect of rapamycin on the content
and phosphorylation of critical insulin signalling proteins was as-
sessed only in sc adipocytes. As expected, incubation of human adi-
pocytes with rapamycin resulted in almost complete prevention of
p70S6K phosphorylation (mTORC1 substrate). These results dem-
onstrate that rapamycin can, already after short-term incubation,
effectively block the mTOR activity ex vivo in human sc adipocytes.
Rapamycin treatment inhibited insulin induced PKB Ser473
phosphorylation at all incubation time points, but did not change
PKB Thr308 phosphorylation. A marked decrease in PKB Ser473
phosphorylation has previously been described in adipose tissue
from rapamycin treated mice (Sarbassov et al., 2006) and in
circulating mononuclear cells of rapamycin treated transplanted
patients (Di Paolo et al., 2006). PKB activation requires the phos-
phorylation of Thr308 by PDK1 and of Ser473 by mTORC2 (Sarbas-
sov et al., 2005; Stephens et al., 1998). Rapamycin is generally
known to be an mTORC1 inhibitor (Guertin and Sabatini, 2007),
however, it has been proposed, that prolonged rapamycin treat-
ment of 3T3-L1 adipocytes and other cells can disrupt the mTORC2
and thereby decrease phosphorylation of PKB at Ser473 (Hagan
et al., 2008; Sarbassov et al., 2006). Fat cell speciﬁc ablation of ric-
tor in mice has previously been shown to impair insulin-regulated
glucose transport in adipocytes and whole body (Kumar et al.,
2010). In fact, in the present study we also demonstrated that rap-
amycin reduces the mTOR–rictor and mTOR–Sin1 interaction
(mTORC2) in human sc adipocytes after 3 h incubation. The reduc-
tion in mTOR–rictor and mTOR–Sin1 interaction by rapamycin
might indicate a reduction in mTORC2 assembly and cause im-
paired insulin stimulated PKB Ser473 phosphorylation and, conse-
Fig. 4. Effect of the mTOR/p70S6K1 pathway down-regulation by rapamycin on the activation of IR/IRS1 in human sc adipocytes. (A–C) Isolated adipocytes were exposed for
the indicated times, in absence or presence of 0.01 lM rapamycin and thereafter stimulated with insulin (1000 lU/ml) for additional 15 min for immunoblotting analysis of
(A) GLUT4, GLUT1, p85 subunit of PI3K and GAPDH (n = 5–8), (B) IR and phosphospeciﬁc antibody against IR Tyr1146 (n = 4–6) and (C) IRS1 (n = 5–6). (D) IRS1 mRNA levels
measured by real-time PCR in sc adipose tissue incubated in absence and presence of 0.01 lM rapamycin for 20 h (n = 21). (E) Isolated adipocytes were exposed for the
indicated times, in absence or presence of 0.01 lM rapamycin and thereafter stimulated with insulin (1000 lU/ml) for additional 15 min for immunoblotting analysis of
phosphospeciﬁc antibody against IRS1 Ser307, 616 and 636 (n = 4–5). (F) IRS1 immunoprecipitates prepared from isolated sc adipocytes incubated for 3 h in absence or
presence of 0.01 lM rapamycin were analysed by immunoblotting for levels of IRS1, tyrosine phosphorylation and p85 subunit of PI3K (n = 3). Results (A–C, E, and F) show
representative gels and mean ± SEM of densitometry analysis. Control and rapamycin treated conditions for each incubation time are different parts of the same gel. (B)
Densitometry measures of phosphorylation were normalised for the respectively protein levels. Ins, insulin; Rap, rapamycin; p(Y), phospho-tyrosine. ⁄p < 0.05; ⁄⁄p < 0.01.
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quently, a reduction in glucose uptake. While the reduced phos-
phorylation of PKB at Ser473 was observed after 15 min pre-incu-
bation with rapamycin, the mTOR–rictor and mTOR–Sin1
dissociation was observed at 3 h incubation with the compound.
Thus, the time periods of incubation are different and we cannot
ﬁrmly conclude by what mechanism rapamycin is affecting PKB
phosphorylation at 15 min.
In addition, we demonstrated that phosphorylation of the PKB
substrate AS160 on residue Thr642 was signiﬁcantly reduced by
rapamycin at both short- and long-term incubations. Phosphoryla-
tion of AS160 at Thr642 is required for insulin stimulated GLUT4
trafﬁcking and glucose transport in adipocytes (Ramm et al.,
2006). Due to limited amounts of tissue the translocation of GLUT4
to the cellular membrane was not assessed in the present study.
However, impaired translocation of GLUT4 is a likely consequence
of the attenuated insulin signalling following rapamycin treat-
ment, and could explain the reduction in glucose uptake observed,
since the GLUT4 protein levels were unchanged even after 20 h
with rapamycin treatment.
Chronic activation of mTORC1 by nutrients, growth factors or
insulin, increase IRS1 serine phosphorylation, which generally
leads to reduced IRS1 function and impaired insulin signalling in
several cell lines (Tremblay and Marette, 2001; Tzatsos and Kand-
ror, 2006), but it can also positively modulate insulin action (Copps
et al., 2010; Greene and Garofalo, 2002). IRS1 Ser307 in mice, is a
positive regulatory site that moderates the severity of insulin resis-
tance rather than inhibiting insulin sensitivity (Copps et al., 2010).
mTOR regulates phosphorylation of IRS1 Ser307 in 3T3-L1 cells
(Carlson et al., 2004), in adipocytes from type 2 diabetes patients
(Danielsson et al., 2005), in adipocytes from healthy lean volun-
teers after overeating (Danielsson et al., 2009) and in adipocytes
made insulin resistant by exposure to retinol-binding protein-4
(Ost et al., 2007). In agreement with these observations, the pres-
ent study showed that the feedback signal to the phosphorylation
on IRS1 Ser307 is prevented by rapamycin in human sc adipocytes.
It has also previously been suggested that the mTOR pathway is in-
volved in the phosphorylation of Ser616/Ser636 (corresponding to
Ser612/Ser632 in mice) following prolonged insulin stimulation of
3T3-L1 adipocytes and in muscle and adipose tissue from insulin-
treated mice (Gual et al., 2003). In the present study, the ability of
rapamycin to prevent the insulin phosphorylation of Ser616 and
636 on IRS1 is consistent with this hypothesis. The IRS1 serine
phosphorylation sites at 616 and 636, located in the PI3K binding
domain of IRS1, are well established to be inhibitory of the tyrosine
phosphorylation of IRS1 that leads to the termination of the insulin
signalling (Tanti and Jager, 2009). However, the described preven-
tion of insulin-stimulated phosphorylation of IRS1 Ser616/Ser636
and of IR Tyr1146 induced by rapamycin was not associated, as ex-
pected, with changes in the insulin-stimulated IRS1 tyrosine phos-
phorylation or in IRS1 associated p85 subunit of PI3K. A likely
explanation is that the remaining IR phosphorylation has sufﬁcient
catalytic activity towards the IRS1 substrate. Moreover it is also
possible that prevention of IRS1 serine phosphorylation by rapa-
mycin reduces the pathways that normally act to attenuate the
IRS1 signalling. This also suggests that PI3K-mediated PDK1 trans-
location to the membrane is intact and under these conditions rap-
amycin inhibitory effects in the IR tyrosine phosphorylation and
IRS1 serine phosphorylation may be not physiologically relevant.
In the present study a time-dependent decrease in IRS2 protein
levels was observed in rapamycin treated adipocytes. It has previ-
ously been shown that after prolonged insulin exposure (4–48 h),
or in insulin resistant states, a reduction in IRS2 gene expression
is observed in rat adipocytes (Renstrom et al., 2005). Therefore, a
reduction or dysfunction on the IRS2 protein levels may contribute
to the development of impaired insulin signalling. In addition, a
polymorphism in the IRS2 gene is known to be a determinant of
insulin sensitivity in both healthy, glucose tolerant individuals
and those with type 2 diabetes (Mammarella et al., 2000). To deter-
mine if the reduction in protein content was related with the pro-
tein gene expression, the mRNA levels were determined and
showed that IRS2 gene expression was increased after rapamycin
treatment. Thus, the decrease IRS2 protein levels may instead be
due to protein degradation or post-translational modiﬁcations
and the increase in mRNA expression could therefore be a compen-
satory phenomenon.
Taken together (Fig. 6), this study demonstrated that therapeu-
tic rapamycin concentrations impaired glucose uptake in human sc
and omental adipocytes. This effect may be explained by decreased
mTORC2 assembly and PKB Ser473 phosphorylation, with a conse-
quent down-regulation of AS160 Thr642 phosphorylation, which is
required for efﬁcient glucose uptake. Rapamycin also promotes re-
duced IRS2 protein levels and pTyr–IR. These ﬁndings reinforce
mTOR as being a central regulator of glucose metabolism in human
adipocytes and its inhibition may potentially contribute to the
development of new onset diabetes associated with rapamycin
therapy in organ-transplanted patients. Future studies on
Fig. 5. Rapamycin regulates sc adipocyte IRS2 protein level and mRNA expression. (A) Isolated adipocytes were exposed for the indicated times, in absence or presence of
0.01 lM rapamycin and thereafter with or without insulin (1000 lU/ml) for additional 15 min for immunoblotting analysis of IRS2 protein levels in human sc adipocytes
(n = 4–7). Control and rapamycin treated conditions for each incubation time are different parts of the same gel. Results show representative gels and mean ± SEM of
densitometry analysis. (B) The IRS2 mRNA levels was measured by real-time PCR in sc adipose tissue incubated in absence or presence of 0.01 lM rapamycin for 20 h, n = 21.
⁄p < 0.05; ⁄⁄⁄p < 0.001.
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adipocytes and adipose tissue from transplanted patients with and
without rapamycin therapy are suggested to further assess these
ﬁndings.
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ABSTRACT 
Immunosuppressive agents are associated with metabolic side effects including new-onset 
diabetes after organ transplantation. We investigated the effects of therapeutic concentrations of 
the calcineurin inhibitors, cyclosporin A (CsA) or tacrolimus, on glucose uptake and insulin 
signalling in human isolated adipocytes and on the regulation of cellular trafficking of the 
GLUT4 in differentiated human pre-adipocytes and L6 cells.  
CsA and tacrolimus had a concentration-dependent inhibitory effect on basal and insulin-
stimulated 14C-glucose uptake in adipocytes. Although phosphorylation at Tyr1146 of insulin 
receptor was inhibited by tacrolimus, the phosphorylation and/or protein levels of insulin 
signalling proteins: IRS1/2, p85-PI3K, PKB, AS160 and mTOR1C as well as GLUT4 and 
GLUT1 were unchanged by CsA and tacrolimus incubation. Furthermore, CsA and tacrolimus 
reduced the GLUT4 amount localized at the cell surface of differentiated human pre-adipocytes, 
and they reduced cell surface amount of myc-tagged GLUT4 in L6 cells in the presence of 
insulin. This occurred by increased GLUT4 rate constant for endocytosis, with no changes in the 
exocytosis trafficking.  
These results suggest that therapeutic concentrations of CsA and tacrolimus can inhibit glucose 
uptake independent of insulin signalling by removing GLUT4 from the cell surface via increased 
rate constant for endocytosis. Such mechanisms can contribute to the development of insulin 
resistance associated with immunosuppressive therapy, and they may provide novel 
pharmacological approaches for treatment of diabetes. 
 
Keywords: Cyclosporin A, Tacrolimus, Glucose uptake, Insulin signalling, Immunosuppressive 
agents, New onset diabetes after transplantation, Adipocytes, GLUT4 endocytosis, L6 cells  
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INTRODUCTION 
The calcineurin inhibitors, cyclosporin A (CsA) and tacrolimus, are immunosuppressive agents 
frequently used to prevent rejection after solid organ transplantation, as well as for treatment of 
autoimmune diseases (1). Despite the expected action on the immune system, long-term treatment 
with either CsA or tacrolimus is associated with toxic effects, which have a negative impact in 
the patient’s long-term outcome (2). Experimental and clinical studies suggest that CsA and 
tacrolimus are associated with increased risk for developing new-onset diabetes after 
transplantation (NODAT) (3, 4). NODAT has been reported to occur in 15-50% of the transplant 
recipients and is recognized as a risk factor for cardiovascular diseases, graft rejection and death 
(5, 6).  
Both in vitro and ex vivo biopsy studies, from either animals or humans, indicate that calcineurin 
inhibitors have dose-dependent inhibitory effects on beta-cell function, resulting in reduced 
insulin synthesis and secretion (7, 8). Furthermore, recent studies in both mice and humans have 
indicated that treatment with calcineurin inhibitors is associated with reduced insulin sensitivity 
in peripheral tissues, as well as, impaired endothelial function (9-14). However, the mechanisms 
for glucose intolerance are not known, and the direct effects of CsA and tacrolimus on human 
adipocytes have never been studied. 
CsA and tacrolimus mediate their immunosuppressive action by interrupting Ca2+/calmodulin – 
calcineurin signalling pathways on T cells, thereby blocking antigen-stimulated gene expression 
of interleukin-2, a growth factor critical for T cell proliferation (15). In other cells types, 
calcineurin is also implicated in the control of transcription factors (16), ion homeostasis (17), 
intracellular inositol 1,4,5-triphosphate receptor expression (18) and actin cytoskeleton 
organization (19).  
Glucose uptake into muscle and adipose tissue is the major mechanism by which normal whole-
body glycaemia levels are maintained (20). This process is stimulated by insulin, and mediated by 
glucose transporters, mainly GLUT4 (20). In the absence of insulin, only 5-10% of the total 
cellular GLUT4 content is present at the cell surface in both adipocytes and muscle cells (21, 22). 
Insulin induces the translocation of GLUT4 from intracellular vesicles to the plasma membrane, 
mostly through signalling from the insulin receptor via the insulin-receptor substrates (IRS), to 
phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB) (23). Skeletal muscle is the 
main tissue responsible for insulin-dependent glucose uptake, whereas adipose tissue accounts for 
only a small fraction (24). Despite this, mice with adipose-selective depletion of GLUT4 develop 
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impaired glucose tolerance, apparently due to insulin resistance induced in muscle and liver (25). 
Thus, adipose tissue is crucial in regulating glucose metabolism beyond its intrinsic contribution 
to whole-body glucose handling and signalling, e.g. via adipokines and neuroendocrine pathways, 
it can contribute to insulin resistance and the development of type 2 diabetes (26).    
The main objectives of this study were to investigate the direct effects of therapeutic 
concentrations of either CsA or tacrolimus on glucose uptake and effects on insulin signalling in 
human isolated adipocytes, and on the regulation of cellular trafficking of the glucose transporter 
GLUT4 in differentiated human pre-adipocytes and L6 cells.  
 
MATERIAL AND METHODS 
Adipose tissue donors  
Human abdominal subcutaneous (n=44) and omental (n=11) adipose tissue biopsies were 
obtained from a total of 44 non-diabetic subjects (19 men/25 women; age 23-70 years; body mass 
index (BMI) 20-36 kg/m2). Subjects fasted overnight (>10 h) and venous blood samples were 
collected for analysis of glucose, insulin and lipids by routine methods at the Department of 
Clinical Chemistry, Sahlgrenska University Hospital. Adipose tissue biopsies were performed by 
needle aspiration from the lower part of the abdomen after local dermal anaesthesia with 
lidocaine (Xylocain; AstraZeneca, Södertälje, Sweden), or by elective abdominal surgery after 
induction of general anaesthesia.  
Clinical and biochemical characteristics of the adipose tissues donors are shown in Table 1. Some 
of the subjects donating adipose tissue in this study were also part of a previous published study 
elucidating metabolic effects of rapamycin (27). Subjects with diabetes, other endocrine 
disorders, systemic illnesses or malignancy, as well as ongoing medication with systemic 
glucocorticoids and immune modulating therapies were excluded from the study. The study 
protocol was approved by the Regional Ethics Review Board in Gothenburg. Written informed 
consent was received from all subjects.  
 
Adipocyte isolation  
Isolated adipocytes were obtained from both needle and surgical biopsies after collagenase type II 
digestion (from Clostridium histolyticum, Sigma Chemical Co., St. Louise, MO, USA), in Hank’s 
medium  (Invitrogen Corporation, Paisley, UK) containing 6 mM glucose, 4% BSA (Sigma), 0.15 
µM adenosine (Sigma), pH 7.4 for 60 min at 37ºC in a shaking water-bath. Isolated adipocytes 
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were filtered through a 250 µm nylon mesh and were washed four times in Hank’s medium 
without glucose (4% BSA, 0.15 µM adenosine and pH 7.4). The average cell diameter was 
measured in isolated subcutaneous and omental adipocytes (28).  
 
Culture of adipocytes 
To investigate the effects of short-term pre-incubations (15 min) with either CsA (Sigma) (1-
1000 nM) or tacrolimus (Sigma) (1-1000 nM) on glucose uptake, freshly isolated subcutaneous 
(n=8-17) and omental adipocytes (n=8) were diluted to a lipocrit of 5% in Hank’s medium (4% 
BSA, 0.15 µM adenosine and pH 7.4) without glucose.   
To further investigate the effects of long-term pre-incubations (20h) of either CsA or tacrolimus 
on glucose uptake, the subcutaneous and omental adipocytes (n=8 and n=5, respectively) were 
placed in polystyrene flasks containing DMEM (Invitrogen) with 6 mM glucose, 10% FBS 
(Invitrogen), 1% PEST (Invitrogen) in the absence or presence of either CsA or Tacrolimus (100 
nM). Adipocytes were pre-incubated at 37ºC under a gas phase of 5% CO2 with gentle agitation 
(∼ 30 rpm) in a culture chamber (29). After incubation the cells were washed and diluted in fresh 
Hank’s medium without glucose and placed in a shaking water-bath in the absence or presence of 
CsA or tacrolimus (100 nM) before glucose uptake was assessed.  
For immunoblotting analysis, freshly isolated subcutaneous adipocytes were diluted to a lipocrit 
of 5% in Hank’s medium (4% BSA, 0.15 µM adenosine and pH 7.4) with 5.6 mM glucose, and 
pre-incubate with either CsA or tacrolimus (100 nM) for 15 min (n=5) or 20 h (n=4-6).  
 
Assessment of cell viability 
The effect of CsA and tacrolimus on adipocyte viability was assessed by using the water-soluble 
tetrazolium-1 colorimetric assay (WST-1, Roche, Mannheim, Germany). Adipocytes were placed 
in a 48 well plate at a lipocrit of 5% in Hank’s medium (5.6 mM glucose, 4% BSA, 0.15 µM 
adenosine and pH 7.4) with or without CsA or tacrolimus (100 and 1000 nM). After 24 h, WST-1 
was added to each well, and the cells were incubated for 2 h at 37ºC before absorbance was 
measured at 450 nm.  
The viability of adipocytes was not significantly affected after 24 h incubation with CsA or 
tacrolimus (90 to 100%, p=ns), when compared to untreated cells. 
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Glucose uptake 
Glucose uptake in subcutaneous and omental adipocytes was assessed as previously reported (27, 
30). Briefly, after short-term (15 min) and long-term (20 h) pre-incubations with or without either 
CsA or tacrolimus, adipocytes were incubated at 37ºC for a further 15 min with or without human 
insulin (6 nM; Actrapid, Novo Nordisk A/S, Copenhagen, Denmark) and/or okadaic acid (1 µM; 
Alexis Biochemicals, Lausen, Switzerland) before the addition of D-[U-14C] glucose (0.26 
mCi/L, final conc. 0.86 µM; Amersham Biosciences GE HealthCare, Buckinghamshire, UK) for 
another 45 min (total incubation time was 75 min and 21 h for short-term and long-term 
incubation, respectively). Glucose uptake was stopped and the cell-associated radioactivity was 
determined by scintillation counting. Experiments were performed in triplicates.  
 
Adipocyte lysates and immunoblotting 
Immunoblotting was performed as previously described (27). Briefly, after the indicated pre-
incubations, adipocytes were stimulated with or without a maximal insulin concentration (6 nM) 
for an additional 15 min, before the cells were lysed in ice-cold buffer containing 25 mM Tris-
HCl pH 7.4, 0.5 mM EGTA, 25 mM NaCl, 1% Nonidet P-40, 1 mM Na3VO4, 10 mM NaF, 0.2 
mM leupeptin, 1 mM benzamidine, 0.1 mM 4-(2-aminoethyl)-benzenesulfonylfluoride 
hydrochlorine and 0.1 µM okadaic acid. Aliquots of total lysate (15 µg/lane), a fat free extract, 
were subjected to SDS-PAGE, transferred to a nitrocellulose membrane and were immunoblotted 
with primary antibodies: anti-IRS1, anti-IRS2, anti-insulin-receptor β-subunit (IR),  anti-p85 
subunit of phosphoinositide 3-kinase (p85-PI3K) and anti-GLUT1 (Upstate Biotechnology, Lake 
Placid, NY, USA); and anti-AS160, anti-phospho-AS160 Thr642, anti-PKB1, anti-phospho-PKB 
Thr308, anti-phospho-PKB Ser473, anti-mammalian target of rapamycin (anti-mTOR), anti-
p70S6 Kinase, anti-phospho p70S6K (Thr421/Ser424), anti-insulin receptor β  (Tyr1146), anti-
GLUT4 (Cell Signaling Technologies, Beverly, MA, USA). Antibodies were diluted according to 
the manufacturer’s instructions and incubated over-night at 4ºC. Thereafter membranes were 
incubated during 1 h with HRP-conjugated secondary antibody (anti-rabbit or anti-mouse 
secondary antibodies, Cell Signaling Technologies). Detection was made with 
chemiluminescence reagent (ECL, Amersham Biosciences) using a high performance 
chemiluminescence film (Amersham Biosciences).  
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Human preadipocytes differentiation and GLUT4 immunofluorescence analysis 
Human primary preadipocytes (n=4) were cultured in DMEM supplemented with 10% FBS and 
1% PEST in Lab Tek II chamber glass slides (Nalgene Nunc International, Naperville, IL, USA). 
Confluent pre-adipocytes were differentiated with DMEM containing 3% FBS, 850 nM insulin, 
10 µM dexamethasone (Sigma), 0.50 mM 3-isobutyl 1-methylxanthine (Sigma), 10 µM 
pioglitazone (Sigma), 33 µM biotin (Sigma) and 17 µM pantothenate (Sigma). After 4 days the 
differentiation medium was replaced with growth medium (10% FBS, 142 mU/ml insulin, 1 µM 
dexamethasone and 1 µM pioglitazone), and incubated for additional 15 days. Differentiated 
adipocytes were serum starved over-night and were incubated with or without CsA or tacrolimus 
(100 nM) for 75 min, and 6 nM insulin was added in the last 20 min.     
For GLUT4 cell-surface labelling the cells were washed with ice-cold PBS and then fixed in 4% 
paraformaldehyde/PBS (Histolab Products AB, Gothenburg, Sweden) for 20 min. This and all 
subsequent steps were performed at room-temperature. After fixation, non-specific staining was 
reduced by incubation cells in blocking buffer containing 20% FCS in PBS during 30 min. The 
cells were incubated with rabbit polyclonal anti-GLUT4 antibody (diluted 1:200, antibody 
recognizing several epitopes in various regions of GLUT4 potentially including extracellular 
parts, from Millipore Corporation, Darmstadt, Germany) in 5% FCS in PBS for 3 h. After 
washing, the cells were incubated with the secondary antibody conjugated with the fluorochrome 
Alexa Fluor 594 goat anti-rabbit IgG (Molecular Probes, Eugene, OR, USA) diluted 1:500 in 5% 
FCS in PBS during 1 h. After washing in PBS, the cover slips were mounted in vectashield H-
1000 (Vector Laboratories, Burlingame, CA, USA) for confocal microscopy. Confocal 
microscopy was performed with a Leica SP5 confocal system, attached to a Leica DMI6000 
inverted microscope and using a 63x oil immersion objective. Images were processed with NIH 
ImageJ software (Java-based public version).  
 
Culture of L6-GLUT4myc cells and assessment of its 2-deoxy-D-[3H] glucose uptake  
L6 cells that stably expresses the GLUT4 protein containing a fourteen amino acid epitope human 
c-myc within its first exofacial loop, were kindly provided by Dr. A. Klip (The Hospital for Sick 
Children, Toronto, Ontario, Canada), and were cultured as previously described (31). By 
allowing highly reproducible quantitative measurements of the cell surface availability of the 
myc-epitope, L6 cells expressing GLUT4myc are an ideal model to study GLUT4 traffic and 
have been extensively characterized (31-33). The L6 cells were maintained in minimal essential 
medium-α  (Invitrogen) supplemented with 10% FCS (at 37ºC, 5% CO2), and used at confluence 
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2 days after seeding. The cells were serum-starved for 3-4 h and were incubated with or without 
CsA and tacrolimus (100 nM) for 75 min, and 100 nM insulin (Humulin R, Lilly, Solna, Sweden) 
was added, or not, in the last 20 min. 2-Deoxy-glucose (2-DG) uptake was measured as described 
previously (34). Briefly, 2-DG uptake was measured at room-temperature for 10 min in the 
respective ionic solution containing 10 µM nonradioactive 2-DG (Sigma) and 24.4 nM 2-deoxy-
[3H] glucose (0.5 µCi/ml; Amersham Biosciences). The reaction was stopped by washing twice 
with ice-cold 0.9% NaCl containing 25 mM β-D-glucose (Sigma). Specific uptake was 
normalized to total protein content.  
 
Immunodetection of cell surface GLUT4myc in L6 cells 
The amount of cell surface GLUT4myc was determined by an antibody-coupled colorimetric 
absorbance assay as previously described (32), with some modifications. Briefly, following 
stimulation, L6 cells were fixed with 4% paraformaldehyde/PBS for 10 min, and then neutralized 
with 1% glycine in PBS at 4ºC for 10 min. Cells were blocked with 10% goat serum (Invitrogen) 
in PBS at 4ºC for 30 min and then incubated with polyclonal anti-Myc antibody (diluted 1:100, 
Sigma) for 60 min. After washing with PBS, the L6 cells were incubated with peroxidase-
conjugated goat anti-rabbit IgG (diluted 1:1000) for 1 h. Cells were washed 6 times with ice-cold 
PBS, before OPD reagent (Sigma) was added for 30 min at room-temperature. The reaction was 
stopped with HCl, and optical absorbance of the supernatant was measured at 492 nm.  
 
GLUT4myc internalization (endocytosis) and externalization (exocytosis) 
GLUT4myc internalization and externalization was measured in L6 myoblasts as previously 
reported (32). Briefly, cells were stimulated with 100 nM insulin, rinsed with ice-cold PBS and 
incubated with polyclonal anti-Myc antibody (1:100; Sigma) at 4ºC during 1 h.  
For internalization measurements, the surface-labelled GLUT4myc was allowed to internalize by 
placing the cells at 37ºC in the presence or absence of insulin (100 nM) and either CsA or 
tacrolimus (100 nM). At indicated time points, cells were placed on ice, washed 3 times with ice-
cold PBS, fixed with 4% paraformaldehyde/PBS for 10 min, and incubated with goat anti-rabbit 
IgG for 1 h at 4ºC. The amount of GLUT4myc remaining at the cell surface was measured as 
previously indicated. The data were fitted by nonlinear regression for a single exponential 
association, and the kinetics of GLUT4 traffic was measured with the equation Y(t)=Ymin+(Ymax-
Ymin)(1-e-kt), where Y(t) represents the cell surface GLUT4myc-antibody at time t; Ymin is the 
amount of GLUT4myc-antibody bound at the earliest time point; Ymax is the calculated maximum 
9 
 
amount of GLUT4myc-antibody bound at t = ∞; and k is the rate constant for endocytosis (ken), as 
previously reported (35).    
For measurement of externalization the surface-labelled GLUT4myc was allowed to internalize 
by warming up the cells at 37ºC for 30 min. The cells were then stimulated without or with 
insulin (100 nM) and either CsA or tacrolimus (100 nM) during 5, 10 and 20 min. Cells were 
placed on ice, washed 3 times with ice-cold PBS, fixed with 4% paraformaldehyde/PBS for 10 
min before incubation with goat anti-rabbit IgG for 1 h at 4ºC. The amount of GLUT4myc 
remaining at the cell surface was measured as described above. 
 
Statistical Analysis 
Differences between control and treated conditions were performed pair-wise using Wilcoxon 
signed-rank test or paired Student’s t-test, as appropriate. Thus, comparisons between treated and 
untreated cells were performed pair-wise within the same subject and experiment to minimize 
confounding variables. Results are given as mean ± standard error of the mean (SEM), or as 
indicated. A p-value <0.05 was considered statistically significant. Statistical analyses were 
performed using the SPSS package version 18 (SPSS Inc., Chicago, IL). 
 
RESULTS 
Cyclosporin A (CsA) and tacrolimus inhibit glucose uptake in human adipocytes  
Short-term incubation of subcutaneous isolated adipocytes with CsA (5-1000 nM) or tacrolimus 
(1-1000 nM) significantly decreased basal and insulin-stimulated (6 nM) glucose uptake in a dose 
depended manner by up to 40% (Fig. 1A). The inhibitory effect on insulin-stimulated glucose 
uptake was similar when a lower concentration of insulin (0.15 nM) was used (data not shown). 
In omental adipocytes, similar effects were observed after short-term incubation, both basal and 
insulin-stimulated (6 nM) glucose uptake were significantly decreased by up to 30% (Fig. 1B) 
upon treatment with either drug. After long-term incubation with CsA or tacrolimus, basal 
glucose uptake was inhibited by ~10%, while insulin stimulated glucose uptake was inhibited by 
~20% in subcutaneous as well as omental adipocytes (Fig. 1C). Moreover, short-term pre-
incubation with CsA or tacrolimus (100 nM) also inhibited glucose uptake stimulated by okadaic 
acid by ~20% (Fig. 1D). 
10 
 
CsA and tacrolimus inhibit insulin-stimulated insulin receptor (IR) phosphorylation  
CsA and tacrolimus did not change total IR protein levels after 15 minutes or 20 h pre-
incubations (Figure 2). Instead, tacrolimus reduced insulin-stimulated IR Tyr1146 
phosphorylation at both incubation times by ~30% (p<0.05, Fig. 2A and B).  
 
No effects of CsA and tacrolimus on insulin signalling proximal to AS160 
Incubation with CsA or tacrolimus did not change the protein levels or the insulin-stimulated 
phosphorylation of IRS1, IRS2, p85-PI3K or PKB (Fig. 3A and B). Similar results were obtained 
for AS160 protein levels or phosphorylation, as well as GLUT4 and GLUT1 protein expression 
levels (Fig. 3C). Moreover, CsA and tacrolimus did not affect protein levels or phosphorylation 
of mTOR or its downstream target p70S6K (Fig. 3D). 
 
CsA and tacrolimus reduce the amount of GLUT4 localized at the cell surface 
Fluorescence labelling with anti-GLUT4 in the plasma membrane of adipocytes is shown in Fig. 
4. Insulin increased by ~4-fold the amount of GLUT4 at cell surface, compared with basal (Fig. 
4A and B). Short-term incubation with CsA or tacrolimus (100 nM) significantly reduced the 
amount of insulin-stimulated GLUT4 at the adipocyte surface by ~60% (Fig. 4A and B), and had 
no effect on basal amount of GLUT4 at cell surface (data not shown).  
 
Effects of CsA and tacrolimus on glucose uptake and GLUT4myc trafficking in L6 cells  
Short-term incubation of L6 cells with CsA or tacrolimus (100 nM), significantly reduced insulin-
stimulated (100 nM) glucose uptake by ~15% (Fig. 5A) and cell surface GLUT4myc by ~20% 
(Fig. 5B).  
GLUT4myc internalizes with similar rate constants for endocytosis in basal and insulin-
stimulated conditions (ken= 0.29 and 0.30 min-1, respectively, Fig. 6A and B).  CsA or tacrolimus 
increased the insulin-stimulated GLUT4myc rate constants for endocytosis (ken insulin = 0.30 min-1, 
ken insulin+CsA = 0.39 min-1 and ken insulin+tacrolimus = 0.44 min-1, Fig. 6B), but had modest effect on the 
basal endocytosis (ken basal = 0.29 min-1, ken CsA = 0.31 min-1 and ken tacrolimus = 0.33 min-1, Fig. 6A). 
In addition, CsA and tacrolimus, significantly decreased the fraction of cell surface GLUT4myc 
remaining at the cell surface by up to 30%, after 10 or 20 min incubations and in insulin-
stimulated conditions (Yinsulin ~ 0.30, YCsA+insulin ~  0.19 and Ytacrolimus+insulin ~  0.21, Fig. 6B). To 
identify the effects of CsA and tacrolimus on exocytosis, the re-exocytosis of the internalized 
anti-Myc antibody labelled GLUT4myc was measured (Fig. 6C). The amount of GLUT4myc 
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recycled back to the membrane after 20 min incubation was significantly increased by ~ 2-fold by 
the presence of insulin. CsA and tacrolimus had no effect on the basal or insulin-stimulated re-
exocytosis rate (Fig. 6C).  
 
DISCUSSION  
In this study we demonstrate that the calcineurin inhibitors, CsA and tacrolimus, at therapeutic 
concentrations commonly used in clinic, inhibited glucose uptake in human subcutaneous and 
omental adipocytes and in L6 muscle cells. This appears to be independent of the insulin 
signalling cascade, and removal of GLUT4 from the cell surface via increased rate constant for 
endocytosis may be a novel mechanism for the diabetogenic effects of the calcineurin inhibitors. 
These mechanism clearly differ from that of another class of immunosuppressive agents, namely 
mTOR inhibitors, and we recently reported major alterations in insulin signalling and action in 
human adipocytes exposed to rapamycin (27).    
 
The majority of the studies that have examined the diabetogenic effects of CsA and tacrolimus, 
indicate that these calcineurin inhibitors inhibit insulin production and secretion from the beta-
cells of the islets of Langerhans (7, 8), but a reduction in peripheral insulin sensitivity has also 
been suggested (13, 14).  The reduction of glucose uptake in both subcutaneous and omental 
adipocytes after both short- and long-term incubation with either CsA or tacrolimus, as well as in 
L6 cells, suggests that these drugs may contribute to the development of insulin resistance by 
inhibiting glucose uptake in insulin-sensitive cells. Short-term incubation with CsA or tacrolimus 
(100 nM) seems to have higher inhibitory effect on glucose uptake in human adipocytes (~30%) 
than in L6 cells (~15%).  
 
Results from several randomised clinical trials and meta-analyses, have suggested that tacrolimus 
is more diabetogenic than CsA (36-38), although this has not been confirmed by others (39, 40). 
In our study, however, the dose response relationships with respect to impairment of glucose 
uptake were similar for the two drugs. These effects of CsA and tacrolimus could be detected at 
low concentrations (1-5 nM) that were even bellow the recommended therapeutic ranges for both 
CsA (40-80 nM) and tacrolimus (6-12 nM) (41)  and with similar dose-response effects. The 
proportion of inhibition of basal glucose uptake by CsA and tacrolimus after long-term 
incubation appear to be less severe than short-term inhibition. This effects may be due to a pre-
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existing impairment of glucose uptake in these adipocytes caused by a more prolonged pre-
incubation time (20 h), masking any further effects of the drugs.      
In addition, we show that CsA and tacrolimus inhibit glucose uptake stimulated by okadaic acid. 
Okadaic acid, a protein phosphatases type 1 (PP1) and 2A (PP2A) inhibitor, stimulates adipocyte 
PKB kinase activity and glucose transport independent of PI3K activation (42, 43). These 
observations support that CsA and tacrolimus mediate their effects independent of PI3K 
activation.  
 
A reduction in IR Tyr1146 activation by ~30% was found in adipocytes incubated with 
tacrolimus, when compared with untreated adipocytes. However, the concentration of insulin 
required to maximally activate glucose transport elicits only about 15% of the maximal receptor 
kinase activity (44), compatible with the spare receptor concept. Indeed, the observed inhibitory 
effect on the phosphorylation of the IR, was not associated with any change in expression or 
phosphorylation of the proximal insulin signalling cascade proteins (IRS1/2, p85-PI3K, PKB, 
mTOR, p70S6K), or GLUT4 and GLUT1 protein levels.  
 
Taken together, these data indicate that the inhibitory effects of CsA and tacrolimus on glucose 
uptake are not mediated through effects on the early steps of the insulin signalling cascade. 
Therefore we propose that the reduced insulin-stimulated glucose uptake observed in 
subcutaneous and omental adipocytes treated with either CsA or tacrolimus could be due to 
effects on the intracellular trafficking of GLUT4, independent of the insulin signalling 
machinery. Our results support this hypothesis as they show that CsA and tacrolimus reduced 
GLUT4 amounts at the plasma membrane of differentiated human preadipocytes by up to ~60%, 
returning almost to basal levels. Effects on cell-surface GLUT4 are consistent with the inhibitory 
effects on insulin-stimulated glucose uptake in subcutaneous adipocytes which also almost return 
to basal levels. We also demonstrated that in L6 cells, CsA and tacrolimus inhibited insulin-
stimulated glucose uptake and cell surface GLUT4myc to a similar extent (~15-20%). Moreover, 
CsA and tacrolimus enhanced the insulin-stimulated rate constant for endocytosis of the 
GLUT4myc, but they had no effect on the exocytosis trafficking. Chronic insulin treatment has 
been reported to reduce glucose transport, and to double the rate constants for glucose 
endocytosis in rat adipocytes (45). These effects are ameliorated by inclusion of metformin in the 
culture medium, but the mechanism is not known. It thus could be hypothesised that targeting this 
endocytic pathway by novel pharmacological approaches may be a way to increase cell-surface 
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GLUT4. Since transmembrane glucose transport is considered to be rate-limiting for glucose 
metabolism, such a treatment, could mitigate impaired glucose metabolism during calcineurin 
and moreover, it could potentially provide a novel principle to improve glycaemic control in type 
2 diabetes. 
 
Effects of CsA and tacrolimus on basal glucose uptake seem to differ between human adipocytes 
and L6 cells. Furthermore, neither drug affected basal GLUT4 translocation in human adipocytes 
and L6 cells. These effects seem to suggest that differences in the sensitivity of internalization of 
GLUT4 to CsA and tacrolimus may involve a divergent signalling pathway with different insulin 
dependence. The question remains, about how CsA and tacrolimus increase the rate constant for 
GLUT4 endocytosis. GLUT4 is internalized mainly via clathrin-coated vesicles and a dynamin-
dependent route in adipocytes and muscle cells (46).  
The effect of CsA and tacrolimus on clathrin, dynamin and other adaptors proteins involved in 
docking, fusion and endocytosis of GLUT4 vesicles (e.g. adaptor protein 2, transferrin receptor, 
vesicle-associated membrane protein 2 and insulin-responsive aminopeptidase) should be further 
studied, since changes in the protein composition of GLUT4 vesicles may alter their subcellular 
distribution (47). Another intracellular mechanism required for insulin-mediated GLUT4 
trafficking is dynamic remodelling of actin filaments (48). Calcineurin regulates actin dynamics 
in renal podocytes by dephosphorylation of synaptopodin, thereby blocking the phosphorylation-
dependent synaptopodin-14-3-3β interaction (19). CsA also was reported to affect the actin 
dynamics in podocytes (19), thereby suggesting a possible mechanism affecting cytoskeleton 
function that can lead to altered vesicle trafficking.   
 
The present results indicate that the reduction in glucose uptake on insulin-sensitive adipocytes by 
CsA and tacrolimus could be involved in the pathogenesis of new-onset diabetes in patients 
treated with calcineurin inhibitors, but this in vitro study has several limitations. The number of 
subjects per experiment is limited and the same subjects were not used for all analysis. In 
addition, it should be noted that other cell types (differentiated humans preadipocytes and L6 
cells) were used for mechanistic experiments on GLUT4 localization and trafficking. In addition, 
the in vitro models do not take into account the complex cross-talk between tissues occurring in 
vivo in the regulation of glucose metabolism (26). Thus, the findings in this study need to be 
confirmed in vivo experiments in order to better understand the adverse mechanisms of 
calcineurin inhibitors and to develop strategies to overcome them. 
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In conclusion, we have demonstrated that the calcineurin inhibitors CsA and tacrolimus, impaired 
glucose uptake in subcutaneous and omental adipocytes and in L6 muscle cells. The effects 
appear to be independent of the insulin signalling cascade. Our data also suggest that CsA and 
tacrolimus enhanced rate constant for GLUT4 endocytosis in L6 cells. The described effect of 
CsA and tacrolimus on adipocytes and other insulin-sensitive cells, may contribute to impaired 
glucose handling in peripheral tissues, as reported with calcineurin inhibitor therapy in organ-
transplanted patients. In addition, these findings could potentially point to novel pharmacological 
mechanisms to inhibit endocytosis and increase cell surface availability of GLUT4. Such a 
treatment, would enhanced cellular glucose uptake and potentially improve glycaemic control in 
patients with impaired cellular glucose handling due to calcineurin inhibitor therapy.  
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Table 1 – Characteristics of the adipose tissue donors (n = 44).  
Variable Value 
Sex (male/female; n) 19/25 
Age (years) 50  ± 13 
Body mass index (kg/m2) 27.7 ± 4.0 
Waist-hip ratio (WHR) 0.92 ± 0.09 
Systolic blood pressure (mmHg)  132 ± 18 
Diastolic blood pressure (mmHg) 83 ± 11 
Subcutaneous adipocyte diameter (µm) a 99.8 ± 11.7 
Omental adipocyte diameter (µm) b 88.4 ± 19.7 
HbA1c (mmol/mol, IFCC) c 34 ± 4 
Glucose (mmol/L) 5.1 ± 0.6 
Insulin (mU/L) 8.6 ± 6.0 
HOMA-IR d 1.7 ±  1.1 
Body fat mass (%) 32.1 ± 7.1 
Triglycerides (mmol/L) 1.2 ± 0.4 
Cholesterol (mmol/L) 6.0 ± 1.3 
LDL-cholesterol (mmol/L) 3.9 ± 1.1 
HDL-cholesterol (mmol/L) 1.7 ± 0.6 
Data are means ± SD.  
a
 n=44; b n=11; c Normal range 27-46 mmol/mol (IFCC standard); d Homeostasis model 
assessment-estimated insulin resistance, calculated as: fasting insulin (mU/L) x fasting glucose 
(mM)/22.5 (49); HbA1c, glycosylated haemoglobin; LDL, low-density lipoprotein; HDL, high 
density lipoprotein  
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FIGURES 
Figure 1. 
 
Figure 1. Cyclosporin A (CsA) and tacrolimus reduce glucose uptake in subcutaneous and 
omental adipocytes.  
A: Freshly isolated human subcutaneous adipocytes (n=5-9) were pre-incubated during 15 min 
with or without different concentrations of CsA or tacrolimus (1 –1000 nM) and the incubation 
continued with or without insulin stimulation (6 nM) for an additional 15 minutes, before D-[U-
14C]-glucose was added, and glucose uptake was then assessed during the following 45 min. 
*p<0.05 and #p<0.05 CsA and tacrolimus treated vs. untreated. B and C: Freshly isolated human 
subcutaneous and omental adipocytes were pre-incubated short-term (15 min) (B) and long-term 
(20 h) (C) with CsA or tacrolimus (100 nM) and thereafter glucose uptake was measured as 
previously explained. (B, n=17 and n=8; C, n=8 and n=5 for subcutaneous and omental 
adipocytes, respectively). Total incubation times were 75 min (short-term) and 21 h (long-term). 
*p<0.05 and ***p<0.001 CsA and tacrolimus treated vs. untreated. D: Freshly isolated human 
subcutaneous adipocytes were pre-incubated during 15 min with CsA or tacrolimus (100 nM) and 
the incubation continued with okadaic acid (1 µM) as well as with or without insulin (6 nM) for 
an additional 15 minutes, and thereafter as previously reported (n=5). *p<0.05 CsA and 
tacrolimus treated vs. untreated. OkAc, okadaic acid. 
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Figure 2. 
 
 
Figure 2. Effects of Cyclosporin A (CsA) and tacrolimus on insulin-stimulated insulin receptor 
(IR) Tyr1146 phosphorylation.  
Insulin stimulated IR Tyr1146 phosphorylation is inhibited by 15 min and 20 h pre-incubation of 
adipocytes with tacrolimus (100 nM). Freshly isolated human subcutaneous adipocytes were 
incubated without (control) or with CsA and tacrolimus (100 nM) for 15 min (A) or 20 h (B), 
prior to insulin stimulation (6 nM) for additional 15 min. Lysates were analysed by 
immunoblotting analysis of IR protein levels and phosphospecific antibody against p-IR 
(Tyr1146), n=4-5. Results show representative blots. Data are mean ± SEM of densitometry 
analysis of insulin-stimulated IR Tyr1146 phosphorylation after CsA and tacrolimus treatment 
compared to untreated adipocytes (set to 1) and normalised to the respective protein levels (p-
IR/IR). *p<0.05 and **p<0.01 CsA and tacrolimus treated vs. untreated. 
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Figure 3. 
 
 
Figure 3. Cyclosporin A (CsA) and tacrolimus do not alter insulin signalling or total GLUT1 or 4 
levels.  
Freshly isolated human subcutaneous adipocytes were treated without (control) or with CsA or 
tacrolimus (100 nM) during 20 h and thereafter stimulated with or without insulin (6 nM) for 
additional 15 min. Immunoblotting analysis showed no effects of CsA or tacrolimus on protein 
levels or phosphorylation of IRS1/2 and phosphospecific antibody against p-IRS1 Tyr612, n=4-5 
(A); p85 subunit of PI3K, PKB and phosphospecific antibodies against p-PKB Ser473 and 
Thr308, n=4-5 (B); AS160, phosphospecific antibody against p-AS160 Thr642 and 
GLUT4/GLUT1, n=4-6 (C); and mTOR, p70S6K and phosphospecific antibodies against p-
mTOR Ser2448 and p-p70S6K Thr421/Ser424, n=3-4 (D).  
21 
 
Figure 4. 
 
 
Figure 4. Cyclosporin A (CsA) and tacrolimus inhibit the amount of GLUT4 localized at the 
adipocyte surface.  
Human pre-adipocytes differentiated into adipocytes were serum starved and incubated without 
or with CsA or tacrolimus (100 nM) during 75 min, and insulin (6 nM) was added in the last 20 
min. Cells were fixed and probed with anti-GLUT4 and with Alexa Fluor 594 goat anti-rabbit 
IgG. A: Immunofluorescence was detected using laser confocal microscopy. A representative 
image of 4 separate experiments is presented. Bars represent 25 µm. B: The fluorescence intensity 
(mean pixel density per are unit) was quantified and is represented as % relative to insulin. 
*p<0.05 and **p<0.01.  
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Figure 5. 
 
 
Figure 5. Cyclosporin A (CsA) and tacrolimus reduce glucose uptake and the amount of 
GLUT4myc at the L6 cell surface.    
Confluent L6-GLUT4myc cells were incubated in the presence or absence of CsA or tacrolimus 
(100 nM) for 75 min, and 100 nM insulin was added in the last 30 min. 2-deoxyglucose uptake 
(A), or cell surface density of GLUT4myc (B) were measured in culture plates. Glucose uptake 
and cell surface GLUT4myc detection are expressed relative to the respective basal control 
values. Data are presented as mean ± SEM of 8 separate experiments performed in duplicates. 
*p<0.05 CsA and tacrolimus treated vs. untreated. 
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Figure 6. 
 
Figure 6. Cyclosporin A (CsA) and tacrolimus increase insulin-stimulated endocytosis of 
GLUT4myc in L6 cells, and have little effect on the exocytosis.    
Confluent L6-GLUT4myc cells were incubated in the absence or presence of 100 nM insulin at 
37ºC for 30 min and thereafter with anti-Myc antibody for 1 h to label cell surface GLUT4myc. 
To measure the time course of internalization, cells were then re-warmed to allow endocytosis in 
the absence (A) or presence of 100 nM insulin (B) and CsA or tacrolimus (100 nM) for 2-20 min. 
At the indicated times cells were put on ice and the Myc antibody-labelled GLUT4myc remaining 
on the surface was measured with the optical densitometry detection assay. C: To measure the 
time course of stimulation, the cells were re-warmed to allow endocytosis in absence of insulin 
during 30 minutes. Cells were then incubated in absence or presence of insulin (100 nM) and 
CsA or tacrolimus (100 nM) for 5, 10 or 20 minutes. Cells were placed on ice again and the Myc 
antibody-labelled GLUT4myc remaining on the surface was analysed by the OPD optical 
densitometry detection assay. The amount of GLUT4myc remaining at the cell surface at any 
time point is expressed as a percentage of the cell surface GLUT4myc level at 0 min of 
incubation. Data points are mean ± SEM of 4-5 separate experiments each performed in 
duplicates. Line, single exponential fits. Rate constants for endocytosis (ken) were calculated from 
single exponential fits.   *p<0.05 CsA or tacrolimus and insulin-treated vs. insulin.   
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Abstract  
Cyclosporin A (CsA), tacrolimus and rapamycin are immunosuppressive agents (IA) associated 
with insulin resistance and dyslipidemia, although their molecular effects on lipid metabolism in 
adipose tissue are unknown.  
We explored IAs effects on lipolysis, lipid storage and expression of genes involved on lipid 
metabolism in human isolated adipocytes and/or adipose tissue obtained via subcutaneous and 
omental fat biopsies.  
CsA, tacrolimus and rapamycin increased isoproterenol-stimulated lipolysis and inhibited lipid 
storage by 20-35% and enhanced isoproterenol-stimulated hormone-sensitive lipase Ser552 
phosphorylation. Rapamycin also increased basal lipolysis (~20%) and impaired insulin’s 
antilipolytic effect. Rapamycin, down-regulated the gene expression of perilipin, sterol regulatory 
element-binding protein 1 and lipin 1, while tacrolimus down-regulated CD36 and aP2 gene 
expression. All three IAs increased IL-6 gene expression and secretion, but not TNF-α  or 
adiponectin.   
These findings suggest that CsA, tacrolimus and rapamycin enhance lipolysis, inhibit lipid 
storage and expression of lipogenic genes in adipose tissue, which may contribute to the 
development of dyslipidemia and insulin resistance associated with immunosuppressive therapy. 
 
Keywords: Cyclosporin A, Tacrolimus, Rapamycin, Lipolysis, Adipocytes, Lipid storage 
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1. Introduction 
The calcineurin inhibitors (CNIs), cyclosporin A (CsA) and tacrolimus, as well as the mTOR 
(mammalian target of rapamycin) inhibitor, rapamycin, are frequently used immunosuppressive 
agents (IA) to prevent rejection after solid organ transplantation and treat autoimmune diseases 
(Scherer et al., 2007). However, standard recommended doses are associated with the 
development of metabolic complications, including hyperlipidemia, and new-onset diabetes after 
transplantation (NODAT) (Parekh et al., 2012). The reported prevalence of these conditions has 
varied greatly, with estimates up to 50% for diabetes (Montori et al., 2002) and 20% to 80% for 
dyslipidemia (Kesten et al., 1997; Parekh et al., 2012), depending on the population, diagnostic 
criteria, mean follow-up time and type of IA therapy. These complications are well known risk 
factors for cardiovascular diseases and are associated with reduced graft and patient survival in 
transplant recipients (Massy, 2001). Clinical studies have shown that the IA increase serum levels 
of cholesterol, triglycerides and low-density lipoprotein (LDL), usually in a dose-dependent 
manner (Ichimaru et al., 2001; Li et al., 2012; Morrisett et al., 2002; Spinelli et al., 2011). In 
addition, rapamycin increases plasma free fatty acids (FFA) levels (Morrisett et al., 2002). 
Although CsA and tacrolimus are similar in terms of their mechanism of action, tacrolimus is 
associated with less adverse effects on the patient’s lipid profile (Bakar et al., 2009; Ichimaru et 
al., 2001; Vincenti et al., 2007), and one study even suggested beneficial effects (Perrea et al., 
2008).  
 
The underlying causes for this dyslipidemia are not clear, but CNIs therapy have been associated 
with reduced lipoprotein lipase (LPL) activity in plasma samples (Derfler et al., 1991; Tory et al., 
2009), thereby limiting triglycerides-rich lipoprotein clearance, while rapamycin has been shown 
to increase lipolysis rates in 3T3-L1 cells (Chakrabarti et al., 2010; Soliman et al., 2010). 
However, effects of immunosuppressive agents on lipid metabolism and on gene and protein 
expression of factors involved in regulation of lipid metabolism in human adipose tissue have 
never been studied.  
 
Adipose tissue is an important metabolic and endocrine organ involved in the regulation of 
energy intake and expenditure (Ahima, 2006; Ost et al., 2010). Postprandially, adipose tissue 
takes up glucose and FFA from the circulation and stores it as energy in the form of triglycerides 
(Large et al., 2004). During starvation, adipose tissue provides energy via breakdown of 
triglycerides into FFA and glycerol, a process known as lipolysis. Lipolysis is regulated by 
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various lipolytic and anti-lipolytic hormones. Adipocyte lipolysis is activated by catecholamines 
(e.g., epinephrine) binding to the β-adrenergic-receptors (β1, β2 and β3), which results in 
increased adenylate cyclase activity and cAMP formation (Jaworski et al., 2007). This leads to 
subsequent activation of protein kinase A (PKA) (Kraemer and Shen, 2002) and downstream 
targets, including adipose triacylglycerol lipase (ATGL), hormone-sensitive lipase (HSL) and 
perilipin (Kraemer and Shen, 2002; Schweiger et al., 2006; Tansey et al., 2004). Insulin is a 
powerful anti-lipolytic hormone in adipose tissue that inhibits lipolysis by stimulating 
phosphodiesterase 3B resulting in decreased cAMP levels and suppressed activation of PKA and, 
subsequently, HSL (Degerman et al., 1990).  
 
Dysregulation of fatty acid metabolism in adipose tissue may contribute to elevation of FFA in 
plasma and contribute to ectopic fat deposition in liver and skeletal muscle (Roden et al., 1996). 
These perturbations can promote systemic insulin resistance through several mechanisms, such as 
increased hepatic gluconeogenesis and decreased glycogen synthesis and glucose oxidation in 
skeletal muscle (Jensen, 2006).  
In addition to fatty acids, cytokines and adipokines are produced by human adipocytes and play a 
major role in glucose and lipid metabolism (Bastard et al., 2006). Increased levels of IL-6 and 
TNF-α  contribute to insulin resistance and dyslipidemia, while adiponectin is an insulin 
sensitizing adipokine (Bastard et al., 2006).  
 
The main objective of this study was to investigate the direct effects of the IA CsA, tacrolimus 
and rapamycin, at therapeutic concentrations, on lipolysis including interactions with 
catecholamine (isoproterenol) and insulin, and effects on lipid storage in human adipocytes, and 
expression of genes involved in regulation of lipid metabolism in human adipose tissue. 
 
 
2. Methods 
2.1 Subjects- Adipose tissue donors 
Human abdominal subcutaneous (n=57) and omental (n=18) adipose tissue biopsies were 
obtained from 60 non-diabetic subjects (26 men/34 women; age 18-72 years; body mass index 
(BMI) 20.9-36.4 kg/m2). Paired subcutaneous and omental adipose samples were obtained from 
15 of these subjects. Due to limited amount of adipose tissue obtained, not all experiments were 
performed in all biopsies and the number of experiments is indicated in each section bellow. 
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Subjects fasted overnight (>10 h) and fasting venous blood samples were collected in the 
morning for analysis of glucose, insulin and lipids by routine methods at the Department of 
Clinical Chemistry, Sahlgrenska University Hospital. Thereafter, adipose tissue biopsies were 
performed by needle aspiration of subcutaneous fat from the lower part of the abdomen after 
dermal local anaesthesia with lidocaine (Xylocain; AstraZeneca, Södertälje, Sweden) (n=36), or 
during elective abdominal surgery after induction of general anaesthesia (subcutaneous and/or 
omental, n=24).  
 
The clinical and biochemical characteristics of the adipose tissue donors are shown in Table 1. 
Anthropometric measurements including body composition assessed by bioimpedance were 
measured in all subjects (Lukaski et al., 1986). Subjects with diabetes, other endocrine disorders, 
systemic illnesses or malignancy, as well as ongoing medication with systemic glucocorticoids 
and immune modulating therapies were excluded from the study. One subject used local 
inhalation treatment with β2-agonist and glucocorticoids for asthma, two subjects had ongoing 
treatment due to depressive disorder (low-dose venlafaxine and lamotrigine plus aripiprazol, 
respectively) and one subject used oral contraception. The study protocol was approved by the 
Regional Ethics Review Board in Gothenburg. Written informed consent was obtained from all 
subjects.  
 
2.2 Isolation of subcutaneous adipocytes 
Adipocytes were isolated from subcutaneous fat obtained from both needle and surgical biopsies 
after collagenase type II digestion (from Clostridium histolyticum, Sigma Chemical Co., St. 
Louise, MO, USA) in Hank’s medium 199 (Invitrogen Corporation, Paisley, UK) that contained 
6 mM glucose, 4% BSA (Sigma), 0.15 µM adenosine (Sigma) (pH 7.4) for 60 min at 37ºC in a 
shaking water-bath. Isolated adipocytes were filtered through a 250-µm nylon mesh and washed 
four times in Hank’s medium. The average cell diameter was measured in isolated subcutaneous 
and omental adipocytes from all subjects (Lundgren et al., 2007).  
 
2.3 Lipolysis 
Effects of the IA on lipolysis in isolated subcutaneous adipocytes were essentially performed as 
previously reported (Lundgren and Eriksson, 2004; Palming et al., 2006). The adipocyte 
suspension (lipocrit 3-5%) were incubated in the presence or absence of CsA (0.1 µM) (Sigma), 
tacrolimus (0.1 µM) (Sigma) or rapamycin (0.01 µM) (Sigma) in Hank’s medium containing 5.6 
mM glucose, 4% BSA, 0.15 µM adenosine, pH 7.4 in a gently shaking water bath at 37ºC for 2 h. 
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To test the effect of the IA on lipolysis (n=13 with all conditions and additional 3 with all but 
0.01 µM isoproterenol-stimulated conditions; duplicates) and on the antilipolytic effect of insulin 
(n=6; duplicates), the medium was supplemented or not with isoproterenol (0.01 or 1 µM) and 
insulin (0-100 µU/ml) and glycerol released into the medium was measured by colorimetric 
absorbance in a kinetic enzymatic analyser (Microdialysis Analyser CMA600; CMA 
Microdialysis AB, Sweden), and used as an index of lipolysis.  
 
2.4 Lipid storage 
Lipid storage in subcutaneous adipocytes was measured using glucose (lipogenesis) and 
palmitate, as substrates, and essentially performed as previously reported (Gathercole et al., 2011; 
Palming et al., 2006). For the 14C-glucose experiments (n=8; duplicates), the adipocyte 
suspension (lipocrit 3-5%) were incubated without or with CsA (100 nM), tacrolimus (100 nM) 
(Sigma) or rapamycin (10 nM) in Hank’s medium (5.6 mM glucose, 4% BSA, 0.15 µM 
adenosine, pH 7.4) supplemented or not with insulin (1000 µU/ml) and with D-[U-14C] glucose 
(0.26 mCi/L, 0.86 µM, Amersham Biosciences GE Healthcare, Buckinghamshire, UK) in a 
gently shaking water bath at 37ºC for 2 h. In the 14C-palmitate assay (n=5; duplicates), the 
adipocyte suspension (lipocrit 3-5%) was treated without or with CsA (100 nM), tacrolimus (100 
nM) (Sigma) or rapamycin (10 nM) in DMEM (5.6 mM glucose, 10% FCS, 1% penicillin-
streptomycin) (Invitrogen) and sodium-palmitate/BSA-mix (Sigma) (0.12 mM sodium palmitate, 
40% BSA) supplemented with [1-14C] palmitic acid (1.0 µCi/ml, Perkin Elmer, Boston, MA, 
USA), in a gently shaking water bath at 37ºC for 2 h. Then, the adipocytes were separated by 
centrifugation through silicone oil and the cellular lipids, which mainly consist of triglycerides 
(Large et al., 2004), were immediately extracted according to the two-phase method described by 
Dole and Meinertz (Dole and Meinertz, 1960). The upper n-heptane phase (1 ml) was evaporated 
to dryness and the 14C-glucose incorporation in the glyceride-glycerol moiety (lipogenesis) and 
the 14C-palmitate esterification in cellular triglycerides, was determined by scintillation counting 
as measures of lipid storage.  
 
2.5 Adipocyte lysates and immunoblotting 
Isolated subcutaneous adipocytes (n=6, single) were diluted (lipocrit 3-5%) in Hank’s medium [6 
mM glucose, 4% BSA, 0.15 µM adenosine, (pH 7.4)] and single samples were pre-incubated for 
15 minutes in the absence or presence of CsA (0.1 µM), tacrolimus (0.1 µM) or rapamycin (0.01 
µM) at 37ºC in a shaking water-bath, before isoproterenol (1 µM) was added for additional 60 
min. In addition, to test effects of CsA (0.1 µM) and tacrolimus (0.1 µM) on mTOR activation,  
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isolated adipocytes were pre-incubated for 15 minutes or 20 h in the absence or presence of the 
agents, before insulin (6 nM) was added for additional 15 min.    
Immunoblotting was performed as previously described (Pereira et al., 2012). In brief, adipocytes 
were separated from medium and total protein was extracted in lysis buffer [25 mM Tris-HCl (pH 
7.4), 0.5 mM EGTA, 25 mM NaCl, 1% Nonidet P-40, 1 mM Na3VO4, 10 mM NaF, 0.2 mM 
leupeptin, 1 mM benzamidine, 0.1 mM 4-(2-aminoethyl)-benzenesulfonylfluoride hydrochlorine 
and 0.1 µM okadaic acid] and insoluble substances were sedimented through centrifugation. 
Aliquots of  total lysate (15 µg/lane) were loaded into 4–12% gels (Invitrogen Corporation, 
Paisley, UK), subjected to SDS-PAGE and transferred to a nitrocellulose membrane and 
immunoblotted with primary antibody: anti-HSL, anti-phospho HSL Ser552 (equivalent to 
Ser563 of rat HSL), anti-perilipin, anti-mammalian target of rapamycin (anti-mTOR), anti-
phospho mTOR (Ser2448), anti-p70 ribosomal S6 kinase (p70S6K) and anti-phospho p70S6K 
(Thr421/Ser424)  (Cell Signaling Technologies, Beverly, MA, USA); and anti-α/β-hydrolase 
domain containing 5 (CGI-58) and anti-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Antibodies were diluted according to the manufacturer’s instructions, and thereafter with the 
appropriate secondary antibody. Detection was made by Immuno-star HRP luminol/enhancer 
(Biorad Laboratories, Hercules, CA, USA), with Chemidoc XRS (CCD camera). Intensity of the 
bands was quantified by densitometry and phosphospecific protein quantifications were adjusted 
for the corresponding protein level. 
 
2.6 Subcutaneous and omental adipose tissue incubation 
Effects of long-term incubation (20h) with the immunosuppressive agents on gene and protein 
expression of lipogenic factors was performed in single samples of subcutaneous and omental 
adipose tissue instead of adipocytes. Preservation of the interaction between the different cell 
types in the adipose tissue may be critical for its function during long-term incubation. For this, 
adipose tissue pieces (300 mg) were incubated for 20 h without or with CsA (0.1 µM), tacrolimus 
(0.1 µM) or rapamycin (0.01 µM), in 6 well polystyrene plates containing 5 ml of DMEM (6 mM 
glucose, 10% FBS, 1% penicillin-streptomycin) (Invitrogen) at 37ºC under a gas phase of 5% 
CO2 with gentle agitation (∼ 30 rpm) in a culture cupboard. Adipose tissue was thereafter snap-
frozen for gene and protein analysis, while incubation media was used to measure IL-6 and 
adiponectin secretion.  
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2.7 Immunoblotting analysis of adipose tissue 
Adipose tissue was homogenized, and total protein was extracted in lysis buffer as previously 
described for the adipocytes. Subcutaneous and omental adipose tissue lysates (n=5, single) were 
used for western-blot analysis of anti-ATGL (Santa Cruz Biotechnology) anti-HSL, anti-perilipin, 
anti-CGI-58 and anti-actin, as previously described.  
 
2.8 Adipose tissue gene expression  
 Total RNA from adipose tissue was isolated with RNeasy Lipid Tissue Mini Kit (Quiagen, 
Hilden, Germany), and used for cDNA synthesis using High Capacity cDNA Reverse 
Transcriptase kit (Applied Biosystems, Foster City, CA, USA). The gene expression was 
analyzed using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems) 
applying gene-specific custom-designed primers and probes from Applied Biosystems (sequences 
used are available on request). Relative quantification of mRNA levels was plotted as the fold 
change compared with basal and were normalized to the housekeeping gene 18S rRNA (Applied 
Biosystems). The gene expression of the lipolytic genes ATGL, HSL and perilipin were 
investigated in subcutaneous and omental adipose tissue (n=21 and n=17, respectively, single). In 
addition, expression of genes involved in the uptake (LPL and CD36), transport (ap2/FABP4, 
fatty acid binding protein 4) and storage (SREBP1, sterol regulatory element-binding protein 1 
(both SREBP1-a and 1c isoforms); DGAT1, diglyceride acyltransferase 1; lipin 1; FAS, and fatty 
acid synthase) of fatty acids and the adipokines IL-6, TNF-α  and adiponectin were also 
investigated.  
 
2.9 Determination of IL-6 and adiponectin in the culture medium 
IL-6 and adiponectin released in the medium from the subcutaneous and omental adipose tissue 
incubations in the presence or absence of CsA, tacrolimus or rapamycin were measured after 20 
h. Commercial sandwich ELISA kits were used (PeliKine Compact™ Human IL-6 ELISA kit, 
Sanquin Reagents, Amsterdam, The Netherlands and Human Adiponectin ELISA kit, Millipore, 
Billerica, MA, USA) according to the manufacturer’s instructions. Samples were diluted 1:100 
for IL-6 measurement and 1:30 for adiponectin measurement in the kit dilution buffer to be 
within the linear range of the assay (0.6-450 pg/ml for IL-6 and 1.56-100 ng/ml for adiponectin). 
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2.10 Assessment of cell viability 
The viability of adipocytes was not significantly affected after 24 h incubation with either CsA 
(0.1 µM), tacrolimus (0.1 µM) or rapamycin (0.01 µM) (93 to 100%, p=ns), when compared to 
untreated cells. See supplementary Fig. 1 for details. 
 
2.11 Statistical analysis 
Differences between control (no-treatment) and treated conditions were performed pair wise 
using Wilcoxon signed-rank test. Comparisons between treated and untreated cells were 
performed within the same individual to minimize confounding variables. Results are given as 
mean ± standard error of the mean (SEM), or as indicated. A p-value <0.05 was considered 
statistically significant. Statistical analyses were performed using the SPSS package version 18 
(SPSS Inc., Chicago, IL). 
 
 
3. Results 
3.1 Effects of CsA, tacrolimus and rapamycin on lipolysis  
Treatment of subcutaneous adipocytes with CsA, tacrolimus or rapamycin significantly enhanced 
lipolysis rate during concomitant stimulation with isoproterenol (0.01 or 1 µM) by 20-35% 
(p<0.05), compared to control (Fig. 1A). In addition, the rate of basal lipolysis was significantly 
increased by ~20% (p<0.05), in adipocytes incubated with rapamycin, but not with CsA or 
tacrolimus. Rapamycin significantly reduced the antilipolytic effect of insulin (10-100 µU/ml, 
p<0.05) (Fig. 1B), while CsA and tacrolimus did not (Fig. 1C).  
 
3.2 Effects of CsA, tacrolimus and rapamycin on lipid storage 
CsA, tacrolimus and rapamycin decreased insulin-stimulated lipogenesis rate as measured by 14C-
glucose incorporation into lipids (~10%, p<0.05). However, after subtracting the basal from the 
insulin-stimulated lipogenesis, the changes induced by the immunosuppressive agents are not 
significant (Fig. 2A). In addition, CsA, tacrolimus and rapamycin reduced the 14C-palmitate 
storage by 20-35%, compared to control (Fig. 2B). 
Correlations between the effects of the IA on lipolysis/lipid storage and several metabolic 
variables (BMI, WHR, % body fat mass, adipocyte diameter, HbA1c, HOMA and serum glucose, 
insulin and lipids) were performed, but no significant correlations were identified. However, the 
number of subjects is limited (13-16 and 8 for lipolysis and lipid storage, respectively) and we 
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can not rule out the possibility that adipocytes from individuals with different insulin sensitivities 
may respond different to the effects of the immunosuppressive agents.   
 
3.3 HSL and perilipin protein amount in incubated adipocytes 
Although there were no differences in cellular HSL protein levels, CsA, tacrolimus and 
rapamycin significantly increased isoproterenol-stimulated HSL Ser552 phosphorylation in 
subcutaneous adipocytes (CsA ~100% increase; tacrolimus and rapamycin ~230% increase, 
p<0.05) (Fig. 3A and B). Perilipin and CGI-58 protein levels were not changed by any of the IA 
(Fig. 3C). There is a tendency to decrease HSL and increase perilipin protein levels in adipocytes 
treated with isoproterenol, when compared to non-treated (Fig. 3A and C). This may be explained 
by a loss of the proteins in the lipid fraction during preparation of the lysates, due to HSL and 
perilipin translocation between the cytosol and the lipid droplet upon lipolytic stimulation 
(Brasaemle et al., 2000; Tansey et al., 2001). Although we have not used optimized mobility shift 
assay to determine the phosphorylation state of perilipin, the 4-12% polyacrylamide gel used for 
the SDS-PAGE allows some degree of electrophoretic separation, as observed by the mobility 
shift in the isoproterenol-stimulated conditions (Fig. 3C). None of the IA seems to change the 
phosphorylation state of perilipin. However, we can not exclude the possibility that the 
immunosuppressive agents may change phosphorylation of individual sites of perilipin that are 
not detected by mobility shift. 
 
3.4 Effects of CsA and tacrolimus on mTOR and p70S6K protein levels and phosphorylation 
To study the effects of CsA and tacrolimus on the mTOR pathway, the phosphorylation of mTOR 
and its downstream substrate p70S6K was assessed (supplementary Fig. 2, n=4). CsA and 
tacrolimus did not affect phosphorylation of mTOR or p70S6K, in the absence or presence of 
insulin, and the cellular content of both these proteins was left intact.  
 
3.5 Expression of genes and protein involved in the regulation of lipolysis and lipid storage in 
subcutaneous and omental adipose tissue  
The gene expression of the lipolytic mediators ATGL, HSL and perilipin were investigated in 
human subcutaneous and omental adipose tissue after 20 h incubation in the absence or presence 
of CsA (0.1µM), tacrolimus (0.1 µM) or rapamycin (0.01 µM). Using real-time PCR we found 
that rapamycin significantly decreased perilipin gene expression in both subcutaneous and 
omental adipose tissue by ~20%, p<0.05, and had no effect on ATGL or HSL gene expression 
(Fig. 4A). The perilipin protein levels also decreased significantly in both subcutaneous and 
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omental adipose tissue by ~50%, p<0.05 (Fig. 4B and C), compared to control. CsA and 
tacrolimus did not change ATGL, HSL and perilipin gene expression or protein amount, and 
CGI-58 protein amount was not changed by any of the immunosuppressive agents (Fig. 4A-C).  
 
In addition, the expression of several key lipogenic genes SREBP1, FAS, lipin 1, DGAT1, LPL, 
CD36 and aP2 involved in the clearance and storage of circulating lipids was assessed.  
Rapamycin reduced the gene expression levels for SREBP1 and aP2 by ~20%, in subcutaneous 
adipose tissue, p<0.05, (Fig. 5A and B) and lipin 1 by ~20%, in both subcutaneous and omental 
adipose tissue, p<0.05 (Fig. 5A). In addition, rapamycin increased the LPL gene expression by 
~15% and 25%, in subcutaneous and omental adipose tissue, respectively, p<0.05, (Fig. 5B), 
compared to control. The CD36 and the aP2 gene expression was reduced by tacrolimus in both 
the subcutaneous and omental adipose tissue (20-30%, p<0.05, Fig. 5B), compared to control. 
CsA and tacrolimus had no effect on the gene expression levels for SREBP1, FAS, lipin 1, 
DGAT1 and LPL in subcutaneous and omental adipose tissue (Fig. 5A and B).  
 
CsA, tacrolimus and rapamycin increased IL-6 gene expression in subcutaneous and omental 
adipose tissue, although this effect was only significant in subcutaneous adipose tissue 
(subcutaneous: CsA ~35%; tacrolimus ~240%; rapamycin ~82%, p<0.05; omental: CsA ~85%, 
p=0.55; tacrolimus ~440%, p=0.17; rapamycin ~230%, p=0.80, Fig.6 A). The IL-6 release into 
the incubation media was also increased in both subcutaneous and omental adipose tissue 
incubated with IA, compared to control (Fig. 6B). However, this increase was only significant for 
the subcutaneous adipose tissue incubated with rapamycin (p<0.05). TNF-α  and adiponectin 
gene expression and adiponectin release into the medium was not changed after incubation with 
any of the IA (Fig. 6C and D). 
 
 
4. Discussion  
In the present study, we show that CsA, tacrolimus and rapamycin increase isoproterenol-
stimulated lipolysis in human subcutaneous adipocytes by 20-35%. Rapamycin also increased 
basal lipolysis and impaired insulin’s antilipolytic effect. In addition, the IA, reduced lipid 
storage by 20-35%, which may potentially contribute to dyslipidemia. Rapamycin effects on 
 
α  3.6 IL-6, TNF-  and adiponectin gene expression and secretion  
12 
 
lipolysis and on the insulin antilipolytic effect, together with impaired lipid storage, suggest that 
rapamycin modulates FFA mobilization, which could contribute to insulin resistance.  
 
In addition, we demonstrate that CsA, tacrolimus and rapamycin, in mature human adipocytes, 
significantly increase isoproterenol-stimulated phosphorylation of HSL on Ser552, one of the 
major sites controlling HSL activity (Anthonsen et al., 1998). These results are in agreement with 
previous studies that show that rapamycin increases basal and isoproterenol-stimulated lipolysis 
and enhanced isoproterenol-stimulated phosphorylation of HSL on Ser563 (equivalent to Ser552 
of human HSL) in 3T3-L1 adipocytes  (Chakrabarti et al., 2010; Soliman et al., 2010). In 
contrast, treatment of 3T3-L1 cells with CsA has been shown to inhibit basal and TNF-α -induced 
lipolysis (Holowachuk, 2007). The apparent discrepancy between the present and the previous 
study regarding the effects of CsA on lipolysis could be due to different effects of CsA in the 
different activated lipolysis pathways in these studies. The catecholamine isoproterenol is a 
synthetic β-adrenergic agonist that activates PKA activity by stimulating production of cAMP 
(Anthonsen et al., 1998), while the TNF-α  stimulates lipolysis through the MAPKs (Ryden et al., 
2004).  
 
Lipogenesis was only modestly affected by the IA (~10% reduction) and this effect does not 
seem to be mediated through direct effects on insulin signalling. Notably, a reduced adipocyte 
glucose uptake caused by rapamycin (Pereira et al., 2012) and by CsA and tacrolimus (Pereira MJ 
et al, unpublished data) could also contribute to that finding. Hence the IA may in parallel inhibit 
glucose uptake, enhance lipolysis and attenuate lipid storage. These findings may contribute to 
higher circulating levels of glucose, glycerol and FFA and might lead to fatty acid deposition as 
ectopic triglycerides in insulin target tissues such as liver and skeletal muscle (Roden et al., 
1996). High levels of FFA may also promote insulin resistance via several mechanisms and also 
directly compete for substrate utilization in skeletal muscle, thus reducing glucose utilization 
(Boden, 1997; Roden et al., 1996). In fact, recent studies in animal models have shown that 
treatment with either rapamycin (Deblon et al., 2012; Houde et al., 2010) or CsA (Delgado et al., 
2012; Ikeuchi et al., 1992) cause both muscle and liver insulin resistance resulting in severe 
glucose intolerance. In addition, glycerol is as important substrate for hepatic gluconeogenesis 
directly contributing to glucose production (Baba et al., 1995). Therefore, increased lipolysis and 
reduced lipid storage could be a cellular basis for elevation of circulating FFA and VLDL-
particles (Ichimaru et al., 2001; Morrisett et al., 2002) and also provide one explanation for 
insulin resistance and development of NODAT during immunosuppressive therapy.  
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Perilipin coats the surface of intracellular lipid droplets, and its down-regulation facilitates 
lipolysis (Brasaemle et al., 2000; Tansey et al., 2001). Thus, the reduced perilipin gene and 
protein expression during rapamycin treatment may contribute to a non-stimulated (basal) 
lipolysis. One must, however, bear in mind that perilipin gene and protein expression were 
reduced after 20 h of incubation, while lipolysis was measured after 2 h of incubation. So, the 
mechanism by which rapamycin is affecting basal lipolysis, remains unexplained. Our results do 
not suggest that ATGL, HSL and CGI-58 protein levels can account for the effects of the IA on 
the lipolysis, since levels of these proteins were similar in the subcutaneous and omental adipose 
tissue after 20 h incubation.  
 
We demonstrate that the IA can enhance IL-6 adipose tissue gene expression and rapamycin also 
increased IL-6 secretion in vitro. This indicates that rapamycin can contribute to increased levels 
of IL-6 in circulation. Thus, an increase in IL-6 production and secretion in adipose tissue during 
rapamycin incubation may be an autocrine and paracrine mediator stimulating lipolysis (van Hall 
et al., 2003). On the other hand, we cannot exclude an indirect effect of FFA influencing IL-6 
gene expression. Thus, effects of IA on IL-6 gene expression should be further evaluated in vivo.  
 
Nonetheless it should be noted that the clinical significance of the modest changes we observed 
after short-term incubation with the immunosuppressive agents is uncertain. However, it is likely 
that the 20-35% increase in lipolysis and decrease in lipid storage may be clinically significant. 
This is supported by the fact that other well know therapies that induce dyslipidemia and insulin 
resistance, such as glucocorticoids (Lundgren et al., 2008) and anti-HIV protease inhibitors 
(Hadigan et al., 2002; Leroyer et al., 2011), cause 20-40% increase in lipolysis rate in human 
subcutaneous adipocytes/adipose tissue during long-term incubation at high exposures in vitro. 
Conversely, nicotinic acid derivatives that are used as treatment for dyslipidemia act mainly by 
inhibiting adipose tissue lipolysis, and in vitro this effect has been reported to be around 25% 
(Stirling et al., 1985). Importantly, our findings occurred at IA concentrations that are commonly 
present in the circulation of treated patients (Schiff et al., 2007; Wyeth, 1999). 
 
It must be emphasized that culture of adipocytes in vitro may not mimic the biological processes 
in adipocytes in their native environment and does not take into account the neuroendocrine, e.g. 
sympathetic and parasympathetic nervous control of adipose tissue metabolism (Kreier et al., 
2002; Sjostrand and Eriksson, 2009). Thus, the findings in this study should be confirmed with in 
vivo experiments. In addition, visceral adiposity is more strongly associated with insulin 
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resistance and cardiovascular diseases. Thus, future studies should also address the effects of the 
immunosuppressive agents on lipid metabolism in omental adipocytes. 
 
The gene expression of LPL was up-regulated in both subcutaneous and omental adipose tissue 
after 20 h incubation with rapamycin. In contrast, others have shown that rapamycin reduces LPL 
gene expression and activity in the retroperitoneal adipose tissue of rats treated with the drug 
(Blanchard et al., 2012; Houde et al., 2010). Important differences between the present study and 
the previous ones include duration of treatment and the species studied. The increased expression 
of the LPL gene might be expected to promote FFA flux from the circulation into the adipose 
tissue. However, the use of only mRNA expression imposes limitations, as LPL activity displays 
a strong post-translational regulation and thus its activity does not necessarily correlate with LPL 
gene expression and protein amount (Ruge et al., 2012; Ruge et al., 2006). 
 
It was previously demonstrated by our group (Pereira et al., 2012) that rapamycin inhibits 
formation of mTOR complex 1 and 2 and insulin-stimulated phosphorylation of p70S6K and 
protein kinase B (PKB) at Ser473 in human adipocytes. PKB activity is required for the insulin-
induced activation of phosphodiesterase 3B and thus for the antilipolytic action of insulin 
(Berggreen et al., 2009). Thus, the interference with the antilipolytic effect of insulin could be 
attributed to rapamycin inhibitory effect on PKB activation. In addition, mTORC1 mediates the 
effects of insulin on lipid storage by regulating the expression and activation of PPARγ and 
SREBP1 (Porstmann et al., 2008), two master transcription factors that stimulate genes involved 
in fatty acid biosynthesis. This very well matches the observed reduction mediated by rapamycin 
on expression of the SREBP1 gene (both 1a and 1c isoforms) as well as downstream target genes 
involved in lipid uptake (aP2/FATP4) and triglyceride synthesis (lipin 1) in subcutaneous adipose 
tissue. By disrupting mTORC1 regulation of expression of genes involved in fatty acid 
biosynthesis, rapamycin may impair the capacity of adipose tissue for plasma lipid clearance, 
which likely contributes to hyperlipidemia. Additional support for the involvement of rapamycin 
in the reduced adipose storage of lipids is provided by the reduction in palmitate incorporation 
into the triglycerides. In contrast, FAS and DGAT1 gene expression were not affected by 
rapamycin, suggesting that SREBP1c activity was not affected by this drug. However we cannot 
exclude that SREBP1a and/or 1c activity will behave differently as compared to gene expression.  
In contrast, neither CsA nor tacrolimus affected the amount or phosphorylation of mTOR or its 
downstream target p70S6K, indicating that these agents do not affect the mTOR pathway. 
Instead, tacrolimus reduced expression of both the CD36 and aP2 genes in subcutaneous and 
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omental adipose tissue, two target genes of proliferator-activated receptor γ (PPARγ) involved in 
cellular transport and metabolism of fatty acids. This suggests that impaired PPARγ activity may 
be a mechanism in the observed down-regulation of lipid storage.  
 
Results are summarised on Table 2. In conclusion, therapeutic concentrations of calcineurin 
inhibitors CsA and tacrolimus and the mTOR inhibitor rapamycin enhance lipolysis, increase the 
phosphorylation of hormone-sensitive lipase (HSL) and inhibit lipid storage and expression of 
lipogenic genes in human adipose tissue. This may contribute to the development of 
dyslipidemia, insulin resistance and new-onset diabetes (NODAT) in patients treated with these 
immunosuppressive agents. 
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Table 1 – Clinical and biochemical characteristics of the adipose tissue donors (n = 60).  
Variables  
Sex (male/female; n) 26/34 
Age (years) 48  ± 14 
Body mass index (kg/m2) 27.2 ±   4.1 
Waist-hip ratio (WHR) 0.91 ± 0.1 
Systolic blood pressure (mmHg)  133 ± 17 
Diastolic blood pressure (mmHg) 83 ± 11 
Subcutaneous adipocyte diameter (µm) a 99.5 ± 12.6 
Omental adipocyte diameter (µm)b 86.0 ± 16.3 
HbA1c (mmol/mol, IFCC) c 30 ±   10 
Glucose (mmol/L) 5.2 ±   0.6 
Insulin (mU/L) 9.2 ±   5.7 
HOMA-IR d 1.9 ±    1.1 
Body fat mass (%) 30.3 ±   7.6 
Triglycerides (mmol/L) 1.2 ±   0.6 
Cholesterol (mmol/L) 5.4 ±   1.2 
LDL-cholesterol (mmol/L) 3.4 ±   1.0 
HDL-cholesterol (mmol/L) 1.7 ±  0.6 
Data are means ± SD; a n=47; b n=18; c Normal range 27-46 mmol/mol (IFCC standard); d 
Calculated as: fasting insulin (mU/L) x fasting glucose (mM)/22.5 (Matthews et al., 1985); 
HbA1c, glycosylated haemoglobin; LDL, low-density lipoprotein; HDL, high density lipoprotein  
 
 
 
Table 2 – Summary of results 
 CsA FK Rap 
Adipocytes (sc)       
    Lipolysis    
            Basal - - ↑ 
            Isoproterenol ↑ ↑ ↑ 
    Lipid storage ↓ ↓ ↓ 
    Lipolytic proteins    
            p-HSL ↑ ↑ ↑ 
Adipose tissue (sc/om)    
    Lipolytic protein    
            Perilipin - - ↓ 
    Lipolytic gene    
            Perilipin - - ↓ 
    Lipogenic genes    
            SREBP1 - - ↓ 
            Lipin 1 - - ↓ 
            LPL - - ↑ 
            CD36 - ↓ - 
            aP2 - ↓ ↓ 
    Adipokine    
            IL-6 ↑ ↑ ↑ 
CsA, cyclosporin A; FK, tacrolimus; Rap, rapamycin; sc, subcutaneous; om, omental. Increase 
(↑) and decrease (↓). 
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Figures 
 
Figure 1 
 
Figure 1. Effects of CsA, tacrolimus (FK) and rapamycin (Rap) on lipolysis and on the 
antilipolytic effect of insulin in human subcutaneous adipocytes. Adipocytes were incubated in 
absence (Control) or presence of CsA (0.1 µM), tacrolimus (0.1 µM) or rapamycin (0.01 µM). 
(A) For lipolysis experiments the medium was supplemented or not with isoproterenol (0.01 or 1 
µM) and the amount of glycerol released into the medium, after 2 h incubation, was taken as an 
index of lipolysis. Lipolysis rate for each condition (n=13-16) was calculated relative to basal 
control in each experiment (overall mean glycerol release in basal condition: 2.0 ± 0.4 nmol/105 
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cells/h) and are presented as mean ± SEM. For the effects of rapamycin (B) and CsA and 
tacrolimus (B) on the antilipolytic effect of insulin (n=5-6), the medium was supplemented with 
isoproterenol (1 µM) and with the indicated insulin concentrations (0-100 µU/ml insulin) and the 
amount of glycerol released into the medium, after 2 hours of incubation, was taken as an index 
of lipolysis. Results are expressed as relative to maximal glycerol release (isoproterenol alone: 
7.5 ± 0.4 nmol/105 cells/h), set to 1, and presented as mean ± SEM. ∗ p<0.05 and ∗∗ p<0.01 
control vs. treated (CsA, tacrolimus or rapamycin) with otherwise identical conditions. Reducing 
the basal from isoproterenol-stimulated lipolysis, the changes are only significant (p<0.05) for 
isoproterenol (1 µM) stimulated conditions (A). 
 
 
Figure 2 
  
 
Figure 2. CsA, tacrolimus (FK) and rapamycin (Rap) inhibits lipid storage in human 
subcutaneous adipocytes. Adipocytes were incubated in absence (Control) or presence of CsA 
(0.1 µM), tacrolimus (0.1 µM) or rapamycin (0.01 µM) and the medium was supplemented with 
D-[U-14C] glucose and with or without insulin (1000 µU/ml) (A) or with 14C-palmitate (B) during 
2 h. 14C-glucose (lipogenesis) or 14C-palmitate incorporation into lipids were taken as a measure 
for lipid storage, and calculated relative to basal control in each condition (14C-glucose uptake 
overall basal: 0.70 ± 0.14 fl/cell/s, n=8; and 14C-palmitate uptake overall basal: 92.0 ± 17,3 
fl/cell/s, n=5) and are presented as mean ± SEM. ∗ p<0.05 control vs. treated (CsA, tacrolimus or 
rapamycin) with otherwise identical conditions. Reducing the basal from the insulin-stimulated 
lipogenesis, the changes are not significant. 
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Figure 3 
 
Figure 3. Cyclosporine (CsA), tacrolimus (FK) and rapamycin (Rap) increase HSL 
phosphorylation in human subcutaneous adipocytes. Isolated human subcutaneous adipocytes 
were incubated without (CTR) or with CsA (0.1µM), tacrolimus (0.1 µM) or with rapamycin 
(0.01 µM) for 15 min and thereafter stimulated with or without isoproterenol (1 µM) for an 
additional 60 min. Fat cell lysates were analysed by immunoblotting for the HSL protein and 
phospho-HSL (Ser552) (A, B), and perilipin and CGI-58 protein levels (C). CsA, tacrolimus and 
rapamycin increased isoproterenol-stimulated phosphorylation of Ser552 of HSL (A). The 
intensity of the phosphorylation of Ser552 of HSL after CsA, tacrolimus and rapamycin treatment 
was quantified, and the results are represented as mean ± SEM compared to isoproterenol alone 
(set to 1) and normalised to the respective protein levels (p-HSL/HSL) (B). Actin was used as the 
loading control protein. n = 5-6, *p<0.05, compared to isoproterenol alone. 
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Figure 4 
 
Figure 4. Regulation of gene expression and/or protein amount of adipose triacylglycerol lipase 
(ATGL), hormone-sensitive lipase (HSL), perilipin and CGI-58 in human subcutaneous and 
omental adipose tissue by CsA, tacrolimus (FK) and rapamycin (Rap). Subcutaneous and omental 
adipose tissue, were incubated for 20 h without (CTR) or with CsA (0.1 µM), tacrolimus (0.1 
µM) or rapamycin (0.01 µM), and mRNA (n = 21 and 17, respectively) was extracted to measure 
gene expression for ATGL, HSL and perilipin (A); and total lysates (n = 4-5) were analysed by 
Western blotting for ATGL, HSL, perilipin, CGI-58 and actin (B). The relative band intensity for 
perilipin was quantified in subcutaneous and omental adipose tissue incubated without (control; 
CTR) or with rapamycin and represented as mean ± SEM compared to control (set to 1) (C). 
mRNA expression data are presented as mean ± SEM, and expressed as mRNA relative 
expression normalised to control (no-treatment). Rapamycin decreased perilipin gene expression 
and protein amount (A-C) in both subcutaneous and omental adipose tissue, compared to control. 
∗ p<0.05 compared with control. 
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Figure 5 
 
Figure 5. Regulation of expression of lipogenic genes in human subcutaneous and omental 
adipose tissue by cyclosporine A (CsA), tacrolimus (FK) and rapamycin (Rap). Subcutaneous and 
omental adipose tissue (n = 21 and n = 17, respectively), were incubated for 20 h without or with 
CsA (0.1 µM), tacrolimus (0.1 µM) or rapamycin (0.01 µM), and mRNA was extracted to 
measure mRNA expression for sterol regulatory element-binding protein 1 (SREBP1), fatty acid 
synthase (FAS), lipin 1 and diglyceride acyltransferase 1 (DGAT1) (A) and lipoprotein lipase 
(LPL), CD36 and fatty acid binding protein 4 (aP2/FABP4) (B). Data are presented as mean ± 
SEM, and expressed as mRNA relative expression normalised to control (no-treatment). ∗ p<0.05 
compared with control. 
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Figure 6. 
 
Figure 6. Regulation of IL-6, TNF-α  and adiponectin gene expression and IL-6 and adiponectin 
secretion in human subcutaneous and omental adipose tissue by cyclosporine A (CsA), 
tacrolimus (FK) and rapamycin (Rap).  
Subcutaneous and omental adipose tissue, were incubated for 20 h without or with CsA (0.1 µM), 
tacrolimus (0.1 µM) or rapamycin (0.01 µM), and mRNA was extracted to measure mRNA 
expression for IL-6 (A), TNF-α  (C) and adiponectin (C). The IL-6 (B) and adiponectin (D) 
concentration in the culture medium was determined by enzyme-linked immunoassay.  
Data for gene expression (n = 21 and n = 17, for subcutaneous and omental adipose tissue, 
respectively) are presented as mean ± SEM, and expressed as mRNA relative expression 
normalised to control (CTR; no treatment). Data for IL-6 (n = 17 and n = 6, for subcutaneous and 
omental adipose tissue, respectively) and adiponectin (n = 16 and n = 4, for subcutaneous and 
omental adipose tissue, respectively) concentrations in the medium are mean ± SEM and 
calculated as ng/mg/h and µg/mg/h, respectively. Data for IL-6 concentration in the media from 
subcutaneous and omental adipose tissue have different scales (y-axis). ∗ p<0.05 compared with 
control. 
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Supplement 
Supplementary Figure 1 
 
Legend - Incubation of adipocytes with CsA, tacrolimus and rapamycin during 24 h did not 
change cell viability. The effect of CsA, tacrolimus or rapamycin on adipocyte viability was 
assessed by using the water-soluble tetrazolium-1 colorimetric assay (WST-1, Roche, Mannheim, 
Germany). Adipocytes were placed in a 48 well plate at a lipocrit of 5% in Hank’s medium (5.6 
mM glucose, 4% BSA, 0.15 µM adenosine and pH 7.4) with or without CsA (0.1 µM), tacrolimus 
(0.1 µM) and rapamycin (0.01 µM). After 24 h, WST-1 was added to each well, and the cells 
were incubated for 2 h at 37ºC before absorbance was measured at 450 nm.  
 
Supplementary Figure 2 
 
Legend - CsA and tacrolimus do not alter protein levels or phosphorylation of mTOR and 
p70S6K.  
Freshly isolated human subcutaneous adipocytes were treated for 15 min or 20 h without 
(control) or with CsA (0.1 µM) or tacrolimus (0.1 µM) and thereafter incubated with or without 
insulin (6 nM) for an additional 15 min. Immunoblotting analyses showed no effects of CsA or 
tacrolimus on protein levels or phosphorylation of mTOR and p70S6K. Actin was used as 
loading control. Representative blot is shown from one subject out of four. The average insulin 
effect on p70S6K phosphorylation was ~40 ± 20% in control adipocytes.    
IV
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ABSTRACT 
Context: Glucocorticoid excess is linked to central obesity, adipose tissue insulin resistance and 
type 2 diabetes mellitus.  
Objective: To study the effects of dexamethasone on gene expression in human subcutaneous 
and omental adipose tissue, in order to identify potential novel mechanisms and biomarkers for 
adipose tissue insulin resistance caused by glucocorticoids. 
Design and Setting: Human subcutaneous and omental adipose tissue was incubated with 
dexamethasone (0.003-3 µM) for 24 h and glucose uptake, gene expression (microarray and real 
time-PCR) and levels of key proteins were assessed. 
Participants: 25 non-diabetic adipose tissue donors (10 M/15 F; age 28-60 yrs; BMI 20.7-30.6 
kg/m2). 
Results: Dexamethasone changed the expression of 527 genes in both subcutaneous and omental 
adipose tissue. FKBP5 and CNR1 were the most responsive genes in both depots (~7-fold 
increase). Dexamethasone increased FKBP5 gene and protein expression in a dose-dependent 
manner in both depots, but FKBP5 protein levels were 10-fold higher in omental that in 
subcutaneous adipose tissue. FKBP5 gene expression in subcutaneous adipose tissue was 
positively correlated with serum insulin, HOMA-IR and subcutaneous adipocyte diameter, while 
fold change in gene expression exerted by dexamethasone was negatively correlated with HbA1c, 
BMI, HOMA-IR and serum insulin. Only one gene was identified, namely SERTM1, that clearly 
differed in response to dexamethasone between the two depots. 
Conclusions: Dexamethasone at high concentrations, influences gene expression similarly in 
subcutaneous and omental adipose tissue and promotes gene expression of FKBP5, a gene that 
may be implicated in glucocorticoid-induced insulin resistance. 
 
Key terms: Glucocorticoids; Adipose tissue; FKBP5; Gene expression; Insulin resistance, 
Human 
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INTRODUCTION 
Cortisol, the active endogenous glucocorticoid secreted by the adrenal cortex, is a powerful 
insulin-antagonistic hormone (1). Excess cortisol promotes the development of insulin resistance, 
hyperglycaemia and features of the metabolic syndrome (2, 3). Cortisol opposes insulin’s effects 
to stimulate peripheral glucose utilization and to suppress hepatic glucose output and can also 
impair insulin secretion from pancreatic β-cells. This is mediated mainly via effects on gene 
transcription (4, 5). Furthermore, elevated plasma cortisol, as in Cushing’s syndrome or during 
prolonged corticosteroid therapy, is associated with redistribution of fat from peripheral to central 
depots and other components of the metabolic syndrome, such as hypertension and dyslipidemia 
(6, 7). Central obesity, in particular visceral adiposity, is associated with insulin resistance, 
cardiovascular disease and the metabolic syndrome (8, 9).  Consequently, it is of interest to 
further explore the response of adipose tissue to cortisol. 
 
Some adipose-secreted molecules are differentially regulated by glucocorticoids in different fat 
depots. For example, adipose tissue lipoprotein lipase production is stimulated to a higher extent 
in visceral fat, thus partitioning free fatty acids delivery to that depot (10). In contrast, in 
subcutaneous adipose tissue glucocorticoids induce lipolysis (11), possibly resulting in increase 
release of free-fatty acids and reduced lipid storage. This may partly explain the ability of 
glucocorticoid excess to promote intra-abdominal adiposity. Moreover, the glucocorticoid effect 
to stimulate leptin secretion was reported to be more pronounced in visceral as compared with 
subcutaneous fat (12, 13), and the effect to impair glucose uptake appears to be more prominent 
in visceral fat (14). Accordingly, a down regulation of the critical signalling proteins insulin 
receptor substrate-1 and protein kinase B has been demonstrated in visceral fat (14, 15). It is also 
of interest that the glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase 1, that 
converts inactive cortisone to active cortisol within tissues, displays a higher expression in 
visceral than in subcutaneous adipose tissue, and this might be of relevance in the pathogenesis of 
visceral adiposity and insulin resistance (16). However, the molecular mechanisms for the 
underlying differential regulation of subcutaneous and visceral adipose tissue by glucocorticoids 
are still unknown.  
 
Recently, key metabolic pathways were identified to be regulated by dexamethasone incubation 
in human subcutaneous and omental adipose tissue from severely obese individuals (17) and in 
human skeletal muscle and subcutaneous adipose tissue after short-term dexamethasone treatment 
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(18). Identification of biomarkers and possible new pharmacological targets would be valuable in 
the prevention and treatment of glucocorticoid-induced metabolic dysregulation and could 
potentially also be of relevance for other metabolic conditions. 
The aim of this study was to explore effects of dexamethasone on gene expression in 
subcutaneous and omental adipose tissue, in order to identify potential novel mechanisms and 
biomarkers for adipose tissue insulin resistance caused by glucocorticoids. 
 
SUBJECTS AND METHODS 
Subjects 
Paired biopsies from human abdominal subcutaneous and omental adipose tissue were obtained 
from subjects going through elective surgery (n=25, 10 men, 15 women), mainly kidney 
donation. Adipose tissue was used to study the effects of dexamethasone on glucose uptake, gene 
expression and protein levels. Anthropometric measurements were obtained from all subjects and 
fasting blood samples were collected for analysis of glucose, insulin and lipids by routine 
methods at the Department of Clinical Chemistry, Sahlgrenska University Hospital. Clinical and 
biochemical characteristics of subjects are shown in table 1.  
For additional analyses of the effect of the immunosuppressive agents tacrolimus (also known as 
FK506) and rapamycin (also known as sirolimus) on FKBP5 (FK506-binding protein 5) gene 
expression in human subcutaneous and omental adipose tissue, biopsies (n=22, 5 men, 17 
women) were obtained either from the lower part of the abdomen after dermal local anaesthesia 
with lidocaine (subcutaneous, n=7, Xylocain; AstraZeneca, Södertälje, Sweden), or by elective 
abdominal surgery after induction of general anaesthesia (subcutaneous and/or omental, n=15). 
The clinical and biochemical characteristics of these subjects are shown in supplemental table 1.  
Subjects with type 2 diabetes, hypertension, endocrine disorders, cancer or other major illnesses 
as well as ongoing medication with systemic glucocorticoids and immune modulating therapies 
were excluded from this study. The study was approved by the Regional Ethics Review Board in 
Gothenburg. All participants gave their written informed consent. 
Adipose tissue incubations 
Dexamethasone  
Abdominal subcutaneous and omental adipose tissue obtained from surgery was cut into small 
pieces, approximately 5-10 mg (1-2 mm3) and was incubated in DMEM containing 6 mM 
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glucose (Sigma Chemical Co., St. Louise, MO, USA), 10% BSA (Sigma) and 1% penicillin-
streptomycin (PEST, Invitrogen Corporation, Paisley, UK) in the absence or presence of 
dexamethasone (0.003-3 µM, Sigma) for 24 h in 37C, 5% CO2. Adipose tissue was thereafter 
snap-frozen for gene expression (n=25) and protein (n=10) analysis or treated with collagenase 
for adipocyte isolation and glucose uptake (n=12). Adipocytes were also used for measuring cell 
size as previously described (19). Due to limited amount of tissue, not all experiments were done 
in every subject’s adipose samples.  
 
After adipose tissue incubation in the absence or presence of dexamethasone (0.01-3 µM; unless 
otherwise indicated 3 µM as a maximally effective concentration), adipocytes were isolated and 
glucose uptake was performed with or without insulin (1000 µU/ml), as previously described 
(20). Moreover, immunoblot analysis of FKBP51 was performed. See Supplemental Methods for 
details. 
Tacrolimus and rapamycin 
Subcutaneous and omental adipose tissue (n=18 and 13, respectively) was incubated for 20 h in 
absence or presence of either tacrolimus (0.1 µM, Sigma) or rapamycin (0.01 µM, Sigma), as 
previously described for dexamethasone. 
Gene expression 
RNA preparation 
Total RNA was prepared from subcutaneous and omental adipose tissue using the Lipid Tissue 
Kit (Qiagen, Hilden, Germany). The RNA was used for microarray analysis as well as real-time 
PCR analysis. 
Microarray Analysis 
Gene expression in subcutaneous and omental adipose tissue was assessed by mRNA 
measurement using microarray analysis (Affymetrix, Human Exon 1.0 ST Array, Santa Clara, 
CA, USA; n=4) in accordance with the guidelines detailed by the manufacturer. Background 
adjustment, quantile normalization and summarization were computed in the Array Studio 
software (Omicsoft Corporation) to generate RMA (Robust Multichip Average, (21)) expression 
values. The core set of transcripts (exon-level probe sets that map to BLAT alignments of mRNA 
with annotated full-length CDS regions) were summarized using the mean value of all probe sets. 
See Supplemental Methods for further details.  
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To determine the tissue distribution of FKBP5 expression, microarray expression profiles 
(Human U133 plus 2.0 DNA microarray, Affymetrix, Santa Clara, CA) from skeletal muscle, 
omental and subcutaneous adipose tissue, kidney cortex, liver, heart ventricle and cerebral cortex 
were downloaded from the GEO database (data set GSE3526). FKBP5 expression was 
determined using the 224840_at probeset. 
Real-time PCR 
Real-time PCR was used for validation of microarray results. RNA samples of an additional 21 
subjects and 2 of the subjects used for microarray analysis were used. Reagents for real-time PCR 
analysis were purchased from Applied Biosystems (Foster City, CA) and used according to the 
manufacturer’s protocol. cDNA was synthesized using the High Capacity cDNA Reverse 
Transcriptase kit and used for real-time PCR amplification and detection by the ABI Prism 
7700HT Sequence Detection System (Applied Biosystems) using default parameters. A standard 
curve for each primer-probe set of pooled adipose tissue cDNA was used. The gene expression 
levels were normalized to the housekeeping gene 18S rRNA (Applied Biosystems). 
Statistical Analysis 
All data are presented as mean ± SEM unless stated otherwise. Comparisons between treated and 
untreated adipose tissue were performed pairwise within the same individual to minimize 
confounding variables. Wilcoxon signed-rank test, Kruskal-Wallis test or paired t test were used 
to analyse differences in gene expression, protein levels and glucose uptake between treated and 
untreated adipose tissue/adipocytes, as appropriate. Spearman's correlation test was used to assess 
correlations between FKBP5 gene expression and effects of dexamethasone on FKBP5 gene 
expression and metabolic variables (BMI, WHR, % body fat mass, adipocyte diameter, HbA1c, 
HOMA and serum insulin and lipids). Only significant associations are shown. Significant 
variables in the bivariate regression were subsequently included in a multivariate step-wise 
regression analysis.  A P-value <0.05 was considered statistically significant. Statistical analyses 
were performed using the SPSS package version 18 (SPSS Inc., Chicago, IL). 
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RESULTS 
Dexamethasone reduced the glucose uptake capacity in human subcutaneous and omental 
adipocytes 
Dexamethasone (3 µM) decreased both basal (subcutaneous 30%; omental 41%) and maximal 
insulin stimulated (both depots ∼ 20%; 1000 µU/ml) glucose uptake in subcutaneous (P<0.05; 
n=12) and omental adipocytes (P<0.01; n=12) (Fig. 1). Both basal and maximal insulin 
stimulated glucose uptake was significantly higher in omental compared to subcutaneous 
adipocytes (P<0.05). Dexamethasone (0.01-3 µM) had a dose-dependent effect to inhibit basal 
and maximal insulin-stimulated glucose uptake in both subcutaneous and omental adipocytes 
(n=6, data not shown). EC50 for dexamethasone to inhibit insulin-stimulated glucose uptake was 
about 5-fold higher in subcutaneous compared to omental adipocytes (P<0.05). 
Effects of dexamethasone on gene expression 
Microarray Analysis 
In total, 527 genes, represented by 543 probe sets, were changed in dexamethasone-treated 
adipose tissues compared to non-treated tissues (false discovery rate of 0.05). Pathway analysis of 
the 527 dexamethasone-regulated genes showed a clear over-representation of functions and 
pathways related to immune/inflammatory responses (Supplemental Table 2). Single genes 
affecting lipolysis, glucose uptake and oxidation or adipocyte differentiation were changed after 
dexamethasone incubation. The two genes with the greatest increase in gene expression after 
dexamethasone incubation were FKBP5 and cannabinoid receptor 1 (CNR1) with more than 7-
fold higher expression compared to non-treated tissues (Fig. 2A and B and Supplemental Table 
3). Dexamethasone also increased the expression of the secreted proteins leptin and TIMP4 
(metallopeptidase inhibitor 4) in both fat depots (Fig. 2C and D). No genes responded in opposite 
directions to dexamethasone treatment. However, SERTM1 (serine-rich and transmembrane 
domain containing 1) displayed the most differential response to dexamethasone and was clearly 
down-regulated in omental adipose tissue, but unchanged in subcutaneous adipose tissue (Fig. 
2E). 
Real-time PCR 
We used real-time PCR in a larger cohort (n=23) to verify effects of the following genes: FKBP5 
and CNR1, the two genes with highest increase in expression after dexamethasone incubation; 
leptin and TIMP4, that are possible to measure in blood; and SERTM1 that was differently 
regulated by dexamethasone between the adipose tissue depots (Fig. 2A-E). The expression 
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pattern for all the genes analyzed by real-time PCR analysis very well matched the microarray 
analysis data, and the expression in both subcutaneous and omental adipose tissue were 
significantly different for all genes analyzed between control and dexamethasone incubated 
adipose tissue (P=0.011 to P<0.0001). 
FKBP5 tissue distribution 
To verify whether expression of FKBP5 may have potential implications for metabolism, its 
tissue distribution was determined in metabolically active tissues. FKBP5 is widely expressed in 
metabolically active tissues with the highest expression in muscle and adipose tissue 
(Supplemental Fig. 1). 
Dexamethasone effects on FKBP5 expression  
To further investigate the effects of glucocorticoids on the expression of the FKBP5 gene in 
human subcutaneous and omental adipose tissue, we assessed the concentration-response for 
dexamethasone effects on the expression of FKBP5 gene and its protein product, FKBP51 (51 
KDa FK506-binding protein 5), in both depots. Incubation of subcutaneous and omental adipose 
tissue with dexamethasone (0.003-0.3 µM) increased FKBP5 gene and protein expression in a 
dose depended manner (Fig. 3A and B). The basal FKBP51 protein levels were ~10 fold higher in 
omental than in subcutaneous adipose tissue (P=0.005, Fig. 3C). Dexamethasone (3 µM) 
significantly increased FKBP51 protein levels in subcutaneous by ~4-fold (P=0.005), while in 
omental by ~2-fold (P=0.028) (Fig. 3C).  
Effects of tacrolimus and rapamycin on FKBP5 gene expression in human adipose tissue 
To study whether FKBP5 gene expression could be regulated by other immune-modulators drugs, 
effects of tacrolimus and rapamycin on FKBP5 gene expression were explored. Incubation of 
subcutaneous and omental adipose tissue with rapamycin (0.01 µM) decreased FKBP5 gene 
expression by 20-30% (P<0.01, Fig. 4), while tacrolimus had no effect.  
Correlation between FKBP5 gene expression and metabolic variables  
FKBP5 gene expression correlated positively with insulin, HOMA-IR and cell diameter in 
subcutaneous but not in omental adipose tissue (Table 2). After entering serum insulin, HOMA-
IR, and cell diameter in a step-wise multivariate analysis only HOMA-IR remained a significant 
predictor of FKBP5 gene expression (r2 = 0.31, P=0.01). Furthermore, the dexamethasone effects 
on FKBP5 gene expression (calculated as delta change) correlated negatively with HbA1c, BMI, 
HOMA-IR and insulin in subcutaneous but not in omental adipose tissue. When included in a 
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step-wise multivariate analysis to predict the dexamethasone increase on FKBP5 gene expression, 
all variables were significant (r2 = 0.82, P<0.001 for model with HbA1C, P<0.001; HOMA, 
P<0.05 and BMI, P<0.05; and r2 = 0.81, P<0.001 for model with HbA1C, P<0.001; insulin, 
P<0.05 and BMI, P<0.05). Interestingly, effects of dexamethasone on FKBP5 gene expression 
did not correlate with the dexamethasone-induced inhibition of adipocyte glucose uptake of the 
fat depots.  
 
DISCUSSION 
Dexamethasone changed the expression of 527 genes in both subcutaneous and omental adipose 
tissue at a supra-physiological and maximally effective concentration (3 µM), according to 
microarray analysis. Pathway analysis showed a clear over-representation of functions and 
pathways related to inflammation. Single genes affecting lipolysis, glucose uptake and oxidation 
or adipocyte differentiation were changed after dexamethasone incubation. FKBP5 was identified 
for the first time as one of the genes with the highest increase in gene expression after 
dexamethasone incubation in subcutaneous and omental adipose tissue. Moreover, FKBP5 gene 
expression in subcutaneous adipose tissue appears to be positively correlated to biomarkers of 
insulin resistance, and its basal protein levels were higher in omental than in subcutaneous 
adipose tissue.  
 
These results are in accordance to a previous microarray study (17), that reported that 
dexamethasone changed the gene expression of 535 genes in both subcutaneous and omental 
depots and that most genes were commonly regulated by dexamethasone in both depots. 
Dexamethasone reduced both basal and insulin stimulated glucose uptake capacity in omental 
adipocytes, which was in line with previous data (14). In contrast to previous data (14), 
dexamethasone also reduced glucose uptake in subcutaneous adipocytes. However, omental 
adipocytes had lower EC50 compared to subcutaneous, supporting greater sensitivity to the 
dexamethasone effects.  
 
The concentration of dexamethasone used in this study (3 µM) was at supra-physiological level in 
relation to the normal cortisol range (140-700 nM), since dexamethasone potency has been 
reported to be nearly 5 times higher than cortisol, and EC50 was 4.8 nM for dexamethasone and 
24 nM for cortisol when assessed as effects on β-adrenergic receptor expression (22).  
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The FKBP5 gene was first characterized as coding for a protein product, denoted 51 KDa FK506-
binding protein 5 (FKBP51), which is a member of a family of immunophilins with peptidyl-
propyl cis-trans isomerise activity (23). The designation of immunophilin refers to the capacity to 
bind two immunosuppressant drugs, tacrolimus (also known as FK506) and rapamycin (24). The 
immunosuppressive properties of tacrolimus and rapamycin arise from the formation of the 
immunophilin-immunosuppressant complex that inhibits two distinct T cell activation signalling 
pathways, T cell activation and T cell proliferation, respectively (25, 26). In addition to the 
capacity to bind to immunosuppressant drugs, FKBP51 was shown to inhibit glucocorticoid 
action (27, 28).  FKBP51 has co-chaperone activity by participating in the heat shock protein 90 
(Hsp90)-steroid receptor complex and regulating the glucocorticoid receptor activity (28). During 
maturation of the glucocorticoid receptor, FKBP51 binds to Hsp90, and the receptor complex has 
lower affinity for cortisol (27). Upon hormone binding FKBP51 is replaced by FK506-binding 
protein 4, which recruits dynein into the complex, allowing its nuclear translocation and 
transcriptional activity (27, 29). In addition to FKBP5 functions through molecular interactions 
with receptors or proteins, no other mechanism of immunomodulation is known.  
 
Induction of FKBP5 by glucocorticoids has been shown in several studies (28, 30, 31), but to the 
best of our knowledge this is the first study to show that FKBP5 gene expression and protein 
levels are directly regulated by dexamethasone in both subcutaneous and omental adipose tissue. 
In contrast to the dexamethasone effect, we show that rapamycin modestly inhibited FKBP5 gene 
expression in adipose tissue whereas tacrolimus had no effect. Thus, the glucocorticoid up-
regulation of FKBP5 gene expression in adipose tissue is not a general effect related to 
immunosuppressive drugs.  
 
Furthermore, FKBP5 gene expression was similar in both subcutaneous and omental depots, but 
omental adipose tissue had a larger increase in FKBP51 protein levels compared with 
subcutaneous. This may suggest that FKBP5 has different post-translational regulation, e.g. 
involving protein stability, in subcutaneous and omental adipose tissue, respectively. Since 
FKBP51 appears to inhibit nuclear translocation of the glucocorticoid-receptor following ligand-
binding (27, 29), excess of FKBP51 might contribute to a desensitization for glucocorticoids. It is 
interesting that obese individuals with elevated insulin resistance are less sensitive to the effects 
of dexamethasone on FKBP5. It is conceivable that the lesser increase in FKBP5 gene expression 
in adipose tissue in obese subjects, after incubation with dexamethasone, may be due to an 
already pre-existing high level of FKBP5 on these tissues. 
11 
 
We also show that FKBP5 gene expression in subcutaneous adipose tissue correlates positively 
with HOMA-IR, subcutaneous adipocyte diameter and serum insulin, which suggests that FKBP5 
expression, is linked to insulin resistance. FKBP51 has been reported to function as a negative 
regulator of the PKB pathway by acting as a scaffolding protein for PKB and its phosphatase, the 
PH domain leucine-rich repeat protein phosphatase (PHLPP) (32). Therefore, the FKBP51 up-
regulation caused by glucocorticois, may have important implications on the negative regulation 
of the PKB pathway and thus contibute to desensitization of the insulin signalling.  
 
Both the syndrome of glucocorticoid excess, i.e. Cushing’s syndrome, and the metabolic 
syndrome are characterized by alterations in glucose and lipid metabolism, body fat accumulation 
and redistribution and immune function (6, 7). Obesity is associated with activation of 
inflammatory/immune system, including elevation in cytokine levels (e.g. interleukin-6, and 
tumor necrosis factor-α), that are known to be associated with insulin resistance (33).  Thus, it 
would be of particular value to identify genes that are dysregulated in these two conditions and 
that may contribute to the perturbations described. Such studies might provide unique 
pharmacological targets and/or biomarkers for common metabolic disorders. Our present findings 
on regulation of FKBP5 can be of importance in this context, since its expression in subcutaneous 
adipose tissue appears to be correlated to insulin resistance and adiposity and since it is also 
regulated by dexamethasone and the immunosuppressive drug rapamycin. This suggests that 
FKBP5 can be involved in inflammation as well as in metabolic dysregulation, and FKBP5 
overexpression could possibly be a common mechanism linking these two phenomena, e.g. in 
obesity. 
 
CNR1 was, together with FKBP5, the gene with the greatest increase in gene expression after 
dexamethasone incubation. CNR1 is most abundantly expressed in the central nervous system, 
but it is also expressed in other tissues for example liver, muscle and adipose tissue. Activation of 
the central cannabinoid system promotes food intake and weight gain. The CNR1 gene expression 
has previously been shown to be higher in visceral compared to subcutaneous adipose tissue (34). 
The CNR1 expression has also been shown by some to be reduced with obesity in subcutaneous 
and visceral adipose tissue (34, 35), whereas others found an increased CNR1 expression with 
obesity in subcutaneous and visceral adipose tissue (36) or did not find any association between 
CNR1 expression and measures of body fat, metabolic parameters or fat cell function (37). 
We show that leptin and TIMP4 expression, two regulatory genes encoding for secreted factors, 
are increased after dexamethasone treatment of both depots. Both leptin expression in adipose 
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tissue and concentrations of leptin in serum has previously been shown to be increased by 
dexamethasone (13, 38). However, differences in leptin secretion in both sexes (38) and fat 
depots (12, 13) and the fact that serum level is tightly linked to BMI and fat mass, argues against 
leptin as a suitable biomarker to study dexamethasone responses. TIMP4 has not previously been 
studied in the context of glucocorticoids and adipose tissue. TIMP4 is an inhibitor of the matrix 
metalloproteinases and microarray based tissue distribution datasets (GEO database GSE3526 
data set) show that adipose tissue is a major site of TIMP4 expression. This suggests that TIMP4 
is a putative dexamethasone-response biomarker that warrants further investigation. 
 
One additional aim of this study was to search for depot differences in gene expression in 
response to dexamethasone treatment. Genes differentially regulated in the two adipose depots, 
may provide insights into accumulation of omental adipose tissue seen after glucocorticoid 
treatment. In this study, only SERTM1 displayed a clearly different response to dexamethasone in 
the two fat depots. SERTM1 is a gene with unknown function and therefore these findings 
provides no mechanistic insight into processes that are related to metabolic disease. Otherwise, 
we could not find any clear depot differences in the gene expression response to dexamethasone.  
This study has several limitations. We report effects of dexamethasone in adipose tissue in vitro, 
which may not reflect measurements in vivo. We mainly used a very high concentration of 
dexamethasone, corresponding to supraphysiological glucocorticoid levels, and therefore we 
cannot exclude that some genes may respond differentially in the two depots with exposure to 
more physiological levels. We only studied 24 h of dexamethasone incubation, which does not 
identify genes that might be regulated only during shorter- or longer-term treatment. Thus, further 
studies could be of value in order to identify genes differentially regulated between the depots 
across a range of glucocorticoid concentrations and duration of treatment.  
 
In conclusion, FKBP5 is a novel gene regulated by dexamethasone in both subcutaneous and 
omental adipose tissue, and its expression in subcutaneous adipose tissue appears to be correlated 
to markers of insulin resistance and adiposity. However, the gene product was present at 
markedly higher levels in the omental than in the subcutaneous depot. FKBP5 is a potential 
mechanism linking insulin resistance with alterations in immune function and inflammatory 
responses. Further studies should address whether FKBP5 can provide novel pharmacological 
targets for the treatment of insulin resistance in the context of glucocorticoid excess as well as in 
the metabolic syndrome and type 2 diabetes. 
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TABLES 
Table 1. Clinical and biochemical characteristics of study participants, in whom the effects of 
dexamethasone on adipose tissue was evaluated (n=25). 
Variable Value 
Sex (male/female; n) 10M/15F 
Age (years) 45±10 
BMI (kg/m2) 27±3 
WHR 0.95±0.05 
Fat mass (%) 28±7 
Subcutaneous adipocyte diameter (µm)  94.9±10.4 
Omental adipocyte diameter (µm)  84.2±14.7 
HbA1c, IFCC (mmol/mol) 32±4 
Serum insulin (mU/L) 10.2±6.9 
Plasma glucose (mmol/L) 4.8±0.4 
HOMA-IR 2.2±1.4 
Serum triglycerides (mmol/L) 1.5±0.7 
Serum total cholesterol (mmol/L) 5.4±0.9 
Serum LDL-cholesterol (mmol/L) 3.4±0.7 
Serum HDL- cholesterol (mmol/L) 1.4±0.3 
Data are mean ± SD; n for each variable=20-25; BMI, body mass index; WHR, waist to hip ratio; 
HbA1c, glycosylated hemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance 
index (fasting blood glucose × fasting insulin/22.5); LDL, low density lipoprotein; HDL, high 
density lipoprotein. 
 
 
Table 2. Correlations between FKBP5 gene expression in subcutaneous and omental adipose 
tissue (control and dexamethasone-induced increase) and metabolic parameters.  
 FKBP5 mRNA  
(control) 
 ∆ - FKBP5 mRNA  
(dexa treated-control, %) 
 Sc  Om  Sc  Om 
 r P  r P  r p  r P 
Serum -insulin 0.58 0.008  0.06 0.813  -0.67 0.001  -0.21 0.384 
HbA1c 0.28 0.248  -0.26 0.277  -0.60 0.007  0.10 0.690 
HOMA-IR 0.59 0.006  0.09 0.704  -0.66 0.002  -0.25 0.279 
BMI 0.09 0.672  -0.03 0.911  -0.41 0.050  -0.17 0.449 
Fat cell diameter 0.48 0.020  0.16 0.464  -0.30 0.165  -0.23 0.293 
∆ - basal glucose uptake  
(dexa treated-control, %) - -  - - 
 
-0.22 0.533  0.25 0.489 
∆ - insulin-stimulated glucose 
uptake  
(dexa treated-control, %) 
- -  - - 
 
0.30 0.405  0.37 0.293 
Sc, subcutaneous; Om, omental; dexa, dexamethasone; HbA1c, glycosylated hemoglobin; 
HOMA-IR, homeostatic model assessment of insulin resistance index; BMI, body mass index. r-
values are Spearman correlation coefficients. 
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FIGURES 
Figure 1. 
 
Figure 1. Effects of dexamethasone incubation on glucose uptake in human subcutaneous 
and omental adipocytes. Dexamethasone (3 µM) decreased both basal and maximally 
insulin (1000 µU/ml) stimulated glucose uptake in subcutaneous and omental adipocytes 
after 24 h incubation (n=12). Sc, subcutaneous; Om, omental. * P<0.05; ** P<0.01. 
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Figure 2. 
 
Figure 2. Gene expression in subcutaneous and omental adipose tissue after incubation in 
absence or presence of dexamethasone (3 µM). Array, microarray analysis (n=4); RT PCR, 
real-time polymerase chain reaction (n=20-23); FKBP5, FK binding protein 5; CNR1, 
cannabinoid receptor type 1; LEP, leptin; TIMP4, metalloproteinase inhibitor 4, SERTM1, 
serine-rich and transmembrane domain containing 1; Sc, subcutaneous; Om, omental. 
Means not sharing the same letter are significantly different from each other (P<0.05). 
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Figure 3.  
 
Figure 3. Dose-response curve for the effects of dexamethasone on FKBP5 gene and 
protein expression in subcutaneous and omental adipose tissue. (A) Dexamethasone 
(0.003-3 µM, n=3-10) increases in a dose dependent manner the FKBP5 gene expression 
in subcutaneous and omental adipose tissue vs. untreated cells (n=3-10), P<0.05. (B) 
Dexamethasone (0.003-0.3 µM) increases in a dose dependent manner the FKBP51 protein 
levels in subcutaneous and omental adipose tissue. Graph represents FKBP51 
quantification data (n=3). (C) FKBP51 protein levels in subcutaneous and omental adipose 
tissue incubated without or with dexamethasone (3 µM, n=10), and quantification of 
protein levels. Actin was used as a loading control protein. Results show representative 
gels and mean ± SEM of densitometry analysis. Densitometry measures of FKBP51 were 
normalized for the respectively actin protein levels. Sc, subcutaneous; Om, omental. 
Means not sharing the same letter are significantly different from each other (P<0.05). 
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Figure 4. 
 
Figure 4. Effects of tacrolimus and rapamycin on FKBP5 gene expression in subcutaneous 
and omental adipose tissue after 20 h incubation. n= 18 and 13 for subcutaneous and 
omental adipose tissue, respectively. Sc, subcutaneous; Om, omental. Means not sharing 
the same letter are significantly different from each other (P<0.05). 
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Supplemental Methods 
Glucose uptake 
After collagenase type II digestion (from Clostridium histolyticum, Sigma) the adipocytes 
were washed four times with medium without glucose and pre-incubated for 15 minutes in 
absence and presence of human insulin (1000 µU/ml; Actrapid, Novo Nordisk A/S, 
Copenhagen, Denmark). Thereafter, D-[U-14C]-glucose was added and the cells were 
incubated for an additional 45 minutes before the glucose uptake was terminated and the 
cell-associated radioactivity was measured by scintillation counting. The cellular clearance 
of glucose from the medium was taken as an index of the rate of glucose uptake and 
calculated according to the following formula: cellular clearance of medium glucose = 
(cell associated radioactivity x volume)/(radioactivity in medium x cell number x time). 
Microarray Analysis 
Array data was subjected to quality control assessments for GeneChip arrays and data 
integrity which indicated that all samples showed high quality profiles and passed data 
integrity controls. 
 
Target was prepared for hybridization to Affymetrix GeneChip® Human Exon 1.0 ST 
arrays in accordance with the guidelines detailed by the manufacturers: Total RNA was 
amplified using the NuGEN™ WT-Ovation™ Pico RNA Amplification System. The 
NuGEN WT-Ovation™ Exon Module was used to generate sense-strand cDNA targets 
ready for fragmentation and labelling with NuGEN’s FL-Ovation™ cDNA Biotin Module 
V2. The resultant fragmented and labelled cDNA was added to the hybridization cocktail 
in accordance with the NuGEN™ guidelines for hybridization onto Affymetrix 
GeneChip® arrays. Following the hybridization for 16-18 hours at 45°C in an Affymetrix 
GeneChip® Hybridization Oven 640, the arrays were washed and stained on the 
GeneChip® Fluidics Station 450 using the appropriate fluidics script, before being 
scanned using the GeneChip® Scanner 3000. 
 
The General Linear Model implemented in Array Studio (Omicsoft Corporation) was used 
to compare the effects of dexamethasone treatment on subcutaneous and omental adipose 
tissue. The model included the factors Subject (random), Tissue (with levels subcutaneous 
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and omental adipose tissue), and Treatment (with levels control and dexamethasone). Pair 
wise comparisons were performed within the model and multiple test correction was 
applied using False Discovery Rate (FDR, Benjamini and Hochberg) on a per-test basis. 
Multiple test correction-adjusted p-values with an alpha level of 0.05 were used to filter for 
genes changed in any tissue in response to treatment. When each tissue was compared 
separately (controlling for Subject and Treatment) this proved overly stringent, therefore 
the data was filtered using an unadjusted p-value threshold. 
 
Genes that were significantly changed in response to dexamethasone (controlling for tissue 
type, i.e. in the general linear model described in the supplement) were imported to the 
Ingenuity Pathway Analysis software (Ingenuity Systems). 
Adipose tissue lysates and immunoblotting 
Adipose tissue was homogenized in ice-cold lysate buffer (25 mM Tris-HCl pH 7.4, 0.5 
mM EGTA, 25 mM NaCl, 1% Nonidet P-40, 1 mM Na3VO4, 10 mM NaF, 0.2 mM 
leupeptin, 1 mM benzamidine, 0.1 mM 4-(2-aminoethyl)-benzenesulfonylfluoride 
hydrochlorine and 0.1 µM okadaic acid) with the TissueLyserII (Qiagen). The 
homogenates were lysed at 4ºC for 2 h, before being centrifuged (12 000 g, 15 min, 4ºC), 
and the supernatant was collected and saved at -80ºC. Protein content was measured with 
the BCA protein assay kit (Thermo Scientific, Rockford, IL, USA).  Total lysate (20 
µg/lane) were subjected to SDS-PAGE, transferred to nitrocellulose membrane and 
immunoblotted with anti-FKBP51 (1:1000, Cell Signaling Technologies, Beverly, MA, 
USA) and anti-actin (1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 
thereafter with secondary antibody linked to horseradish peroxidase (1:2000, Cell 
Signaling Technologies). Detection was made with chemiluminescence reagent (ECL, 
Amersham Biosciences GE Healthcare, Buckinghamshire, UK) using a ChemiDoc XRS 
detection system (Bio-Rad, Richmond, CA, USA). Bands were quantified using Quantity 
One Imaging software (version 4.6.6. from Bio-Rad).  
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SUPPLEMENTAL RESULTS 
Microarray Analysis 
Changes in gene expression among 18 686 well annotated transcripts of the “core” subset 
were investigated using Affymetrix GeneChip Exon 1.0 ST arrays.  
147 probe sets representing approximately 144 genes differed in their expression levels in 
subcutaneous versus omental adipose tissue when controlling for treatment with 
dexamethasone and whiten subject (false discovery rate of 0.05). 121 probe sets 
(representing 118 genes) were expressed at higher levels and 26 genes at lower levels in 
omental compared to subcutaneous tissue. Something more, or just delete 
 
SUPPLEMENTAL TABLES 
Supplemental Table 1. Clinical and biochemical characteristics of study participants in 
whom the effect of the immunosuppressive agents, tacrolimus and rapamycin on adipose 
tissue was evaluated (n=22). 
 Variable Value 
Sex (male/female, n) 5M/17F 
Age (years) 51±12 
BMI (kg/m2) 26±3 
WHR 0.90±0.08 
Fat mass (%) 30±8 
Subcutaneous adipocyte diameter (sc) 97.3±11.6 
Omental adipocyte diameter (om)a 87.3±14.2 
HbA1c (mmol/mol)b 34±3 
Serum insulin (mU/L) 7.3±3.5 
Plasma glucose (mmol/L) 5.1±0.6 
HOMA-IR 1.7±0.8 
Serum triglycerides (mmol/L) 1.1±0.5 
Serum total cholesterol (mmol/L) 5.7±1.1 
Serum LDL-cholesterol (mmol/L) 3.4±0.9 
Serum HDL-cholesterol (mmol/L) 2.0±0.7 
a
 n=11 
b Normal range 27-46 mmol/mol (IFCC standard) 
BMI, body mass index; WHR, waist to hip ratio; HbA1c, glycosylated hemoglobin; 
HOMA-IR, homeostatic model assessment of insulin resistance index (fasting blood 
glucose × fasting insulin/22.5) (39); LDL, low density lipoprotein; HDL, high density 
lipoprotein. Data are means ± SD.   
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Supplemental Table 2. List of the 20 genes with the greatest decrease in gene expression 
after dexamethasone incubation of subcutaneous and omental human adipose tissue as 
analyzed by microarray analysis (Affymetrix, n=4). 
Subcutaneous 
Fold 
change Omental 
Fold 
change 
CCL81,2 -19,05 CXCL101,2 -22,76 
CXCL101,2 -18,51 CXCL111,2 -19,45 
CXCL111,2 -17,35 CCL81,2 -13,12 
IFIT11,2 -12,93 CXCL91,2 -10,31 
RSAD21,2 -12,31 IL1B1,2 -8,59 
IFIT21 -11,65 IFIT31,2 -7,72 
IFI44L1,2 -9,11 LOC100288077 // MMP11 -7,55 
PTGS21,2 -9,09 PTGS21,2 -7,43 
IFIT31,2 -9,00 IFIT11,2 -6,96 
LOC100288077 // MMP11 -8,30 RSAD21,2 -6,84 
IL13RA2 -8,10 IFIT21 -6,43 
IL1B1,2 -7,48 IFI44L1,2 -6,33 
CCL3 // CCL3L1 // CCL3L32 -6,72 SFRP4 -5,8 
CXCL91,2 -6,42 LOC100131190 // MX1 // MX2 -5,29 
MX1 -6,41 
GBP1 // GBP2 // GBP3 // 
LOC400759 -4,78 
FST -6,33 OAS11,2 -4,76 
IL61,2 -6,12 IL61,2 -4,58 
OAS11,2 -6,09 CCL72 -4,35 
TNIP32 -5,94 INHBA -4,35 
SAMD9L -5,91 OAS22 -4,31 
 
1
 Common genes in both subcutaneous and omental adipose tissue. 2 Genes known to be 
involved in immune/inflammatory pathways. 
  
25 
 
Supplemental Table 3. List of the 20 genes with the greatest increase in gene expression 
after dexamethasone incubation of subcutaneous and omental human adipose tissue as 
analyzed by microarray analysis (Affymetrix, n=4). 
Subcutaneous Fold change Omental Fold change 
CNR11 10.82 FKBP5 // LOC2858471 7.69 
FKBP5 // LOC2858471 7.76 CNR11 6.95 
PPP1R3C1 6.21 POSTN 4.39 
F81 4.42 FBLN51 3.88 
FBLN51 4.25 LAMA21 3.75 
PDK41 4.25 STEAP41 3.76 
LAMA21 3.97 PPP1R3C1 3.51 
CIDEC // CIDECP1 3.88 MS4A4A1 3.35 
HSPB71 3.82 F81 3.31 
KIAA0040 3.80 HSPB71 3.18 
VSIG41 3.78 CPM1 3.14 
CYP4B1 3.63 ZBTB161 3.12 
CD1631 3.58 CD1631 3.11 
CPM1 3.50 SRPX 3.09 
MS4A4A1 3.30 ADAMTS5 3.10 
MAOA 3.29 CIDEC // CIDECP1 3.06 
LOC648149 // MAP2 3.04 VSIG41 3.00 
STEAP41 3.01 LMO3 3.01 
ZBTB161 3.01 PDK41 2.96 
SERPINA3 3.00 COPS8 2.90 
1
 Common genes in both subcutaneous and omental adipose tissue. 
SUPPLEMENTAL FIGURES 
 
Supplemental Figure 1. Gene expression of FKBP5 in metabolically active tissues, 
skeletal muscle, adipose tissue (omental and subcutaneous), kidney, liver, heart and brain 
measured by microarray analysis. The relative expression in each tissue was determined as 
described in Methods. 

